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Abstract 
Sebastien Woynar, The Impact of Political Governance on Biomedical Research 
Performance: A Study of 50 Countries 
Under the direction of Thomas C. Ricketts 
 
 
This study tries to understand why certain countries have a stronger biomedical research than 
others. Our hypothesis is that the national political governance plays a major, yet under-
recognized, role. Biomedical research performance was calculated as the number of publications 
from the country’s research teams in the top 97 biomedical journals per annum per capita. 
Governance is the sum of the 6 country level governance indicators used by the World Bank. 
Relevant co-factors extracted from the literature were also included: GNI per capita, the 
percentage of GDP allocated to R&D, the economic value of international trade, immigrants per 
capita, English proficiency, the percentage of households connected to Internet and the population 
size. 
The sample includes the top 50 countries in terms of number of publications. They represent 99% 
of the World’s publications, 70% of the World’s population and 90% of the World’s economic 
production. Data collected for all years between 1996 and 2008 was analyzed using cross 
sectional and longitudinal (panel data) methods. 
Our results challenge the perceived ranking order of country level biomedical research 
performance factors, previously based on the prominence of economic resources. Economic 
resources such as gross national income (GNI) per capita and the percentage of gross domestic 
product (GDP) allocated to R&D are still fundamental in the long run. However, compelled by 
the World’s globalisation, a fast growth in population, international trade and immigration are 
today’s drivers of biomedical research performance. Most importantly, governance appears to be 
the most important factor, having the ability to transform these resources into top biomedical 
research. One point of governance (ranging from -6.9 to 10.8) increases, depending on the model, 
from 11% to 16% the publications per capita ratio, the other variables held equal. The 
implications for public health leaders are fourfold. First, they must understand the true dynamics 
iv 
of innovation, based on diversity, volume and resilience. Second, they must appreciate the 
political importance of biomedical research and the impact governance has on innovation. Third, 
they must understand that good governance and good leadership have similarities. Finally, public 
health leaders should see in the World’s globalisation an opportunity for innovative solutions. 
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Chapter 1: Significance of the topic 
 
This study will try to understand why certain countries have stronger biomedical research than 
others. Amongst the factors that could explain a difference in performance, my hypothesis is that 
the political governance of a country plays a major, yet under-recognized, role in fostering 
biomedical research development. The relevance of this topic is largely due to the importance 
given to biomedical research. Indeed, biomedical research has the responsibility not only to 
improve the health of the citizens of a country, but also to be a contributing force of its economy.  
Biomedical Research: A Determinant of Health and Economic Growth 
A. Biomedical research as a determinant of health 
Products and services discovered through biomedical research determine, along with genetics, 
socio-economics status and environmental factors, a significant part of the health of a population 
(Commission on Macroeconomics and Health, 2001). In this light, biomedical research is one of 
the primary contributors to and a stimulus for improvement of the health care system and of the 
overall health of the population (Cockburn, 2004). While this perspective may be true on a global 
level, the picture is different from an individual country perspective. Indeed, because biomedical 
research results and products can easily be transferred from country to country (Falagas, 2008), an 
individual country may decide not to develop an effective structure for supporting its own 
biomedical research program. Such a country may still benefit from international innovation, for 
example, by simply granting market approval for innovative drugs developed elsewhere or by 
scanning breakthrough findings within open science peer-reviewed academic publications. 
However, many countries, such as the United States, France, England and Germany, rely on the 
development of their own biomedical research as an explicit way of improving the overall health 
of their population. For example, the recent creation of the French National Cancer Institute, in 
charge of implementing a full range of health policies to fight cancer (fostering research, 
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increasing epidemiologic intelligence, and improving quality of care) attests to the central role of 
research in public health (INCa, 2010). At the health care provider level (such as hospitals), 
successful initiatives have demonstrated that conducting research is associated with better quality 
of care through direct (such as the application of the results of research) and indirect mechanisms 
(such as provider knowledge improvement) (Kaluzny, 2008).  
B. Biomedical research as a determinant of economic growth 
Biomedical research and subsequent innovation has the potential to boost a country’s economy. 
From this perspective, the Organization of Economic Cooperation and Development (OECD) has 
defined innovation as “the creative use of various forms of knowledge when responding to 
market-articulated demands and other social needs” (Box, 2009; Lederman, 2005). Evidence has 
confirmed the following two mechanisms: (1) investments in Research and Development (R&D) 
have a positive impact on real per capita growth and, (2) investments in innovation have a positive 
impact on the economy’s productivity (Box, 2009)1. Because the market economy (today’s 
dominant form economic exchange) is based on growth, the links between innovation, 
productivity and growth create an endless demand for further innovation (Heilbroner, 1999). As in 
research based economies, biomedical research has the capacity to create jobs, increase 
productivity and welfare and its demand is unlikely to diminish in the coming years.  
C. National biomedical research policies and globalisation 
Whether the objective is to improve the health of its population or to strengthen their competitive 
economic position, several countries have, in the last decade, developed policies to stimulate their 
biomedical research and boost innovation. In the USA, Congress sharply increased the National 
Institutes of Healths’ (NIH) budget from $14 billion in 1998 to $27 billion in 2003. After a stall 
between 2004 and 2008, the NIH’s budget has been increased again since 2009 (National 
Institutes of Health, 2010).  
                                                 
1
 It is worthwhile noting however that, in the biomedical sector, innovative technologies may increase costs, 
potentially yielding a decrease in overall productivity (Porter, 1998; Cockburn, 2004; Herzlinger, 2006; 
Hwang, 2008; Leatherman et al, 2003). 
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To boost all their research based economies, including the biomedical sector, the European Union 
determined in 2000 that every Member State should increase their national spending on research 
and development up to an ambitious target of 3% of the gross domestic product. Similar policy 
initiatives have been launched around the globe in India, China, Persian Gulf countries, and Brazil 
(OECD, 2010). 
These national policies, when viewed in the context of economic globalization, support the 
proposition that biomedical research is now and increasingly a competitive international market. 
In fact, recent trends signal that countries with historic dominance in biomedical research are now 
at risk of being surpassed by emerging countries (Falagas, 2008). More dramatically, the concept 
of “reverse innovation” has recently been introduced to describe the mechanism of research and 
development being used in emerging and poorer markets, and later successfully introduced in 
older and richer economies (Immelt, 2009). 
The Research Problem 
No matter how important biomedical research is for today’s world, we are far from knowing 
precisely what promotes or discourages it at a country level. This limitation is problematic 
because solutions to improve its performance and expand its impact to improve health are, and 
will always be, needed. 
On the one hand the citizens, often as patients, and healthcare professionals are demanding more 
effective, and safer treatments. In response, politicians have placed healthcare in general, and 
biomedical research specifically, as one of their priorities and have taken responsibility for 
delivering results. On the other hand, governments and companies are trying to maintain a 
competitive position in the global biomedical industry. They know that innovation is the key to 
success and that innovation is largely driven by a vibrant research program. However, the 
biomedical industry is experiencing the problem of declining R&D productivity: while the cost 
keep rising, the number of innovative drug launched have stagnated (Danner, 2008).  
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There are some opponents and critics of biomedical research. However, most on them do not 
oppose its overarching purpose, improving the health of human beings, rather the ethics around 
certain scientific methods (human or animal clinical trials). Consequently, most stakeholders 
would agree that there is and always will be a “performance problem” with biomedical research: 
better, more effective research is always in short supply. Any practical guidance to improve it 
should be welcomed. This attitude may be even more necessary during the current period of 
economic deceleration in which resources are scarce.  
Sluggish biomedical research is a problem for patients, healthcare professionals, citizens, 
governments and companies. This study will try to address this problem by understand country 
level factors of biomedical research performance. 
Deficiencies in the Current Literature 
An abundance of literature exists on what promotes research and innovation1 in general. However, 
it addresses the research problem tackled here only in part. What drives biomedical research 
specifically remains an unanswered question.  
We have identified 6 deficiencies in the current body of knowledge. (1) Few studies focus 
specifically on biomedical research and innovation at the country level. This lack is regrettable 
because the dynamic of research may vary from field to field and widely across countries. For 
example, the ethical issues that are raised in human research impose specific political rules 
specific to different countries. (2) Very few studies are global in the sense that they have 
examined innovation and the potential factors for a broad range of countries. Most often, only the 
OECD countries are examined. This focus is a problem because it prevents us from learning from 
emerging countries that have developed a high level of innovation in research, it reduces our 
understanding of the influence of globalization, and it limits the external validity of the studies. 
(3) The vast majority of studies are theoretical and lack quantitative analysis. Additionally, the 
few quantitative studies available derive primarily from the field of economics which has focused 
                                                 
1
 In the common understanding, innovation refers to the commercialization of a new product or service, 
often discovered through the process of research 
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on loosely related factors such as the percentage GPD invested in R&D or the number of doctoral 
degrees. Few studies rely on quantitatively measurable variables identified in other social 
disciplines. In particular, no studies have quantitatively looked at the role of the global political 
structure of a country on its level of innovation, although emerging paradigms suggest it is 
important. (4) The previous point suggests the fourth deficiency: the lack of cross-disciplinary 
work. Economists have focused on the appropriate level of public and private investment in 
research and development, on property rights of research discoveries, and on the industry 
structure. Sociologists have studied how the environment supports innovation. Regional studies 
have looked at the importance of providing a dense network of research related organizations. In 
the biomedical field, this issue has also been raised although it has led more to opinionated 
commentaries than to rigorous studies. Most studies within these disciplines, although sometimes 
acknowledging the existence of other constructs and variables, focus their analysis on their own 
specific constructs and variables. For example, economic quantitative studies focus on human and 
capital resources but neglect governance issues (Rahman, Fukui, 2003). No real suggestions are 
provided as to how the innovation factors identified in each social science come into play 
together, specifically at the country level. This deficiency provides an opportunity to bridge these 
constructs and variables together within a same analysis. (5) The literature review points to the 
central role of time in innovation dynamics. Innovation builds on past knowledge and takes place 
in a context of limited information about future risks and outcomes that reveal themselves with 
time. In the biomedical field, time links the evolution research from the understanding of 
fundamental biological mechanisms, to the engineering of therapeutic drugs. Unfortunately, the 
bulk of quantitative studies on innovation are cross-sectional. The few studies that actually 
account for time do it either it by: analyzing the evolution of a specific scientific and technologic 
product family within a fixed institutional context, or by analyzing the impact of the evolution of 
an institutional context on a specific product family. Very few studies analyze throughout time the 
co-evolution of the product family and the institutional environment. (6) The literature (much of 
which will be reviewed in the next chapter) suggests that the dynamic of innovation is not a linear 
process, with factor A (an independent variable) leading to productivity X (the dependant 
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variable). Rather, within the innovation mechanism, factors continuously interact and modify each 
other over time. The term “co-evolution” is often used (Consoli, 2009). There is a clear need to 
account for the interactions of all possible factors together, which has not been done in the 
previous quantitative studies. 
Our study will try to address these deficiencies and allow for progress in understanding what 
promotes biomedical research performance. 
Purpose of the Research 
The purpose of this research is to explore quantitatively at the nation level the relations between 
biomedical research performance and a set of intermediating factors. Among these factors, our 
hypothesis is that the political governance of a country plays a major, yet underestimated, role. 
We will measure the performance1 of a country by dividing the number of publications its 
research teams have published in top biomedical journals over a given period of time by its 
population. This variable will be called “publications per capita” and its justification and 
construction will be discussed at length in the following chapters.  
Within the set of possible factors that drive research; this study will focus on the political 
structure of the country through the lens of “governance”, a modern political science concept 
increasingly used in place of traditional concepts such as “governments” or “States” (Duit, 2008; 
Hirst, 1995).  
The Importance of this Research for the Audience 
This study is timely for policy makers as well as for business, academic and public health leaders. 
The reality is that economics is driving biomedical research on a global scale and understanding 
factors that drive country level performance is important in order to survive in international 
competition. Actors in the biomedical research sector, from academic centres, biotechnology and 
                                                 
1
 Instead of performance, the term “productivity” is also appropriate (and has been used by other authors, 
(Rahman, Fukui, 2003)) because it also captures the notion of an output adjusted to a level of resources. 
However, the general term “performance” will be used because of its neutral connotation, the fact that it is 
not a standard economic term and that it can encompass additional concepts. 
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pharmaceutical companies, to regulators and public health officials may be interested in 
understanding the performance of biomedical research and its drivers, in their country, in 
competing or collaborating countries, and in countries in which they wish to invest. This 
assumption may be particularly true in a time of a global decline of biomedical R&D productivity 
and deep changes in national (China, India) and supra-national political governance (European 
Union, the international agreements such as the Agreement on Trade-Related Aspects of 
Intellectual Property Rights” (TRIPPS)).  
Scholars may also find the methodological approach inventive, and more integrative than classical 
approaches. Finally, first line biomedical research professionals (physicians and scientists may be 
interested to learn to what extent their work is being influenced by national level factors. 
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Chapter 2: The literature review 
 
Method  
A. Objective  
The objective of the review is to identify in the scientific and policy relevant (scientific articles, 
reports, books, data, etc.) literature the information concerning: 
 The dependent variable of our study: biomedical research performance. We also included in 
the search the broader and more commonly used concept of “innovation”. 
 The independent variables of our study: factors that may impact the performance of 
biomedical research and innovation. 
The information derived from the literature could take the form of: 
 constructs: a theoretical understandings of a variable that will support the conceptual validity 
of our analysis; 
 quantitative variables, used or not by previous research, usually linked to constructs, that 
could be numerically included in our quantitative analysis.  
In addition, we searched for databases containing data with multiple countries and multiple points 
of time.  
B. Search Method 
Search strategies 
Five complementary search strategies were used to triangulate relevant information:  
 A systematic search within the biomedical literature (in PubMed);  
 A systematic search within the social science literature (in Web of Science®);  
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 A search using bibliometric tools (tools that evaluate research patterns by the use of indicators 
such a number of citations and co-citations between articles) to identify “cutting” edge 
research (emerging and leading research topics, articles or authors; 
 Grey literature review (non peer reviewed yet technical documents on the subject published 
by trustworthy organizations, including international agencies such as the World Bank, 
national agencies, think tanks, etc.); 
 Bookshelf review. 
 In addition, we searched for international quantitative databases that would provide data for 
the variables needed in this study. 
For each strategy, we relied heavily on a “spin-off” search. Using the initial document or article 
selected, we analyzed the material it had cited in its bibliography or documents that had cited the 
initial document. Furthermore, when this led to the identification of an interesting research front 
(a core set of studies on a specific sub-topic, usually characterized by specific keywords), 
additional keywords specified were included in the search.  
For each item retrieved by the search strategies, the titles and the abstract were reviewed and the 
inclusion in the literature review was done according to the selection criteria presented in the next 
section. 
The details of the search strategies (including key works used, the number of articles retrieved) 
are presented in Appendix 1. 
 “Hard” and “Soft” Selection criteria 
Prior to executing the 5 search strategies, and in order to meet the literature review’s objectives, a 
list of “hard” selection criteria was set. They are presented in the following table. 
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Table 1: Literature Search Criteria 
Criteria type Definition 
Inclusion criteria Studies analyzing a link between biomedical research production and a set of 
factors, political governance being the primary focus.  
Quantitative variables or at minimum, constructs that could be operationalized in a 
variable 
Exclusion criteria  Studies without any form of quantitative outcome (such as number of patents, 
number of innovation technologies, number of publications) were excluded 
Origin All articles were considered, so long as they were published in a peer review 
journal indexed in one of the computerized systems identified below. 
Time  No limits of time were set 
Unit of analysis Studies with any unit of analysis could potentially be considered: national level 
(research policy), organizational level (research institute, academic medical 
hospitals, firms), team level and individual level. 
Language Studies of all countries could have been potentially included but only articles in 
English or French were considered.  
 
However, it quickly became apparent that the number of studies meeting the “hard” criteria was 
very small. Consequently, we relaxed the hard criteria and introduced three “soft” criteria to 
capture a sufficient amount of appropriate material for our literature review. The soft criteria were 
(1) relevance for our study; (2) simplicity of use of the findings; and (3) trustfulness of the 
authors, the publisher or organizations that provides the data. 
Methodological evaluation  
The following table presents the methodological evaluation of the 5 search strategies. Done 
together, they are complementary. 
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Table 2: Summary of the 5 Search Strategies 
Strategy Data source Number of 
documents 
selected 
Advantage Weakness 
Search within the 
biomedical body of 
knowledge 
Pubmed 49 articles Within the 
biomedical body of 
knowledge.  
Content relevant to 
our topic 
Limited to the 
biomedical body of 
knowledge 
Search within the 
social science body 
of knowledge 
ISI Web of 
Science® 
(WOB) 
128 articles Identification of 
seminal work 
360° perspective 
Important or emerging  
studies may not have 
been selected because 
of the top ten ranking 
selection 
Search using 
bibliometric tools to 
identify cutting edge 
research 
ISI Science 
Watch® 
3 articles Identification of 
cutting hedge 
research on 
innovation within 
social science 
Possible to overlook 
major research findings 
because of the limited 
scope 
Search within the 
grey literature 
 
Trustful 
organization 
Google scholar 
14 reports or 
book chapter 
Information from 
leading organization 
Practical and 
accessible 
information 
Limited to the 
organizations selected. 
Questionable quality of 
the non peer reviewed 
literature. 
Bookshelf review 
 
University and 
general library 
3 Best selling books on 
innovation 
Selection driven by 
sales and marketing 
Questionable quality of 
the non peer reviewed 
literature. 
 
Literature review synthesis 
Grouping key messages into construct families 
To synthesize the literature review, we grouped the articles into construct families. For this 
purpose, we created an Excel® database containing all documents selected (articles, books, 
reports). For each document, the key ideas were abstracted. We then grouped these key ideas 
using a “brown paper” positioning methods. We took guidance in the following frameworks:  
 The Balanced ScoreCard® (customer, financial, operational and human resource focus 
organizational performance framework) (Kaplan, 2010, 1992); 
 Economic: economies of scale and scope and externalities; 
 Sociological: environment versus organizations interactions; 
 Political: top down politics versus bottom-up participatory politics. 
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From this process, we identified three levels of information: 
 Information concerning biomedical research and innovation helpful in framing the perspective 
of our study and to construct the dependant variable; 
 5 construct families relating to the independent variables: “governance”, “economic 
resources”, “human resources”, “critical mass” and “actors and their behavior”. These 
constructs families contain one or several constructs that theorize a dependant variable of this 
study. This classification was created specifically for the purpose of the study. Each article 
was assigned to a major construct family. 
 Methodological issues concerning the conduct of our study. 
Description of the literature review 
In total, 179 documents were selected; most were recent with 2004 being the “median” year, with 
documents ranging from 1945 to 2010. The following graph represents the number articles for 
each year since 1945. Most documents are concentrated between 2000 and 2010. Although few in 
number, the articles written before 1990 are valuable because they correspond to seminal work 
that needs to be considered. 
Figure 1: Number of Documents Collected for Each Year Since 1945 
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The 179 documents selected originated from 100 different sources. The top 11 sources are 
presented in table 3. This ranking suggests that documents originated from biomedical journals, 
non biomedical journals, and research organizations in a balanced way.  
Table 3: List of Most Cited Journals 
Journals or organizations % of documents selected 
Academic Medicine 5.7% 
Journal of the American Medical Association 5.1% 
Social Studies of Science 3.4% 
Journal Evolutionary Economics 2.8% 
Journal Product Innovation Management 2.8% 
Nature 2.8% 
Technological Forecasting & Social Change 2.8% 
World Bank  2.8% 
Harvard Business Review 2.3% 
Health Affairs 2.3% 
The Lancet 2.3% 
As the following table shows, governance is the most documented construct family with 38.6% of 
all documents. The 4 other families are represented in a balanced way between 11.4% and 19.7%. 
Table 4: Distribution of the Documents within the 5 Constructs Families1. 
Construct family % of documents selected 
Governance 38.6% 
Economic resources 19.7% 
Actors and their behavior 18.2% 
Human resources 12.1% 
Critical mass 11.4% 
Total 100% 
 
It is interesting to note that the biomedical community (assuming it communicates through 
Pubmed) has not paid the same attention to a governance concern in the conduct of research in 
comparison to the social science community (assuming it communicates through Web of 
Science). Indeed, governance is the third construct family raised in the Pubmed search (in terms 
of the percentage of documents selected) but the first in the social science search (see Appendix 2 
for details). In fact, the majority of the studies in the Pubmed search focus on “hard” factors such 
financial resources or number of researchers. Other “softer”, more complex, factors, such as the 
                                                 
1 The construct family corresponds to the most important construct family for a given document. Indeed, 
most documents have been related to more than one construct family. 
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organization of biomedical research centres, research policy and political governance, are less 
analyzed in the biomedical community. This lack of analysis confirms other reports (Consoli, 
2009). 
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Findings of the literature review 
A. Evaluating research and innovation performance 
We start by defining research and innovation. We then describe the biomedical research and 
innovation stakeholders. We look at the indicators that are used to evaluate their performance. We 
finally specify the performance variable used in our study. 
Defining biomedical research and innovation  
Biomedical research 
Building on the studies selected in the literature review, we will define biomedical research as the 
body of knowledge created by the use of the scientific method to understand human health and 
diseases and to find new, safe and effective prevention strategies, disease prediction techniques, 
diagnostics, treatments and funding, and delivery of care for human well being. This list means 
that our definition includes biological level research (basic, translational, preclinical), individual 
level (medical, clinical, applied) and population-based (epidemiology, health service research). It 
can be conducted in vitro or in vivo, including human and animal studies. The term “human 
health research” is defined more accurately within the scope of this dissertation. However, we will 
keep “biomedical research” for two reasons: (1) it is a commonly used designation; (2) “pure” 
biomedical research (i.e. biological and medical research) accounts for the major part of the 
human health research. 
Biomedical research is considered as a branch of science. Therefore, research is commonly 
conducted by teams of scientists led by medical doctors and scientists (biological, immunological, 
epidemiological) working either in public or private settings. Although bench scientists (e.g. 
Pasteur, Fleming or Salk) have long worked with practitioners, the interdisciplinarity of research 
is increasing (Cech, 2005) (Mabry et al., 2008; Committee on Facilitating Interdisciplinary 
Research, 2005). For example, geneticists have teamed up with epidemiologists to study the 
genetic susceptibly of infectious diseases (Ranque, 2005).  
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Biomedical Innovation 
It appears quite clearly in the literature that “innovation” is a concept closely tied to “research”. 
However, by most definitions found in the literature review, biomedical innovation means that 
there has been at one point an economic transaction (with or without money). In a common 
understanding, the major difference between a biomedical research advance and a biomedical 
innovation is that the latter is ultimately judged by how the market accepts it; whereas the former 
can be exclusively a scientific breakthrough even without market application1.  
Innovation has been defined in many ways. But because biomedical innovations are usually 
created within a clear organization2 (a country, a firm or a research centre), we will use the 3 
dimensions of organizational analysis defined by Pettigrew: content (product), process, and 
context (system) to distinguish the different perspectives on innovation (Pettigrew, 1992; 2001).  
Taking the product or service perspective, Christensen describes innovation as cost-reducing 
technology within a business model that delivers increasingly affordable and accessible products 
and services. In other words, disruptive innovations are the fusion of two complementary 
innovations: the technology and the business models (Smith, 2007;Hwang, 2008;Christensen, 
2009). This approach, positing that true innovations always have a technological and 
organisational component, is in line with our hypothesis that improved (new?) governance 
(organization) is a factor of biomedical research performance (technology). 
From a process point of view, Hauser describes innovation “as the process of bringing new 
products and services to the market” (Hauser, 2006). This process can be summarized in three 
generic stages: basic or fundamental research, applied research and diffusion in the market. In this 
view, research is a stage of innovation. This model is valid for biomedical research, although the 
concept and practice of translational research have been introduced in the last decade to close the 
research gap between fundamental research and clinical research (Zerhouni, 2005;Zerhouni, 
                                                 
1
 Of course, there are innovations, for example in government, in the arts and in sports, that don’t need an 
economic transition. 
2
 It has to be mentioned that some innovations don’t require organizations such as painting or street dance.  
17 
2006;Zerhouni, 2007). The following table presents the biomedical innovation process and the 
place of research within that process. 
Table 5: Biomedical Innovation Process 
Generic stages Biomedical stages 
names 
Example in the biomedical sector 
Fundamental or basic 
research 
Same as generic Fundamental understanding of biologic or 
genomic mechanism 
 Translational research Genetic susceptibly in for breast cancer- 
Applied research or 
development 
Clinical research  Clinical trials (stage 1 to 3) 
Market diffusion Marketing 
 
Production, marketing and phase 4 clinical trials 
Non-marketing dissemination activities such as 
clinical guidelines 
 
Throughout the 20th century and into the 21st, the innovation paradigm has shifted from 
unidirectional process model (from basic non profit science to commercial innovation) (Bush, 
1945) to a more complex systemic model, where innovators, suppliers, customers, competitors, 
and technology act in an integrated way (Dodgson, 2000). This model has been named in different 
ways such as “open innovation”, “innovation systems”, “innovative milieu” or “complex 
innovation systems”. Inter-organisational arrangements such as networks, joint ventures, 
collaborative research groupings, collaborative marketing arrangements and partnerships are now 
essential.  
In line with this important historical transition, industrial economists have described the change of 
the biomedical industry structure from a binary model -up to the 1980’s- (time when the industry 
was characterized by basic research centre on one side and vertically integrated big 
pharmaceutical companies on the other) to a more complex and diffuse structure (with the 
emergence of biotechnology “tool” companies acting as intermediaries) (Cockburn, 2004). From a 
similar perspective, an emerging research front, the evolutionary economics of innovation have 
recently provided interesting theoretical insight on innovation dynamics – although, to date, it 
lacks quantitative evidence. Incorporating a temporal notion of an evolutionary framework, this 
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research front defines biomedical innovation as “new drugs, devices and clinical practises 
introduced over time into the provision of healthcare” (Consoli, 2009). 
As innovation can be at the same time a product, a process, or a system; agreement upon what 
constitutes a reliable and valid measurement of innovation is difficult (Dodgson, 2000) and still 
lacking (Box, 2009). As we will see below, this study will focus on the research side of 
innovation by using the published article as our dependent “performance” variable. 
Biomedical research and innovation stakeholders 
The following table represents the actors in the biomedical stakeholders, their principal mission 
and their business model for “exploiting” research for market gain. 
Table 6: Biomedical Research and Innovation Stakeholders 
Stakeholders Principal mission Business model 
Academic centres / 
public / private non 
for private 
Fundamental research 
 
Possess fundamental and basic science 
knowledge 
Deliver to care to patients / are trusted by patients 
Have access to patient for human research 
Biotechnology “tools” 
companies 
Technological intermediate 
between academic centres and 
drug companies 
Master technology transfer 
“Niche” drug 
companies 
Produce drugs in a specific 
therapeutic area 
Master a single biotechnology (such as particular 
genomic tool) 
High price / low volume 
Exploit niche market position 
Major drug / medical 
equipment companies 
Develop drugs 
Conduct clinical trials and 
market drugs 
Size allows : 
Economies in scale in drug development (clinical 
trials) 
Fund research and hedge financial risks  
Access to providers 
Strong marketing and sales capabilities 
Legal protection of patents 
Clinical research 
organization 
Conduct clinical trials for 
sponsors, including 
pharmaceutical companies 
and government agencies  
Economies of scale to reduce the cost of clinical 
trials  
Access to provider and patients 
 
Research public and 
charity funders 
Fund biomedical research 
without a direct return on 
investments need 
Long term growth of knowledge stock 
Compensate investment market failure 
Public and private 
health insurance and 
pharmaceutical 
benefit manager firms 
Fund health care consequently 
innovation  
Mutualisation of financial health risks within a 
population 
Make actuarial profit 
Regulator Insure efficacy, safety and 
access of new products and 
insure integrity and prevent 
Regulators need something to regulate 
Protection of the public welfare 
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fraud in product development 
Patients in clinical 
trials 
Participate in clinical research Gain access to advanced treatments they could 
not access otherwise 
Often get paid for the work  
Feel of social good and service to society  
 
By stressing the number of stakeholders (and their motives) that are involved in the biomedical 
field, this table points to the importance of understanding innovation as a complex system. 
Effective governance is needed only to insure that the rules of the game are fair and respected by 
all actors. 
Biomedical research and innovation output and performance indicators 
In the last decade, the evaluation of research and innovation has increased in importance. Since 
2003, the University of Shanghai has issued an annual performance review ranking all universities 
in different fields (including biomedical research) based on a mix of scientific research output 
indicators (such as peer reviewed articles, major prizes and international awards). In the USA, 
with a strong tradition of evaluation and accountability, US News and World Report magazine 
ranks US Universities, both in terms of performance of research and teaching1. In France, the 
Ministry of Health has subsidized biomedical research for public and private not-for-profit 
hospitals based on an evaluation of their scientific output (such as the number of articles 
published adjusted for the impact factor of the journal, and number of patents registered) since 
2007. In the UK, the RAE (Research Assessment Exercise) evaluates all academic research 
institutions using similar methods. UNESCO and OCDE produce yearly science and technology 
indicators. 
As we have seen in the previous sections, the actors and steps of the innovation process are 
multiple. Nevertheless, it is common to categorize the biomedical sector in two main types of 
Science: public and private. For each, the actors’ rules and goals are different yielding a certain 
                                                 
1
 These rankings have some face validity, but are also heavily gamed by the universities. 
20 
type of performance or output evaluation. Clinical trials, commonly funded by the pharmaceutical 
industry and conducted in public research institutions, have a high risk of conflicts of interests.  
Table 7: 2 Types of Science 
Components “Open science” “Commercial science” 
Actor Academic centres / public / private 
non for private 
Biotechnology “tools” companies 
“Niche” drug companies 
Major drug companies 
Clinical research organization 
Economic classification Mostly public  good, but increase 
use of science as a private good 
Mostly private good, increase use 
of public good production 
Origin and destination of the 
benefit 
“Communal” or public benefit 
granted by peers 
Private economic benefits granted 
by property rights 
Position in the innovation 
process 
Basic research 
             Market diffusion 
Locus of exchange Peers/Community Market 
Outputs used as a reward 
system  
Articles in peer review journals 
Award and recognition 
Patent & licensing 
 
Patent & licensing 
Financial returns on licensing 
New drug and devise marketed 
Adapted from Hollingsworth (Hollingsworth 2006, Hollingsworth 2007) 
 
Although this distinction is helpful to highlight the two main “arenas” of biomedical research, the 
lines between the academic and the commercial worlds are not as finely drawn. Indeed, a lot of 
commercial work is conducted in academic settings and vice-versa. For example, universities can 
now be granted patent rights and license products and pharmaceutical firms often conduct or fund 
open science research (see part 2.5). 
Evaluating Public “Open” science output and performance 
On the public end, or “open” side, two basic bibliometric variables are commonly used1: the 
number of journals published in peer-reviewed journals and the number of citation. The latter is at 
the origin of the “impact factor”, which is the average of number of citations per article published 
in the journal over a given year, commonly used to distinguish the quality of the journals. 
Bibliometric indicators have been shown to be sensitive to breakthrough research: they provide 
early signals of important advancement in biomedical research (Baudoin, 2004). To increase the 
specificity of the identification of “breakthrough” research, the proportion of articles published 
                                                 
1 The two variables serve as the basis for derived indicators such as the H index or the EingenfactorTM. 
Clinical trial  
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during a period in journals with a high impact factor (usually over 20) or the proportion of articles 
published amongst the top 1% of articles in terms of number of citations is appropriate (Baudoin, 
2004). However, the weakness of the use of citations is that the average number of citations 
within a journal (citation index) is higher in fundamental research journals (such as biology or 
genetics) than in applied research (cardiology, oncology). This weakness is a problem because 
breakthrough results are almost always reported in the latter. This limitation in part has motivated 
the creation of the EigenfactorTM indicator that weighs the citations of an article by adjusting for 
the prestige of the journal that cites it. It uses an iterative algorithm to weight citations (similar to 
the PageRank algorithm used for Google®), and it has been proposed as a more valid method for 
calculating the impact of journals (Fersht, 2009; Bergstrom, 2008). 
A handful of studies have compared biomedical research publications’ performance between 
countries or world regions. These studies rely on the number of articles published in biomedical 
journals as the measure of output and they conclude that production is heterogeneous and highly 
concentrated in rich and developed countries (Soteriades, Falagas 2005; Hausen, Reibnegger & 
Wachter, 1993; Hefler, Tempfer & Kainz, 1999).  
Awards and prizes are also considered public research outputs. In biomedical research, 
international prizes such as the Nobel Prize in medicine or the Lasker award, have been used to 
evaluate the production of biomedical research (Hollingsworth, 2006;Hollingsworth, 2007). 
Evaluating private science output and performance 
On the private side, innovation outputs comprise the number of patents and licenses, sales volume 
and revenue, change in clinical practise (prescription patterns of physicians) and financial returns 
on investment (Box, 2009; Lederman, 2005). The time between research and these commercial 
outputs has also been presented as a process indicator (Baudoin, 2004; Herzlinger, 2006; Hauser, 
2006). Industrial economics have been using the concept of New Molecular Entities (NME) to 
evaluate the output of the biomedical and pharmaceutical industry (Cockburn, 2004). NME drugs 
are real “breakthroughs” meaning that their active pharmacological substance is new and not a 
copy (“me-too”) or a by-product of an old substance.  
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Synthetic view of output and performance indicators 
Table 8 synthesizes the output indicators that can be used to evaluate performance of each stage to 
the biomedical research and innovation process. 
Table 8: Biomedical Research and Innovation Performance Related Output Indicators 
Stage Output  indicators 
Fundamental (basic) research  Number of peer review articles 
Number of citations 
Translational and clinical 
(applied) research 
 
Number of peer review articles 
Number of citations 
Number of patents and licenses contracted 
Diffusion innovation in the 
market 
 
Financials returns on licences 
Volume of products sold 
Change clinical practice patterns 
New molecular entities (NME) 
Performance Variables used in the Study 
The construction of the appropriate variable of country level biomedical research performance is a 
major challenge, in part because of the difficulty in evaluating the “break-through-ness” of 
innovations. For our study several options concerning the “output” part of the performance 
variable were considered: 
The number of Nobel prizes in Medicine, although very good estimators of breakthrough 
research, have been used already in related studies (Hollingsworth, 2006). However, it presents 
two weaknesses. First, it was too selective (a handful of countries have been recipients of a Nobel 
Prize in Medicine since 1907). Second, the time between the bulk of research conducted by the 
recipient and the prize attribution was considered too long (up to 30 years). This delay would have 
been a problem for the cross-temporal analysis. 
The amount of national funding awarded through competitive grants (such National Institutes of 
Health in the USA or French National Cancer Institute) could also be a measure of high quality 
innovative research. However, not all countries use this funding process and fewer have reliable 
data bases. Furthermore, these funds cannot be considered as an output variable because the 
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results are not yet known. Consequently, this measure was not was not considered an appropriate 
metric for this global study.  
The number of patents was another candidate. The right it grants to commercially exploit, in a 
monopolistic way, an innovation makes a patent an economic reward for innovation. However, it 
presented two limitations: (1) it does not measure effectively the “break-through-ness” of the 
innovation (a patent is granted without regards to the quality of the innovation) (Box, 2009) and 
(2) it is impossible to specifically identify patents that are biomedical. In our study, however, we 
analyse the association of our performance measure and patents granted (per capita) to check if 
our performance indicator (publication per capita) also captures private sector performance (see 
part 2 of this chapter). 
Ultimately, we decided to measure a country’s performance using the number of publications its 
research teams have published in top biomedical journals over a given period of time (one year) 
and dividing it by the population of the country. We will refer to it as “publications per capita”. 
Three main arguments support this decision:  
First, research articles are the “purest” and most proximal output in the innovation process even if 
some research articles may be ‘placed’ or ghost written (Flanagin et al, 1998; Phillips, Carey, 
1999). It can be presumed that they have been less distorted by market mechanism and business 
tactics, such as commercial agreements, advertisement, lobbying or marketing that would appear 
for example on sales or financial return figures. In particular, the authorship rules within open 
science are not distorted by commercial mechanisms (such as licensing agreements between 
pharmaceutical firms). It is then possible to identify the origin of the study. This identification 
would not have been the case for other indicators such as “New Molecular Entities” where the 
original innovator is very complicated to identify (for example a pharmaceutical company may 
acquire, through external growth, the license for a new drug developed by a small biotechnology 
firm from another country and market it). 
Second, this variable is accessible: it is possible to identify precisely the publication production 
within a country by using databases such as ISI Web of Science®. 
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Third, previous research has already used the number of publications (per capita) as the variable 
to measure national biomedical research productivity or worldwide geography (Soteriades, 
Falagas, 2005).  
The rules that govern the biomedical scientific enterprise make bibliometric indicators a natural 
evaluation metric of public science. However, about 8% of highly cited papers in Essential 
Science Indicators from Thomson Reuters have at least one author with corporate affiliations, that 
is, authors who work for a private company or corporation as opposed to a university or other 
“public” research institution (Thomson Reuters, 2009). By collaborating with academic research 
centres pharmaceutical companies get closer to the sources of innovation (Danner 2008). The 
following tables illustrate how the performance of each stage of the innovation process is captured 
by publication per capita. 
Table 9: How Publications per capita Captures the Performance of the 3 Stages of Research 
 
Although we anticipate that our performance variable is not the best suited to measure the private 
sectors’ performance within a given country (the private sector is major actor in the stages of 
applied research and diffusion in the market and therefore needs to be accounted for in our study) 
we will however, check that publications per capita also captures part of it. We will do this by 
analyzing the association between publications per capita and patents per capita at the country 
level. 
B. Governance 
“Governance” is the most commonly occurring construct family in the literature review (38.6% of 
the documents selected). This section will explore the concept of governance and examine how 
previous research has analyzed the impact of governance on research. 
Stage of research Performance captured by publications per 
capita 
Basic or fundamental research / public science Highest 
Applied research (clinical trials) Medium 
Diffusion in the market / (private science) Lowest 
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Conceptual outlook and cross-sectional evidence 
The major underlying hypothesis of this dissertation is that there exists a crucial link between 
political governance and biomedical research performance. This issue has been framed differently 
by each scientific discipline. 
The concept of governance in political science 
The concept of “governance” has emerged in the last decades as a key construct in political 
science. Indeed, the concept of the political structure is moving away from the classic concept of 
“Nation State” (“government” or “separation of powers”) to a more dynamic and open approach 
of “Governance” (Duit, 2008; Hirst, 1995). Politics is played less in the traditional realms of 
official public institution, such as the executive, legislative or judicial branch of government but is 
more dependent upon a larger “civil sector” that includes the private business sector, NGOs and 
the media (Rhodes, 1996; Kaufmann, Kraay & Pablo Zoido Lobatón, 1999). 
Politics and science 
Some influential academic sociologists have argued that any intellectual enterprise dedicated to 
discovering a “law of nature” or “truth” is socially constructed (Merton, 1957, Pinch, 1984). 
Scientific facts, no matter how objective, are at some point negotiated. Amongst broad socio-
cultural factors, it can be assumed that the construction of knowledge, largely determined within 
the political game, is a process by which is determined who gets what where and when. While this 
assumption is true for science in general, it is probably even more important in the biomedical 
sector because it deals directly with the human condition. Indeed, the ethics that surround 
biomedical research like no other research field is a clear signal that values and politics are 
involved. Jasanoff posits that differences in national research policies lead in a predictable way to 
different scientific priorities and methods (Jasanoff, 2005). 
The dynamics of science and politics is recursive: while political structures have a fundamental 
role in shaping scientific findings, science in turn shapes them. Robert Merton, for example, has 
illustrated the co-evolution of the democratisation process and scientific enterprise in England in 
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the 17th century focusing on the “Protestant Ethic” as a causal factor (George Becker Sociological 
Forum, 1992).  
Quantitative evidence: National level governance and innovation performance 
Three recent reports from the World Bank, Organisation for Economic Co-operation and 
Development (OECD) and the Rand Corporation have pointed out the specific role of national 
political “governance” on innovation (Box, 2009; Lederman, 2005). The only quantitative 
evidence comes from the World Bank study. Leiderman has shown that the “rule of law”, an 
important governance indicator, and the number of patents per population are associated.  
Shane examined the per capita number of invention patents granted to nationals of 33 countries in 
1967, 1971, 1976, and 1980 and compared it with an index of power distance within the society 
(social hierarchy) and individualism, two governance related dimensions. The data originated 
form from a survey of 88,000 employees at IBM. The results showed that individualistic and non-
hierarchical societies are more inventive than other societies (Shane, 1992). 
Within the biomedical sector, Hollingsworth has studied the link between the environment of 
biomedical research and major “breakthrough” discoveries as awarded by the Nobel Prizes in 
medicine and chemistry and the Lasker award (Hollingsworth, 2006). He describes 4 levels within 
the environment (from top to bottom: the institutional, the research organisation, the department 
or institutes and the laboratories) that promote major biomedical discoveries. Depending on the 
country, the environment may exert weak or strong influence upon (1) the appointment of 
scientific personnel of research organizations, (2) in determining whether a particular scientific 
discipline will exist in a research organization, (3) the level of funding for research organizations, 
(4) in prescribing the level of training necessary for a scientific appointment, and (5) scientific 
entrepreneurship (e.g., the existence of norms that incite young people to undertake high-risk 
research) (Hollingsworth, 2006). This view is strongly related to the concept of governance 
because it depicts the power relationships between actors at the “top” (such as government, 
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regulators, funders or big pharmaceutical companies1) and actors at the “bottom” (laboratories, 
departments or research organizations), a common theme in political science and a major issue in 
our concept of governance. Hollingsworth finds that major discoveries emerge in weak 
environments; meaning by that that top-down authority is limited and that organizations have 
freedom to evolve. One of his hypotheses is that strong environments create “look-alike” 
isomorphic organizations which in turn reduce the probability of radical innovation. Using this 
theory, Hollingsworth explains how the bureaucratization of science has led the leading centre of 
biomedical research to migrate from France (end of the 18th century), to Germany (19th century) 
to the UK (until the Second World War) and finally to the USA. France is a good example having 
created a large biomedical research agency (INSERM, Institut National de la Santé et de la 
Recherche Médicale) whose researchers have been fully salaried and who have practically no 
need to participate in the search of competitive research grants. 
Economic governance of the biomedical and pharmaceutical industry 
The efficiency of resource utilization depends on the appropriateness of the market structure that 
is determined by economic governance, i.e. the set of rules that regulates market actor behaviours. 
The implication for the biomedical and pharmaceutical industry will be discussed in the following 
subchapter (“economic resources”).  
Management: governance at the firm level 
Analysing governance through a management frame is relevant because management is a key 
element in the production and transfer of knowledge. Efficient management structures make for 
more effective and more rapid utilization of research and innovation.  
Management studies look at governance related issues at the level of a firm. In a highly cited and 
comprehensive management review, Hauser identifies 5 areas for focus in innovation 
management research: (1) Consumer response to innovation (2) Organization and innovation (3) 
Strategic market entry (4) Product development and (5) Outcomes from innovations (Hauser, 
                                                 
1 Big pharmaceutical companies may have revenues at the level of the GDP of medium size countries. For 
example, Pfizer’s revenue (50 billions US$) equals Serbia GPD, rank as 69th country on 182 countries 
ranked by the World Bank.  
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2006). The second category explores the contextual and structural drivers of innovation and, the 
way the drivers should be organized. Hauser points out that organizations with project-matrix 
organizational forms, cross-function teams, cross boundary management (with supplier, clients or 
competitor) and organizational commitment perform favourably in regards to innovation. 
Woodman proposes a model that conceptualizes the social context in which creativity drives 
innovation at three levels: the individual, the group and the organisation. At the group and 
organizational level, creativity is optimal when the group is managed in a democratic and 
collaborative way (Woodman, 1993). 
Governance and biomedical science 
The struggle between politics and biomedical science takes on field-specific aspects. As we 
explore below, financial conflicts of interests and private capture of science, government intrusion 
and political capture of science, political struggles on biomedical research priorities, acceptability 
of evidence based medicine and ethical dilemmas in human subject research are all flash points in 
the politics of biomedical research.  
The commercialization of biomedical science (i.e. the increasing role of business thinking in the 
conduct of science) is an observed trend (Johns, 2003). One apparent consequence is the 
emergence of financial conflicts of interests between actors conducting research and those funding 
it, in particular concerning clinical trials. Bekelman has shown an important and statistically 
significant association between industry sponsorship and pro-industry clinical trial conclusions. 
Industry sponsorship was also associated with restrictions on publication and data sharing 
(Bekelman, 2003). One straightforward reason for the possibility of serious conflicts of interest is 
the power of pharmaceutical companies. Some have revenues that equate the GDP of a mid-size 
country. For example, Pfizer’s annual revenue (50 billions US dollars) equals Serbia’s GPD, 
ranked as the 69th country out of 182 countries (World Bank, 2010). 
Industry, academic actors’ and regulators’ relationships can be improved in different ways such as 
disclosing financial conflicts of interest, creating boundary organizations that allow political-
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scientific negotiation (such of the Office of Technological Transfer at the NIH) and restricting 
personal interactions between stakeholders (Guston, 1999;Bekelman, 2003;Rest, Halpern, 2007). 
Biomedical science can be captured as well by governments and be used as a political asset. This 
governmental intrusion may undermine, in the long run, the independence of scientific research 
and ultimately its quality. This capture may take several forms such as misusing of scientific 
evidence, controlling federal scientists, limiting public access to information or interfering with 
the scientific process (Rest, Halpern 2007). 
Biomedical research prioritization is another zone of friction between science and politics 
(Callahan, 1999; Resnik, 2001). The strong participation of biomedical scientists in the politics of 
biomedical research, in particular in the funding process, illustrates well this issue (Pollard, 2001). 
Several governance mechanisms have been used: top down needs driven, bottom-up curiosity 
driven and increased public participation, each having their own pros and cons (Shergold, Grant 
2008; Rest, Halpern, 2007; Delaney, 2006; Epstein, 1995). 
Evidence Based Medicine is a zone where the social order—political negotiated structures—
meets the scientific order –claiming objective decision making (Mykhalovskiy, 2004). Scientific 
facts can be analyzed and interpreted differently depending upon the socio-political environment, 
composed of actors such as patient advocacy groups, pharmaceutical lobbyists or medical 
associations. A recent evaluation of a European cross-national network on the development of 
clinical guidelines pointed that local culture can explain why identical scientific evidence can be 
transformed into different practise guidelines (Collaboration on Cancer Clinical Practice 
Guidelines, 2009).  
Ethical issues on biomedical research, in particular concerning human subjects’ research, are also 
a sign of struggle between politics and science. Page reminds us that the “dilemma lies between 
the potential harm to individuals who participate in research and the knowledge to be gained from 
the research study that might benefit society” (Page, 2004). The role of consensus making 
boundary organisation, such as Institutional Review Boards (IRB), are crucial in this grey zone 
(Kelly, 2003) 
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Variable used in the study 
Since 1996, the World Bank has developed and used indicators to measure how nations function 
as democracies (World Bank, 2010). One of the initial objectives was to track and fight corruption 
amongst countries receiving the Bank’s loans and funds. These measures have evolved into a 
broader concept called “Governance” which is to date the most comprehensive indicator of 
political governance. 
The definition of governance given by the scholars that have constructed it is the following: 
“Governance can be broadly defined as the traditions and institutions by which authority in a 
country is exercised. This includes the process by which governments are selected, monitored 
and replaced; the capacity of the government to effectively formulate and implement sound 
policies; and the respect of citizens and the state for the institutions that govern economic and 
social interactions among them” (Kaufmann, 1999; 2008)  
Governance comprises 6 quantitative indicators that represent 6 attributes of their definition 
of governance (Kaufmann, 1999; 2008): 
1. Voice and Accountability (VA): measures perceptions of the extent to which a country's 
citizens are able to participate in selecting their government, as well as freedom of expression, 
freedom of association, and a free media. 
2. Political Stability and Absence of Violence (PV): measures perceptions of the likelihood that 
the government will be destabilized or overthrown by unconstitutional or violent means, including 
politically-motivated violence and terrorism. 
3. Government Effectiveness (GE): measures perceptions of the quality of public services, the 
quality of the civil service and the degree of its independence from political pressures, the quality 
of policy formulation and implementation, and the credibility of the government's commitment to 
such policies. 
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4. Regulatory Quality (RQ): measures perceptions of the ability of the government to formulate 
and implement sound policies and regulations that permit and promote private sector 
development. 
5. Rule of Law (RL): measures perceptions of the extent to which agents have confidence in and 
abide by the rules of society, and in particular the quality of contract enforcement, property rights, 
the police, and the courts, as well as the likelihood of crime and violence. 
6. Control of Corruption (CC): measures perceptions of the extent to which public power is 
exercised for private gain, including both petty and grand forms of corruption, as well as 
"capture" of the state by elites and private interests. 
To calculate the value of each of these indicators, the World Bank identifies different sources of 
data that can be assigned to these six broad categories (for example data from organizations such 
as Transparency International). These sources can be “de jure” surveys – expert opinion that the 
governance structure and “de facto” – citizen opinion on the democratic outcome of the 
governance structure. The indicators are weighted averages of the underlying data, with weights 
reflecting the precision of the individual data sources. The World Bank acknowledges that the 
method generates margins of error for the estimates of governance for each country, which need 
to be taken into account when making comparisons of governance across countries and over time. 
Each of the 6 indicators is reported by the World Bank for each country every year since 1996 
(expect 1997, 1999 and 2002). The data are available for free download on their website 
www.worldbank.org and data was acquired for every year available since 1996. Data examples 
are shown in Appendix 3. 
For the purpose of our study, we will construct a “global governance”, that is the sum of the 
values of the 6 indicators (see Methods chapter). The literature review having suggested that the 
Governance concept appears to have a great effect on innovation, we will draw from this our 
research hypothesis. 
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C. Economic resources  
”Economic resources” is the second most commonly occurring construct family in the literature 
review (19.7% of the documents selected). The economic literature has produced the majority of 
theories, empirical evidence, and policy prescriptions on the role of economic resources on 
innovation but also the majority of quantitative studies.  
The predominant focus of research in economics has been related to neoclassic micro-economic 
framework, where the State’s role is predominately to correct market failures and thus to maintain 
Pareto-optimal market equilibrium, maximizing at the same time social and private benefits. 
Macro-economic stability is also a positive factor in innovation (Box, 2009).  
Neo-classic micro economic approach  
The neoclassical economics -“orthodox economics”- has constructed their recommendations 
around three policies to correct market failures and efficiently allocate resources (Box, 2009): 
strong public investment in R&D to fund research too risky too be undertaken by private firms 
(Moses et al, 2005; Philipson, 2005; Cech, 2005); assuring the right to claim economic return on 
innovation by granting intellectual propriety rights (Folland, Goodman & Stano, 2003; Cockburn, 
2004) ; assuring competition (when transaction cost are do not outweigh the benefit of 
competition) (Cockburn, 2004; Herzlinger, 2006). When these factors are in place, prices become 
appropriate signals of exchange between actors (Cockburn, 2004). 
Access to capital: Funding R&D  
Conceptual outlook 
The first type of market failure relates to a sort of temporal information asymmetry: at the start of 
the innovation process, the outcomes are highly uncertain (especially in their early stages of 
fundamental research). This uncertainty limits the opportunity for firms to raise funding for 
research and development on the private capital market. When access to capital is crucial, public 
funds need to increase. The target of 3% of GDP set by the European Union in 2000 to its 
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member is an example; however only Finland and Sweden attained this goal in 2005 (OECD, 
2010).  
The ability to convert capital to labour also explains why the scientist pipeline is also an economic 
resource concern (Ley, Rosenberg, 2005). In Europe “Brain drain” is seen as a problem, a fair 
number of EU students cross the Atlantic to pursue doctoral degrees or post-doctoral work in the 
United States. The USA has been able to maintain a steady increase in the number of PhDs by 
benefiting from this migration (Cech, 2005). 
Quantitative evidence in the biomedical sector 
The level of national R&D funding has been used by a handful of worldwide quantitative studies 
in the biomedical sector. Soteriades explained that the number of journals published in the top 50 
biomedical journals in a country could be explained by the population size, the gross domestic 
product, the gross national income per capita and the percentage of GDP spent on R&D and the 
number of researchers (Soteriades et al, 2006). 
Rahman and colleagues have shown, using a univariate analysis, that the percentage of GDP 
allocated to R&D, the number of researchers and PhD students are correlated with the number of 
biomedical articles published by a country. When multiple independent variables were included in 
the linear regression model, the percentage of GDP invested in R&D remained significant at the 
p=0.05 level (along with the GDP per capita) while the number of research and PhD students drop 
out of the model (Rahman, Fukui, 2003). These findings are confirmed by the same author within 
Asian countries (Rahman, Fukui, 2001) and by Man who found that national spending on R&D 
and English proficiency is approximately 71.5% of the variation in biomedical publications rate 
across developed nations around the world (p < 0.01) (Man et al, 2004). 
Variable included in the study 
For the purpose of our study, we will include the percentage GDP invested in R&D as an 
independent variable with the assumption that it is a correct approximation of capital and labour 
investment in R&D. Indeed, based on Rahman’s study (Rahman, Fukui, 2003), we make the 
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hypothesis that the number of PhD or researchers is captured by the percentage of GDP invested 
in R&D. 
Market rewards of innovation 
Conceptual outlook 
The second market failure, knowledge spill over (positive “externality” in micro-economics) 
explains why investment will be less than socially optimal because individual innovators do not 
recoup a fair share of private returns due to knowledge transfer (Box, 2009). Property rights, by 
granting the ability to own, control, and transfer property, is a fundamental aspect of market 
economies. Without these rights, people will overuse shared resources, phenomena explained by 
the "tragedy of the commons" metaphor.  
Evidence in the biomedical sector 
The role of propriety rights within the biomedical industry has been demonstrated as beneficial 
(Cockburn, 2004). However, Heller (1998) suggests the opposite  
“...the recent proliferation of intellectual property rights in biomedical research suggests a 
different tragedy, an "anticommons" in which people underuse scarce resources because too many 
owners can block each other. Privatization of biomedical research must be more carefully 
deployed to sustain both upstream research and downstream product development. Otherwise, 
more intellectual property rights may lead paradoxically to fewer useful products for improving 
human health” (Heller, 1998). 
Variable used in the study 
The number of overall patents awarded to a country (including but not limited to, patents granted 
for biomedical innovation) divided by the population will be introduced as a proxy for the private 
sector innovation performance of the country. We will use a mix database source from OCDE and 
UNESCO. 
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Degree of market competition and transaction cost 
Conceptual outlook and cross sectional evidence 
The efficiency of economic resources utilization is dependent upon market structure. For 
neoclassic economics, a perfect structure includes pure competition, optimal exchange and 
resources allocation. However, in “non ideal” conditions (market failures), the market does not 
have optimal allocation and exchange mechanisms (Rice, 2002). Transaction cost economics 
posits that if transaction costs are too high in a specific area of economic exchange, such as 
between two firms (due to “bounded rationality” for example, where there are specific 
information limits to certain exchanges), internal transactions with a firm are more efficient than 
market exchanges. This common problem is encapsulated in the question posed by many firms to 
“make” or “buy” a certain activity. The trade-off between competition and integration is 
applicable to the biomedical industry (Cockburn, 2004) (Folland, Goodman & Stano, 2003). 
When transaction costs are low between actors (for example between a big pharmaceutical 
companies and an academic centres), market competition efficiently allocates resources. When 
transaction costs are high, internal firm integration is more efficient.  
If competition is needed more than integration, then assuring a swift transition to market 
competition is the third role of governments. This assurance may be done, for example, by issuing 
anti-monopoly laws to reduce inefficient rent situations, regulating contractual content, assuring 
information flow and protecting property rights to assure that innovators are financially rewarded 
(Cockburn, 2004; Folland, Goodman & Stano, 2003). 
The following figure (adapted from Box, 2009) illustrates the theory that the degree of market 
competition has an impact on the intensity of innovation in a recursive way. On the left of the 
optimal point, positions tending toward monopoly reduce innovation. On the right, the number of 
firms is too high and resources are wasted in defensive strategies or transaction costs. Such a 
mechanism has been identified within the biomedical sector where the recent vertical 
disintegration (with the rise of intermediary firms such as the biotechnology tools companies) has 
led to increased drug development cost (Cockburn, 2004). 
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Figure 2: Competition and Innovation Intensity 
 
 
 
 
 
 
Variable used in the study 
Several economic indicators measure the degree of competition, such as the Herfindahl-
Hirschman Index (Folland, Goodman & Stano, 2003). However, they relate only to the number of 
competitors in a market and do not fit well with a global comparison. To capture the quality of the 
market structure, we choose to rely upon one of the 6 World Bank governance variables: 
“regulatory quality” (see part 2.2 for the definition). De facto, this indicator will be included in the 
global governance variable that we will construct. 
Providing an appropriate macroeconomic environment 
Conceptual outlook 
A healthy internal macroeconomic framework -such as GDP growth, fiscal discipline, low 
inflation-, has been shown to improve innovation outcomes (Box, 2009). 
Quantitative evidence in the biomedical sector 
The use of the level of GDP per capita has been used by a handful of worldwide quantitative 
studies in the biomedical sector. Soteriades uses GPD per capita to explain differences in 
publications of different countries in the top 50 biomedical journals (Soteriades et al, 2006). 
Rahman has shown using a univariate analysis that the percentage of GDP per capita was 
correlated with the number of biomedical articles published by a country. When multiple 
covariates were included in the multivariate linear regression model, only the GPD per capita 
(along with the percentage of GDP allocated to R&D) remained significant at the p=0.05 level 
Degree of competition 
Intensity of innovation 
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(Rahman, Fukui, 2003). These findings are confirmed by the same author within Asian countries 
(Rahman, Fukui, 2001). Uthman found that in Africa the most populous and rich countries 
(evaluated by GDP per capita) have correspondingly higher research production (Uthman& 
Uthman, 2007). 
Variable used in our study 
The Gross National Income (GNI) per capita at purchasing parity power (PPP1) for a given year 
seemed the most appropriate World Bank macro-economic indicator for our study because it 
captures resources created specifically within the country (“national”) whatever the citizenship of 
the entity that produces. This perspective fits well with the concept of national governance. 
Furthermore, the PPP improves the comparativeness of the countries. 
Openness to international trade  
Conceptual outlook & Evidence 
A country’s innovation performance is related to the international exposure of its economy. 
Knowledge spill-overs occur within economic channels. Drivers of openness are the magnitude of 
foreign direct investment commonly assessed by the share of import/export activity (valued as 
percent of GDP) within the economy, the mobility of workers, or the degree of international 
collaboration in research and innovation (Box, 2009) (COE, 1995).  
Variable used in our study 
For the purpose of our study, openness to international trade will be captured by the economic 
value of the merchandise imported and exported as a percentage of GDP for a given year and 
included as an independent variable.  
D. Human Resources  
”Human resources” is the fourth most commonly occurring construct family in the literature 
review (12.1% of the documents selected). This section will explore the principal findings of the 
literature review. 
                                                 
1
 Parity Purchasing Power allows comparing national at similar purchasing power. The indicator we used is 
the standard indicator of the World Bank. 
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Conceptual outlook  
The part C of this chapter has stressed the link between the “volume” of human resources 
dedicated to biomedical research and its performance. Indeed, at the national level, Rahman 
demonstrated that the number of researchers is correlated with biomedical research publication 
after adjustment for population (Rahman, Fukui, 2003). Besides the importance of the “volume” 
of human resources, other characteristics impact research and innovation performance. These 
characteristics will be the focus of this section. 
In strategic management discipline, the Resource Based View (RBV) theory proposes a strong 
alternative to the strategic positioning school (Hoskisson, 1999). It stresses that competitive 
advantage is not only due to the position of a firm product within a market (such as niche, low 
cost or quality differentiation) but on the capabilities of the organization (human resource assets 
such as competence and practises). In line with the RBV perspective, this literature review has 
pointed out the importance of three aspects of human resources (diversity, individual 
characteristics and connectivity) to foster innovation.  
The US National Academies devoted an entire report to the benefits of organizational diversity in 
terms of interdisciplinarity of research (Committee on Facilitating Interdisciplinary Research, 
2005). Additionally, facilitating diversity and communication within informal social networks, 
either inside or outside the organization, is fundamental for innovation performance (Allen, James 
& Gamlen, 2007; Mote, 2005).  
The characteristics of the individual engaged in research have also been pointed out as a driver of 
innovation. Woodman, in developing a theory of organizational creativity, described as a subset 
organizational innovation theory, identifies five distinctive inputs of individual creativity: 
antecedent conditions, cognitive styles and abilities, personality, motivational factors, and 
knowledge (Woodman, 1993). These are micro level metrics and will not be used in this analysis 
Finally, information and communication sciences have emphasized the central role of ICTs in 
transforming diversity into collective intelligence able to innovate and accede to a competitive 
advantage position (Mata, 1995; Hevner, 2004). 
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Evidence within the biomedical sector 
Recognition of major biomedical discoveries (Lasker awards or Nobel prizes) are more likely to 
occur in organizations with a moderately high degree of scientific diversity and a high level of 
communication (connectivity) among scientists (Hollingsworth, 2006). The following figure 
summarizes this point. 
Figure 3: Scientific Diversity and Integration (adapted from Hollingsworth, 2006). 
Research conducted by Man (2004) suggests that research funding (the percentage of GDP 
invested in R&D) and English proficiency may be important determinants of national publication 
performance in high ranked journals. Man relies on the average TOEFL (Test of English as a 
Foreign Language) scores of all the candidates for each country to evaluate proficiency. These 
two variables explained approximately 71.5% (p < 0.01) of the variation in publication rates 
across developed nations around the world (Man et al, 2004). 
Variables used in the study 
At the national level, diversity will be captured by the ratio of the number of immigrants relative 
to the population per year. Connectivity has already been captured by the international trade 
variable. However, we will add the number of households that have access to the Internet as a 
variable measuring connectivity. For each country, the average national TOEFL scores of the 
candidates will be used as surrogate for English proficiency. 
Scientific diversity 
Level of 
communication 
and social 
integration 
High 
Low High 
Major discoveries 
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E. Critical Mass  
“Critical mass” is the least occurring construct family in the literature review (11.4% of the 
documents selected). This section will explore the principal findings of the literature review. 
Concept and cross-sectional evidence 
The core idea of “critical mass” is that the concentration or volume of resources (human, 
economic, legal, social…) has an impact on the productivity of research and innovation (measured 
as output for a given level of resources).  
The field of economics has long expressed the importance of economies of scale: as the 
concentration of productive assets increase, the cost per output decreases. For example, in the 
biomedical sector, major drug companies achieve economies of scale when they are able to 
concentrate costly R&D activities. In turn, research productivity rises (Kaplan, 2010).   
More recently, urban and geographical studies have proposed a more integrated approach to 
“critical mass” by mixing different perspectives such as economics, sociology and political 
science. Within a concentrated “eco-system”, for example a city or a region, innovation 
productivity increases in part due to important knowledge spillovers (Consoli, 2009; Lambooy, 
2005). This “systemic approach” is in line with recent understanding of the innovation dynamics 
that departs from the classic “process approach” in which innovation is considered as a linear 
process, driven by fundamental research (Box, 2009; Dodgson, 2000; Bush, 1945). 
A major concept is named “spatial clustering”, commonly referred to as a “cluster”. In a cluster, 
spatial agglomeration enhances innovation through several mechanisms: reduced costs of 
infrastructure, availability of talent and skilled labour force, availability of financial resources, 
mobility and appropriate population density, swift communications and transaction efficiency, 
knowledge spill-overs and the existence of supportive institutions (Malmberg, 2002; Moses et al, 
2005). Examples of scientifically and commercially innovative and attractive clusters fascinate 
politicians and businessmen, and are now a part of many urban planning projects. The Silicon 
Valley in California, the Research Triangle in North Carolina, or more recently the Biotechnology 
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cluster in San Diego are well-known examples. In fact, these cores can either be created de novo 
(such as the Research Triangle) whereas others grew spontaneously (such as the Silicon Valley). 
In industries where innovation is important, knowledge spill-overs (in the forms of industry R&D, 
university research, and skilled labour) increase the propensity for innovative activities within the 
clusters (Audretsch, 1996). 
A cluster allows small innovative organizations to benefit individually from a critical mass of 
resources necessary to innovate as if they were a large organization (such as better access to 
employees and suppliers, access to specialized information, access to sophisticated buyers, 
activity complementarities, access to public institutions and goods, and better motivation and 
measurement) without damaging their flexibility (Porter, 1998). Furthermore, clusters promote 
competition and cooperation at the same time – both relevant in terms of innovation. 
Within clusters, economies of scope have also been pointed out as a possible productivity increase 
mechanism. For example, European clusters tend to be specialized in a therapeutic field and stage 
of research (fundamental or applied). On the contrary, US clusters have a higher level of 
therapeutic and research stage integration. However, the literature remains inconclusive on the 
benefits of economies of scale (Owen-Smith, 2002). 
Attali (2009) has described an historical pattern of 7 successive world “cores” –cities that obtain a 
critical mass to dominate the world in all matters – culturally, financially, commercially, 
scientifically and technologically1. Access to capital, talent, individualism, entrepreneurial spirit, 
freedom, diversity, openness to trade, intellectual freedom, innovation sensitive consumers, and a 
State that guaranties individual economic benefit for individual risk and labour are factors of the 
emergence and decline of these cores.  
The effect of size and density of a country within the biomedical search has been studied in Africa 
by Uthman. He found that the more populous and richer countries (such as South Africa, Egypt, 
                                                 
1
 He argues that cores have emerged in the Mediterranean Basin (Venice, Genoa), continuing into the 
eastern part of the Atlantic (Bruges, London, Anvers),, moving on to the West coast of the Atlantic (New 
York, Boston) and finally establishing today in Los Angeles. He predicts San Diego to be the next “core”. 
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and Nigeria) have higher biomedical research publication (Uthman, 2007). Smaller countries can 
be productive, although the study does not anticipate the role of density.  
Variables used in the study 
Geographic studies confirm the need to capture a broad set of constructs. Some of them have 
already been identified: diversity, connectivity, and access to capital. In addition, “critical mass” 
has emerged as a fundamental construct family. This family will be captured per year by two 
variables: “population” (the national population) and “density” (the national population divided 
by the country’s surface). These variables will capture the critical mass related to the structural 
attributes of the national environment and help to adjust the performance of a country based on its 
size.  
F. Actors and their behaviour 
“Actors and their behaviour” is the third most commonly occurring construct family in the 
literature review (18.2% of the documents selected). The idea behind this construct family is to 
understand how the actors’ (or stakeholders’) behaviours impact research and innovation 
performance. Actors include: academic centres, public/private not for private research centres, 
biotechnology “tools1” companies, “niche” drug companies, major drug or medical equipment 
companies, clinical research organization, research funders, public and private health insurance, 
pharmaceutical benefit manager firms, regulators and patients (see part 2.2 of this chapter). This 
section will explore the principal findings. 
 Concept outlook and cross-sectional evidence 
Management studies have brought about a greater understanding of the behaviours, decisions and 
actions of stakeholders, which makes the diffusion of innovation possible. Within the biomedical 
sector, these actors fall in to two categories: supply (such as academic research centres, 
biotechnology firms, and pharmaceutical companies) and demand (patients and insurance 
                                                 
1
 From genetic sequencing to data analysis companies 
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companies). In addition, regulators and funders also have behaviours which impact research and 
innovation performance (Mintrom, 1997).  
Hauser defines innovation as “the process of bringing new products and services to the market” 
(Hauser, 2006). Hauser identifies 5 focal areas of innovation management research: (1) consumer 
response to innovation; (2) organization and innovation; (3) strategic market entry; (4) product 
development; (5) outcomes from innovations (Hauser, 2006). This classification provides a 
valuable framework for this sub-chapter. Area 1 relates to the demand side whereas areas 2 to 5 
relate to the supply side. It can be noticed that areas 2 and 5 have also been addressed in the 
“governance”, “evaluation” and “economic resources” subchapters. 
Area 1 focuses on two distinctive features that impact the diffusion of innovation: the 
consumer/client/customer behaviour towards innovation (level of “consumer innovativeness”) and 
the specific characteristics of the product (such as simplicity of use or testability). An emerging 
research stream in marketing (the Technological Acceptance Model) combines these two 
approaches to understand the appropriation of technology by customers and its impact on the 
diffusion of innovation (Science Watch, 2009). Aligned with this area, the Disruptive Innovation 
Theory posits future innovation will be cost-reducing technologies within an innovative business 
model that delivers increasingly affordable and accessible products and services. This theory has 
been applied to health care (Hwang, 2008; Smith, 2007; Christensen, 2009; Immelt, 2009). 
Area 2 focuses on contextual and structural drivers of innovation and the way they are organized. 
Hollingsworth identifies 5 characteristics of organizational contexts facilitating major biomedical 
discoveries: (1) Moderately high scientific diversity in research teams; (2) Capacity to recruit 
scientists who internalize scientific diversity; (3) Communication and social integration among 
scientists from different fields through frequent and intense interaction; (4) Leaders who integrate 
scientific diversity, have the capacity to understand the direction in which scientific research is 
moving, provide rigorous criticism in a nurturing environment, have a strategic vision for 
integrating diverse areas, and have the ability to secure funding to achieve organizational goals; 
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(5) Flexibility and autonomy associated with loose coupling with the institutional environment 
(Hollingsworth, 2007).  
The third area focuses on the technological evolution and rivalry between firms, the project 
portfolio management and the strategies for entry. In the pharmaceutical industry, bad corporate 
strategic practices, such as mergers, reliance on blockbuster drugs and fast growth, and the shift of 
control of research from scientist to marketers, have discouraged innovation and caused a 
reduction in productivity (Cuatrecasas, 2006). In the academic medical centres sector, 
organizational transformation is needed to cope with strong external constraints such as reduction 
in public research funding (Kirch et al, 2005). Securing financial resources has become 
fundamental in order to sustain their mission and development (Kirch et al, 2005;Paller, Cerra, 
2006; Mallon, 2006; Mallon, 2005;Campbell, 2009). 
The forth area focuses mainly on four topics: product development processes, the “fuzzy front 
end”, design tools and innovation testing and evaluation. One major idea here is “time to market”; 
firms not only need to innovate but need to do it before competitors. In the biomedical sector, the 
increasing time to market has been identified as a major issue (Cockburn, 2004). 
Finally, the fifth area looks at internal rewards and market rewards. In the biomedical sector, a 
proper balance between academic (public) and commercial (private) sector incentives is needed 
(Dasgupta, 1994; Cohen, Siegel, 2005). 
Variables used in the study 
These studies confirm the need to capture a broad set of constructs related to the behaviours of the 
biomedical innovation actors. In addition to the variables already identified, the behaviour of the 
supply side (strategy, speed and organization to bring innovations to the market) and the decisive 
role of the patient/consumer are relevant constructs to be included in this construct family. We 
will use the “percentage of households with internet connection” to globally capture the fit 
between the supply and the demand in regards to technological innovation. This variable has also 
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been identified as an appropriate variable of the connectivity construct (see part E “human 
resources”).  
G. Methodological issues concerning the study of research and innovation 
Besides identifying appropriate constructs and variables, the literature review was useful to 
identify methodological issues concerning the study of research and innovation. 
Accounting for time 
The importance of accounting for time has been stressed in sociology and evolutionary 
economics1 among researchers studying innovation. Time relates to two major proprieties of 
innovation: “path-dependency” (current knowledge, decisions and actions are dependant upon 
past knowledge, decisions and actions) and bounded rationality (actors engage in a research 
project although the outcomes are uncertain. Time reduces uncertainty. The figure below 
illustrates these two proprieties.  
Figure 4: Time, Knowledge and Uncertainty 
 
 
 
 
 
Consoli defines the temporal dynamics of innovation as “pathways of innovation” (Consoli, 
2009). The importance of integrating time will be done by analyzing data in linear way, from 
1996 to 2008. 
                                                 
1
 With the new economic trends (behavioural economics, institutional economics,), evolutionary economics 
seems to have the potential to provide an appropriate framework to study innovation (Faber, 2009). One 
strong limitation of this subfield of economics is that its theories do not rely on well grounded empirical 
evidence (Lambooy, 2005) 
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Accounting for co-evolution 
In the modern paradigm, innovation is no longer considered a linear process (Dodgson, 2000). 
Rather, technologies, actors and the environment (such as national governance) co-evolve. From 
this complex system emerges innovation (Boschma, 1999). Echoing with “pathways of 
innovation”, Consoli defines these interactions as “gateways of innovation” (Consoli, 2009) . 
Co-evolution will be captured by the multivariate analysis that allows analysing the association of 
each factor with biomedical research accounting for the effects of the other factors. The effects 
will be calculated “all other thing held equal” or “ceteris paribus”. 
Synthesis of constructs and variables  
This literature review has provided a set of appropriate constructs and variables that will answer 
the research questions using quantitative analytical tools. They are summarized in the following 
table summarizes. 
Table 10: Summary of Construct Families, Constructs, Variables and Databases 
 
Construct 
family Construct Variable Database 
Research 
and 
innovation 
Research and innovation 
Number of article published in 
the top 97 biomedical journals 
per capita 
ISI – Web of science 
Governance Governance governance indicators World Bank 
Economic 
resources 
Access to capital % of GDP allocated to R&D World bank 
Macroeconomic environment GNI per capita (at PPP) World bank 
Openness to international trade 
Economic value of import and 
export merchandises as a % of 
GDP 
World bank 
Innovation performance of the 
private sector Number of patents per capita 
UNESCO & World 
bank 
Human 
resources 
Connectivity 
% of households connected to 
internet 
Economic value of import and 
export merchandises as a % of 
GDP 
World bank 
Diversity and interdisciplinary Immigrants per capita World bank 
English proficiency National TOEFL scores TOEFL 
Critical 
mass 
Geographic density Population density World bank 
Size Population World bank 
Actors 
behaviour 
Supply and demand behaviour 
leading to technological 
acceptance 
% of households connected to 
internet World bank 
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Chapter 3: Methods 
 
The research question  
The research question is: “at a country level, what are the factors that promote biomedical 
research and in particular what is the role of national political governance?” The underlying 
hypothesis of this dissertation is that governance is the most significant factor of biomedical 
research performance because it creates the political environment appropriate for breakthrough 
discoveries. This hypothesis is suggested by the literature review although it has not been framed 
or researched so specifically. 
The concept map 
The concept map provides theoretical links between these factors and biomedical research 
performance. It is based on the “structure, process and outcome framework” which has origins 
with Donabedian (Folland, Goodman & Stano, 2003). Governance has a transformative role 
because it transforms structural factors into research outcomes. This framework will provide 
guidance throughout the rest of the dissertation. 
Figure 5: The Concept Map 
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The Study sample 
We want to avoid choosing countries belonging to the same socio-eco-political group (such as the 
OECD countries). Although such limitation would have eased the access to quality databases, it 
would have reduced potential insights from emerging countries and limited the external validity of 
the study. Rather, it was decided to include all countries that have a minimal biomedical research 
output, measured in terms of article publications, no matter their origin.  
The following general method was used. For each year between 1996 and 2008, we measured the 
number of articles published in 97 top biomedical journals (see chapter 5) f this chapter to 
understand the identification of these 97 journals). These articles were classified in terms of the 
country of origin (origin of first author) and the countries ranked according to the number of 
publications. Forty-nine countries accounting for 99% of the articles published between 1996 and 
2008 were identified. These were chosen as a first cut for analysis. Luxembourg and Iceland were 
subsequently added because of their relatively good article-per-capita ratio. Finally, Taiwan was 
excluded because of the lack of data on the independent variables. Ultimately, 50 countries were 
included in the study. The countries are presented in the following table along with their 
abbreviation.  
Table 11: The 50 Countries 
Country Abbreviation Country Abbreviation Country Abbreviation 
Argentina ARG England GBR New Zealand NZL 
Australia AUS Greece GRC Peru PER 
Austria AUT Croatia HRV Poland POL 
Belgium BEL Hungary HUN Portugal PRT 
Brazil BRA India IND Russia RUS 
Canada CAN Ireland IRL Saudi Arabia SAU 
Switzerland CHE Iran IRN Singapore SGP 
Chile CHL Iceland ISL Slovak SVK 
China CHN Israel ISR Slovenia SVN 
Colombia COL Italy ITA Sweden SWE 
Czech CZE Japan JPN Thailand THA 
Germany DEU Kenya KEN Turkey TUR 
Denmark DNK Korea KOR Ukraine UKR 
Egypt EGY Luxembourg LUX United States USA 
Spain ESP Mexico MEX Venezuela VEN 
Finland FIN Netherlands NLD South Africa ZAF 
France FRA Norway NOR   
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Although most countries originated from Europe, all world regions are represented (see graph 
below).  
Figure 6: Geographic Origin of the 50 Countries 
 
 
The 50 countries account for a significant part of the World economy: they represented 
approximately 70% of the world population and 90% of the World’s Gross National Income (at 
parity purchasing power). However, within the time frame of our dissertation (1996 to 2008) these 
percentages have been steadily declining (see graph below). One reason could be that emerging 
countries, not ranked as the top 50 biomedical publishers, have had a higher increase population 
and income than sample countries (for example Indonesia).  
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Figure 7: Total Population and GNI at PPP of the 50 Countries 
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Variables: sources and time period  
The following table presents the dependent and independent variables, their sources, their 
accessibility and the dates. 
Table 12: The Dependent (publications per capita) and Independent Variables 
 Source Publicly 
accessible 
Collection time 
Number of articles within 
a selection of 97 top 
biomedical journals per 
capita 
Web of Science® 
World Bank 
Yes, but not free 
of charge 
1996 to 2008 
global governance: sum of 
the 6 governance 
indicators 
World Bank 
World development indicators 
Yes, free 1996, 1998, 
2000 and 2002 
to 2008 
GNI per capita (at PPP) World Bank, World 
development indicators 
Yes, free 1996 to 2008 
% GDP invested in R&D OCDE + UNESCO + World 
bank  (Lederman 2005) 
Yes, free 1996 to 2007 
International trade: 
economic value of import 
and export merchandises 
as a % of GDP1 
World Bank 
World development indicators 
Yes, free 1996 to 2008 
Number of patent granted 
per capita 
UNESCO + OECD Yes, free 1996 to 2002 
% of households 
connected to internet 
World bank 
World development indicators 
Yes, free 1996 to 2008 
Average national 
TOEFL® scores  
TOEFL® Yes, free 1996 to 2008 
Immigrants per capita World bank 
World development indicators 
Yes, free 1996 to 2008 
Population World Bank 
World development indicators 
Yes, free 1996 to 2008 
Population density World bank 
World development indicators 
Yes, free 1996 to 2008 
 
Constrained mostly by the availability of the governance indicators, we will conduct the analysis 
using data from 1996 to 2008. Interestingly, 12 years is also the average completion time of a 
publicly funded clinical research project in France (French Ministry of Health, 2010). This 
completion time means that policy changes early in the period could lead to visible changes in the 
performance at the end of the period. 
                                                 
1
 Topic awarded with a Nobel Prize in economic in 2009. 
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Data analysis 
For this analysis, we have used STATA version 10 software for a statistical analysis and five 
references books for methodological guidance (Kleinbaum, 2008; Kennedy, 2008; Wooldridge, 
2009; Falissard, 1998;Falissard, 2001). Many of the details of our methods and results are 
reported with their specific references in the appendices. 
A. The construction the dependent variable 
Method 
For the purpose of this study we created an ad-hoc variable that captures breakthrough biomedical 
innovation through the measure of biomedical research articles published in 97 top biomedical 
journals. The details of this method are presented in Appendix 3. A similar method was used by 
Soteriades to assess the research contribution of different world regions in the top 50 journals 
(Soteriades et al, 2006). 
However, our method more accurately measures biomedical innovation, in two ways. First, we 
tried to balance articles originating from fundamental research journals with articles coming from 
applied research journals. Indeed, it is well know that fundamental research journals (genetics, 
biology) have a higher impact factor than applied journals (cardiology, nephrology) although 
applied journals may be the primary references in their field, publishing the most innovative 
articles. These could have been lost if we had chosen journals solely based on their impact factor. 
Second, we integrated the “quality” of the citation using the EigenfactorTM. With this method, a 
citation from highly respected journals is given more value that a citation from a lower impact 
journals (Fersht, 2009, Bergstrom, 2008).  
Among the 97 journals, 54 can be categorized as of fundamental research journals (such as Nature 
or Science) and 43 as applied clinical journals (such as the American Journal of Cardiology or the 
Journal of the American Medical Association). In our view, this provides an appropriate mix 
between fundamental and applied research. 
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B. Constructing the governance variable 
Because of the importance of governance in this analysis, the construction of the variable 
‘governance’ comprised of 6 aggregate indicators (Voice and Accountability, Political Stability 
and Absence of Violence, Government Effectiveness, Regulatory Quality, Rule of Law, Control 
of Corruption) is essential (see Chapter 2 for the definitions of the 6 indicators). These indicators 
are based on underlying variables measuring of different aspects of governance (see Appendix 3). 
For example, in 2007, data was drawn from 35 separate data sources constructed by 32 different 
organizations from around the world (Appendix 3). However, all the data sources are not available 
for all countries (Appendix 3). For example, in 2007, seven countries relied only on one data 
source.  
The authors used unobserved components from the model to construct six aggregate governance 
indicators from the data (Kauffman, 2008). To minimize ceiling and floor effects in the data 
distribution, the 6 aggregate indicators are then rescaled to set their mean at zero and their 
standard deviation to one. To visualize this, the distribution and the margin of error is presented 
for one of the 6 indicators “Corruption Control” in Appendix 3. The evolution throughout time 
(1998 versus 2007) of another indicator of the quality of the measure is illustrated in Appendix 3 
which shows the correlation of the indicator “Voice and Accountability” between 1998 and 2007. 
The World Bank now has 14 years of experience in constructing these indicators and they are 
routinely used in World Bank’s analysis and policy prescription (World Bank, 2010). The authors 
have also published their methodologies and results in peer reviewed articles (Rhodes, 1996; 
Kaufmann, Kraay & Pablo Zoido Lobatón, 1999). Hence, we will consider that each individual 
indicator has enough validity to be used in our methods without re-evaluation. 
However, for the purpose of our dissertation we created a global governance score aggregating 
information by summing all 6 indicators. This summarization will simplify the analysis and 
interpretation. 
To do this we had to explore the relations of the 6 indicators together and in particular understand 
how they behave as items of “global governance”. The detailed method and analysis are the 
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distribution of the global governance score for all 50 countries for the year 2000 is presented 
below. It is skewed towards the right, consistent with the fact that biomedical research is mostly 
produced in countries with a high level of governance. However, we will consider that this 
distribution is compatible with analytical techniques used. 
Figure 8: Distribution of the Global Governance Score for all 50 Countries (2000) 
  
C. Analytical approaches and techniques 
Two approaches will be used: cross-sectional and longitudinal analysis. Bivariate analysis and 
multivariate linear regression will allow cross-sectional analysis. The panel data will allow for 
longitudinal analysis. The combination of the two approaches and the three techniques will be 
helpful to search for complex and multiple “stories” within the data and provide complementary 
information. Using two approaches will also act as a form of sensitivity analysis.  
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Description of variables 
We will start each approach by a description of quantitative variables. This will consists of tables 
presenting the number of observations, means, standard deviations, median and extreme values 
and distribution histograms.  
Cross-sectional Bivariate analysis  
To provide the most recent picture, we will use the data of the last available year (2008). The 
association between the variables will be analyzed using bivariate correlation and plots. These 
analyses will not only help in assessing the correlation between the dependant and independent 
variables but also identify co-linearities between independent variables. The bivariate analysis 
will guide the construction of multivariate models. 
Cross-sectional multivariate linear regression  
To provide the most recent picture, we will use the data from the last available year (2008). The 
Ordinary Least Square estimator provided in the standard STATA package will be used.  
Guided by theory and the results of the bivariate analysis, we will construct different linear 
regression models. The joint analysis of the different models will provide complementary 
information and act as a sensitivity analysis. 
The models will range from a full model including all covariates to more parsimonious models in 
which a covariate will be selected using bivariate analysis results and theory (rather than any 
automatic procedure such as stepwise). If needed, we will also construct models with interaction 
factors. 
For each model constructed, we will test the assumption required by the Ordinary Least Square 
estimator. First, we will check collinearity by calculating and interpreting the Variance Inflation 
Factor (VIF). A VIF > 10 may penalize the quality of the regression (Kleinbaum, 2008). We will 
then test the assumption of normality, homoscedasticity and linearity using residual versus 
predicted value scatterplot and residuals normal probability plots. We will sometimes refer to 
these tests as the “regression diagnostics”. 
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Longitudinal Panel data  
Added value of panel data compared to cross-sectional data 
Panel data allows for analyzing data containing observations on multiple phenomena observed 
over multiple time periods. Consequently, we will be able to analyze inter-year relations as well 
as inter-country relations of our variables. The following table presents the key benefits and 
limitations of panel data compared to a classic cross-sectional analysis and the potential 
application to our study (Kennedy, 2008;Wooldridge, 2009). 
Table 13: Benefits of Panel Data  
 Theory Application our study 
Benefits Better control for unobserved 
heterogeneity (omitted variable bias) 
Account for the unobserved effect of changes 
in research policies, in the economy structure, 
in international exchange regulations, etc… 
More informative data, more variability, 
less collinearity, more degrees of freedom, 
and more efficiency 
Reduce collinearity issues between the 9 
independent variables. Reduce confidence 
intervals of estimates. 
Better able to study dynamics (changes 
over time) 
Explore the dynamic pattern of biomedical 
research 
May enable us to identify and measure 
effects that are simply not detectable in 
pure cross-sections or pure time-series data 
Get a deeper understand of how the 
independent variable panel data estimates 
compare the cross-sectional. 
Allows us to construct and test more 
sophisticated behavioural models. 
Helpful to craft research policy 
recommendations 
Limitations: Data collection is more problematic, 
including attrition, recall bias, fatigue, 
changing instruments, etc… 
 
Bias from measurement errors may 
become magnified 
Our data rely on highly standardized 
measurement 
 
Random versus fixed effect 
Panel data allows us to neutralize the effect of “unobserved” variables that explain, in addition to 
the independent variables selected in the model, heterogeneity “between” entities (for our study 
entities are countries) (Kennedy, 2008). This effect can be fixed or random. Simply put, a fixed 
effect is when the effect is correlated with the predictors. A random effect is when the effect is not 
correlated to the predictor.  When using panel data analysis, the investigators needs to determine 
if the effect is fixed or random. The Hausman test will be used to make this determination. A 
quick technical discussion about this topic is provided in appendix 3. 
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Modelling Strategy 
We will start with the analysis of the “within” and the “between” variations. This analysis will 
help us to understand the how the information contained in the data set is structured. We will then 
analyse the same models that were used in the cross-sectional analysis. 
Statistical testing 
Bivariate analysis, multivariate linear regression and panel data analysis will be computed on 
STATA software version 10. In general the level of significance to accept associations as valid 
will be p<0.05. There are no specific tests for the potential superiority of Type I versus Type II 
errors in specifications—the use of significance tests will thus help us to understand how 
forcefully the conclusion can be presented. 
  
58 
What should this study add? 
We had identified in Chapter 1 six weaknesses of the current literature. As shown in the following 
table, your study addresses each of these deficiencies through specific advantages. 
Table 14: 6 Advantages of the Study 
Advantage Methodological explanation 
Focus on biomedical sector Top 97 biomedical journals adjusted for 
interdisciplinary unjustified impact factor variation 
Global 50 countries 
Quantitative 10 variables backed-up by theoretical constructs 
Cross discipline 6 social science disciplines 
Account for the role of time  Longitudinal 12 years temporal data analyzed using 
panel data 
Account for co-evolution Ceteris paribus approach provided by multivariate 
analysis 
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Chapter 4: Results 
 
This chapter is intended to help us understand the behaviour of the variables and their potential to 
support the hypothesis. It includes three sections: in the first section, after a description of the 
variables, we will analyze the data in a cross-sectional way exploring the relationships between 
the dependant variable and the independent variables and within the independent variables. We 
will use the year 2008 or when the data for 2008 is not available, the last year available. This data 
will be graphed using scatterplot graphs and summarized with correlation coefficients and 
multivariate linear regression. In the second section, guided by the results of the first section, we 
will construct panel data models using data from the years 1996 to 2008. In the third section, we 
will compare the results from the cross-sectional and the panel data analysis. 
Cross sectional analysis (2008) 
A. Description of the variables 
Summary of all the variables 
The summary statistics, for the dependent variable and the 10 independent variables, is presented 
in Table 15. When observing the mean, minimum, the standard deviation and maximum, no odd 
data stands out. The number of observations for each variable ranges between 32 and 50. 
Although not reported here, the variables for all the other years (from 1996 to 2007) display 
similar statistics.  
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Table 15: Summary of Variables 
Variable Label Observations Mean Std. Dev. Min Max 
Publications per 
capita (2008) 
(articles / habitant) pp08 50 0.0000609 0.0000664 4.98E-07 0.0002654 
Patents per capita 
(2002) (patents / 
habitant) patperpop02 50 0.0000498 0.0000725 0 0.0003023 
Global 
Governance 
(2008) gg08 50 4.2 5.3 -6.9 10.8 
GNI per capita 
(2008) ($US) gpc08 48 25633 14855 1580 64320 
% of GDP 
invested in R&D 
(2006) rd06 35 1.8% 1.0% 0.5% 4.5% 
International trade 
(merchandise 
import and export) 
as a % of GDP 
(2008) tr08 50 76.0% 55.2% 23.6% 361.6% 
% of households 
using internet 
(2008) e08 32 45.6% 22.9% 8.6% 86.8% 
Average TOEFL® 
scores  to08 48 87 13.47496 19 102 
Immigrants per 
capita (2005) 
(immigrants / 
habitants) im05 50 0.0113377 0.0168354 
-
0.0262109 0.0576934 
Population (2008) 
(habitants) pop08 50 9.09E+07 2.42E+08 316960 1.33E+09 
Density (2008) 
(habitants / square 
meter) d08 50 251.5 969.7 2.8 6923.3 
Description and transformation of the dependent variable  
Publications per capita and share of publications 
In 2008, the USA produced just above 40% of the total publications, Great-Britain was second, 
but far behind (less than 10%). In terms of publications per capita, the top three countries are 
Switzerland (CHE), the Netherland (NLD) and Denmark (DNK). China and India have a medium 
share of publication value but a low publications per capita ratio. Ukraine and Colombia the worst 
ranked when both indicators are used. 
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Figure 9: Publications per capita and Share of Publications (2008) (logarithmic scale) 
 
In terms of publications per capita, the overall pattern is quite clear: a small number of countries 
(USA and a several Western European countries) have a high biomedical research performance 
while most countries, in particular from Eastern Europe, Africa, Asia and South America, 
demonstrate a lower productivity. This evidence confirms past research (Soteriades, Falagas, 
2005).  
Because the USA has such a big share of publications per capita and can thus be viewed as an 
outlier, we will analyze the data with and without the USA1. 
The following histogram confirms the concentration pattern of publications per capita. All the 
other years for which we have data (1996 to 2007) present a very similar distribution. 
 
 
 
                                                 
1
 Although specifically in terms of “publications per capita”, the USA are not an outlier 
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Figure 10: Distribution of Publications per capita (2008) (density is the proportion of cases) 
 
This highly skewed distribution of our dependant variable may signal potential assumption 
violations when using the Ordinary Least Square estimator (OLS) in subsequent analyses. Hence, 
after having considered the methodological arguments in favour of a transformation, the different 
transformation options, and having tested the impact of a transformation on the quality of the 
regresssion, we have decided to undergo a log transformation and use it in the analysis. A detailed 
discussion is provided in Appendix 4. 
As shown by the following figure, the log transformation allows for a better use of the 
information contained in the bulk of the data (countries like Spain, Japan, Korea or Argentina) 
and reduces the influence of outliers (such as India, Ukraine or Switzerland).  
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Figure 11: Distribution of the Log of Publications (2008) (density is the proportion of cases) 
 
 
B. Bivariate analysis 
Relationships between publications per capita and the 10 independent variables 
In this section, we will analyse the association between the dependent variable and the 10 
independent variables. Scatterplots and correlation coefficients will be discussed in the context of 
the theoretical background described in the literature review chapter. We use data for the year 
2008 (the last year of our data set) for most pairs of variables except for patents per population 
(2002), immigration (2005) and percentage of GDP invested in R&D (2006). 
Log of publication per capita and patents per capita 
Within our conceptual framework, patents and publications can both be considered as 
“performance variables”. For this reason we are anticipating an association between the two. 
Because the number of patents is a research outcome variable that demonstrably has an 
exponential growth pattern (just like publications), we log transform patents per capita. A clear 
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straight linear pattern appears and the correlation coefficient between patents and publications 
increases to reaches 0.92.  
Figure 12: Publications per capita and Patents per capita (2002) 
 
This relationship demonstrates a clear association between publications per capita and patents per 
capita implying that that they measure a similar construct. This builds a stronger case for one of 
the two measures to be a valid measure of biomedical research and innovation. As planned, we 
will continue to use publications per capita as the dependant variable because it is more 
specifically associated with biomedical research, because of its greater assumed accuracy and 
because it is easier to interpret. However, because the two variables provide essentially equivalent 
information we will not use patents per capita as a covariate in our models for reasons discussed 
in the literature review sections.  
Log of publications per capita and governance  
The scatter plot below presents a clear positive log-linear pattern between our key independent 
variable, governance, and publications per capita. This visual association is confirmed by 
correlation coefficient of 0.92. This pattern strongly suggests that governance is a predictor of 
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publication per capita and thus confirms our hypothesis. Governance will be integrated in the 
multivariate model. 
Figure 13: Publications per capita and Governance (2008) 
 
Log of publications per capita and GNI per capita  
The scatterplot below demonstrates a clear positive relationship between log of publications per 
capita and GNI per capita) up to 40,000US$. This finding confirms past research results (Rhaman, 
2005). This correlation coefficient, 0.85, confirms this visual analysis. 
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Figure 14: Publications per capita and GNI per capita (2008)   
 
However, after 40,000 dollars per capita, the relationship flattens out and an increase in GNI per 
capita is no longer associated with an increase of the log of publications per capita. This might 
suggest a “cap” on the effect. Because governance and publications per capita do not have this 
“split” pattern, the question whether the effect of GNI per capita on publications per capita could 
be modified by the level of governance can be raised. In particular, does governance have more 
impact in countries with low GNI per capita? Consequently, besides including GNI per capita in 
the multivariate models, this suggests the need for GNI per capita/governance interaction model.  
Log of publications per capita and Percentage of GDP invested in R&D  
A positive association exists between the log of publications per capita and the percentage of the 
GDP invested in R&D up to per capita) up to 0.02 (2%). This relationship confirms past research 
(Rhaman, 2005). The correlation coefficient of 0.6 confirms the association discovered by the 
visual analysis.  
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Figure 15: Publications per capita and Percentage of GDP Invested in R&D (2006) 
 
However, after 2%, the relationship tends to flatten out and R&D loses its ability to predict the log 
of publications per capita. Again, this might suggest a “cap” on the effect. This split pattern is 
new information. Indeed, the EU has imposed a minimum target of 3% of GDP to be invested in 
R&D.  
As for GNP per capita, this may pose the question of interaction or confounder effects. Does 
governance have more impact in countries with low R&D resources? Consequently, besides 
including the percentage of GPD invested in R&D in the multivariate model, we will also 
construct a model with an interaction between the percentage of GDP invested in R&D and 
governance. 
Because R&D is such an important factor, we need to understand the impact of its missing values. 
Indeed, for the year 2008, 15 out of 50 countries have a missing value of the % of GDP invested 
in R&D. The question is whether this impacts our results and in particular the relationship 
between governance and publications per capita, our major concern. To analysis this, we compare 
the regression line between governance and publications per capita for countries that have and do 
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not have a recorded value of R&D in our dataset (figure 16). The figure 16 suggests that the 
countries with low governance and publications per capita are also those that are missing the 
R&D value. We can assume that these countries have a small investment in R&D. Furthermore, 
because the regression lines are almost parallel, we can assume that the missing values do not 
affect the estimate of the association between governance and publications per capita. 
Figure 16: Publications per capita and Governance (2008) for Countries with and without the 
Value of the Percentage of GDP Invested in R&D (2006) 
 
Log of publication per capita and Percentage of GDP related to international trade  
As pointed out in the literature review, the theory underlying the relation between international 
trade and biomedical research is that international trade increases the information and innovation 
exchange thus enhancing innovation capacity (Box, 2009). 
However, in our data set, no clear associations appear between the two variables. Both graphical 
analysis and correlation coefficient (0.20) support this conclusion. The conclusion remains the 
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same when a Singapore, a strong outlier, is removed: no clear graphical association is seen 
(below) and correlation coefficient is even smaller (0.17). 
Figure 17: Publications per capita and Percentage of GDP Related to International Trade (2008) 
 
A similar conclusion is reached when we use the crude form of publications per capita (not log 
transformed) .This conclusion suggests that percentage of GDP related to international trade could 
be discarded in the cross-sectional multivariate analysis. However, because of its theoretical 
importance, it will be included in the cross-sectional multivariate analysis. 
Log of publications per capita and immigrants per capita (2005) 
As pointed out in the literature review, the theory underlying of the relation between immigration 
and biomedical research is that immigrants bring in new ideas and perspectives on research 
problems.  
The association between immigrants per capita and publications per capita is depicted in Figure 
18. The correlation coefficient is 0.59 which supports this association. Consequently, the 
immigrants per capita will be included in multivariate analysis. 
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Figure 18: Publications per capita and Immigration per capita (2005) 
 
Log of publications per capita and English proficiency (2008) 
As shown in the literature review (Man et al, 2004), the theory underlying the relationship 
between English proficiency and biomedical research is that English proficiency improves the 
information exchange between research actors thus enhancing innovation. The correlation 
coefficient is 0.57 (0.63 when Iran, a strong outlier, is removed) reinforcing the graphical 
impression of association (below). This finding confirms past research (Man et al, 2004). 
Consequently, the English proficiency will be included in multivariate analysis. 
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Figure 19: Publications per capita and English Proficiency (2008) 
 
Log of publications per capita and percentage of households using internet (2008) 
The literature review identified studies that suggested a relationship between Internet usage and 
biomedical research since connectivity provided by the Internet unleashes the innovation capacity 
(Box, 2009; Mata, 1995; Hevner, 2004). 
The graphic analysis (below) shows a robust association between the percentage of households 
using Internet and the log of publications per capita. As with the governance pattern, the extremes 
do not to flatten out. The correlation coefficient (0.85), confirms the strength of the graphic 
association. Consequently, the percentage of Internet users will be included in multivariate 
analysis. 
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Figure 20: Publications per capita and Percentage of Households using the Internet (2008) 
 
Log of publications per capita and population (2008) 
The literature review identified studies that suggested that the relationship between population 
and biomedical research is that the size of a country may have a “volume/outcome” or “minimum 
size required” effects on the production biomedical research (Porter, 1998; Uthman, 2007).  
The graphical analysis between the log of publications per capita and the population is not 
informative due to the presence of two strong outliers, China and India. Because we do not want 
to drop these two countries, we transformed the population values to make the interpretation. The 
graphic analysis between the log of publications per capita and the log of population shows a 
negative relation between population and publication per capita (below), confirmed by a negative 
correlation coefficient (-0.53).  
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Figure 21: Publications per capita and Population (2008) 
 
This suggests an effect of population. Consequently it will be included in the cross-sectional 
multivariate analysis. 
Log of publications per capita and density (2008) 
As pointed out in the literature review, the theory underlying of the relation between density and 
biomedical research is that the population density of country, as the density of a city or a research 
centre, may increase research productivity by facilitating exchange (Porter, 2008). 
The graphical analysis between the log of publications per capita and the population is not 
informative due to the presence of a very strong outlier, Singapore. By excluding Singapore, the 
graphic pattern is not much clearer and the coefficient remains small, 0.21. 
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Figure 22: Publications per capita and Density (2008) 
 
Finally, the log transformation of population density produces neither a clearer pattern (graph) nor 
a higher correlation coefficient (0.0122).  
Consequently, density will not be used in the multivariate model. Preferable variables reflecting 
this concept could have been used, such as the percentage of the population living in urban areas. 
However, these data were not accessible for the 50 countries. 
Relationships between the independent variables 
The literature review has pointed out that innovation is best described as a system in which 
multiple factors interact. Consequently, many associations between factors are expected. 
However, strong associations between independent variables may create collinearity problems in 
the multivariate analysis that have to be managed to understand the true effects of the variables. 
Because governance is crucial in our analysis, we have individually described the relationships 
between governance and each of the remaining 8 covariates (by covariates we mean all of the 
independent covariables excluding governance and density as discussed earlier). We have also 
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analyzed the relationship between each of 8 covariates (excluding governance). Appendix 4 
contains the detailed analysis using scatterplot graphs and correlation coefficient. We have 
reported here only the major findings.  
Governance, as anticipated, is associated with most covariates: GNI per capita; the percentage of 
GDP invested in R&D, the percentage of households using the internet, English proficiency and 
immigrants per capita. Furthermore, most covariates are associated together.  
Summary of bivariate analysis 
The following table provides a summary of relationships between independent variables with the 
dependant variable and between themselves. The relative strength of the relation between 
publication per capita and the independent variables is ranked (very high/high/medium/low) 
according to the visual pattern provided by the scatterplot and by the correlation coefficient. The 
risk of collinearity within the independent variables is ranked (very high/high/medium/low) 
according to the visual pattern provided by the scatterplot, by the correlation coefficient, as well 
as by accounting for the number of associations with dependent variables. The potential of 
interaction with variable of interest, governance, between independent variables is also 
documented.  
Table 16: Bivariate Analysis Summary 
Pair of variables 
Strength of 
relationship to the 
dependent variable 
Risk of 
collinearity 
Possible 
interaction with 
governance to be 
explored 
Included in 
the 
multivariate 
models 
Governance (gg08) Very high (0.9150) Very high N/A Yes 
GNI per capita (gpc08) High (0.8520) Very high Yes Yes 
% of GDP invested in 
R&D (rd06) 
High (0.6038) High Yes Yes 
% of GDP related to 
international trade (tr08) 
Low (0.1990) Low No Yes 
Immigrants per capita 
(im05) 
Medium (0.5942) Medium No Yes 
English proficiency (to08) Medium (0.5721) High Yes Yes 
% of households using 
internet (e08) 
Very high (0.8479) Very high No Yes 
Log of the population 
(lnpop08) 
Medium (-0.5307) Low No Yes 
Density (d08) Low (0.1392) N/A N/A No 
76 
Within the independent variables the most important risk of collinearity is due to the variable the 
percentage of households using internet; in addition to having a strong association with 
governance, this variable has shown to be associated with GNI per capita, R&D and English 
proficiency. This association begs for the use of caution when using this variable. 
Major findings of the bivariate analysis 
First, the close association between the publications per capita and the patents per capita builds a 
case for the former to be used as a specific measure of biomedical research and innovation. 
Second, the bivariate analysis strongly suggests that governance is a predictor of publications per 
capita. Third, it has also leads to us accept 7 covariates to be included in the multivariate analysis 
out of 8 potential variables identified in the literature review (GNI per capita, percentage of GDP 
invested in R&D, immigrants per capita, English proficiency, the percentage of households using 
internet, percentage of GDP related to international trade and the log of population). One variable 
was dropped out (density). Fourth, the multiple associations between the dependant variable and 
the independent variables, and between the independent variables themselves confirm that 
biomedical research behaves as a system of interrelated factors. Finally, this analysis confirms 
past research. In accord with other authors, we have found that GNI per capita, the percentage of 
R&D invested in R&D and English proficiency are associated with biomedical research 
productivity.  
C. Multivariate analysis 
Different models 
The bivariate analysis has confirmed the observations and many of the conclusions from the 
literature review: biomedical research is a system in which most of the variables identified here 
are linked. This environment creates a complex data structure. To untangle this problem, we will 
construct three models, all based on a similar core structure. The joint analysis of the models will 
guide us in the interpretation the data and the validity of each independent variable tested by 
creating a sensitivity analysis. 
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The first model (full analytical model) will include all variables. The second model (reduced 
analytical model) excludes the percentage of households using the Internet. The objective is to 
avoid potential collinearity created by the latter (regression parameters may change dramatically 
in response to inclusion or exclusion of a collinear independent variable). Besides excluding the 
percentage of households using the internet for the same reason as above, the third model 
(parsimonious analytical model) is limited to the variables that have been shown to be 
significantly correlated to publications per capita. Consequently, we will exclude international 
trade and population, the least correlated variables.  
These three models have an objective of validity, i.e. accurately assessing the relationship 
between the independent variables and the dependant variable. A fourth model could have been 
built with an on objective of prediction, i.e. finding the model that gives the most reliable 
prediction of the dependant variables given a selection of dependant variables (Kleinbaum, 2008). 
However, this model would have been out of the scope of our study which focuses on 
understanding rather than predicting. 
Two interaction models, with GNI per capita and the percentage of GDP invested in R&D will be 
tested. 
We will only report in the main text the regression output. The Variance Inflation Factor (VIF) 
test and the graphic analysis of normality, homoscedasticity and linearity for all the models tested 
are presented in the Appendix 4.  
The literature and our bivariate analysis suggest that the percentage of GDP invested in R&D is a 
fundamental variable in understanding biomedical research performance. However, 15 out of 50 
countries have a missing value for that variable. The bivariate analysis has not shown a significant 
impact on the results of these missing values. However, to be consistent throughout our analysis, 
we will rerun each model without R&D.  
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Labels for the variables 
Table 17 presents the labels for each variable used in the multivariate model. 
Table 17: Labels of the Cross-sectional Multivariate Models Variables 
 
Variable Label 
Log of publications per capita (2008) (articles / habitant) lnpp08 
Patents per capita (2002) (patents / habitant) patperpop02 
Global Governance (2008) gg08 
GNI per capita (2008) ($US) gpc08 
% of GDP invested in R&D (2006) rd06 
International trade (merchandise import and export) as a % 
of GDP (2008) tr08 
% of households using internet (2008) e08 
Average TOEFL® scores  to08 
Immigrants per capita (2005) (immigrants / habitants) im05 
Log of population (2008) (habitants) lnpop08 
Density (2008) (habitants / square meter) d08 
The full analytical model 
We ran a “regress” command under STATA using all the variables. The output is presented in 
table 18. 
Table 18: Stata Output for the Full Analytical Cross-sectional Model 
The full analytical model presents high adjusted R2, 0.89. However, only the GNP per capita 
estimate is significant at the 0.05 level. This model was constructed with strong correlations 
between variables. Consequently, the association of a high R2 with statistically insignificant 
covariates’ coefficients is a strong sign of multicollinearity (Kennedy, 2008). The regression 
diagnostic presented in Appendix 4 (including the variance inflation factor) confirms the presence 
of collinearity in particular involving governance. This can be interpreted as a sign of a 
                                                                              
       _cons    -14.23906   3.015883    -4.72   0.001    -20.87697   -7.601147
         e08     1.355141   1.158948     1.17   0.267    -1.195686    3.905967
     lnpop08    -.0939459   .0998663    -0.94   0.367      -.31375    .1258583
        tr08    -.4626236    .353198    -1.31   0.217    -1.240007    .3147599
        to08     .0326558   .0216031     1.51   0.159    -.0148922    .0802038
        im05     5.899043   9.649502     0.61   0.553    -15.33937    27.13745
        rd06    -3.459248   21.29008    -0.16   0.874    -50.31841    43.39991
       gpc08     .0000815   .0000253     3.22   0.008     .0000257    .0001372
        gg08    -.0047649   .0871337    -0.05   0.957     -.196545    .1870151
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    35.3607933    19  1.86109438           Root MSE      =  .44339
                                                       Adj R-squared =  0.8944
    Residual    2.16250046    11  .196590951           R-squared     =  0.9388
       Model    33.1982928     8  4.14978661           Prob > F      =  0.0000
                                                       F(  8,    11) =   21.11
      Source         SS       df       MS              Number of obs =      20
. regress lnpp08 gg08 gpc08 rd06 im05 to08 tr08 lnpop08 e08
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transformative role of governance. The assumptions of normality, homoscedasticity and linearity 
are satisfactorily respected. 
Without R&D, the governance estimate becomes quasi-significant (table 19). 
Table 19: Stata Output for the Full Analytical Cross-sectional Model without R&D 
Reduced analytical model 
We exclude the percentage of households using the internet. The output is presented in table 20.  
Table 20: Stata Output for the Reduced Analytical Cross-sectional Model 
The adjusted R2 of this model remains high (0.80). However, the estimates change a lot. 
Governance and R&D estimates become significant and while GNI per capita is no more 
significant at the 0.05 level. English proficiency is almost significant (p=0.065). This supports the 
                                                                              
       _cons    -13.74423   3.091039    -4.45   0.000     -20.1724   -7.316063
         e08     .4210128   1.109126     0.38   0.708     -1.88554    2.727566
     lnpop08    -.0691473    .100659    -0.69   0.500    -.2784792    .1401846
        tr08    -.2971319   .3813877    -0.78   0.445    -1.090271    .4960072
        to08     .0189491   .0215199     0.88   0.389     -.025804    .0637023
        im05     8.177918   8.491263     0.96   0.346     -9.48063    25.83647
       gpc08     .0000794   .0000232     3.42   0.003     .0000311    .0001277
        gg08     .1010119   .0509629     1.98   0.061    -.0049711     .206995
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    98.9532245    28  3.53404373           Root MSE      =    .537
                                                       Adj R-squared =  0.9184
    Residual    6.05581446    21  .288372117           R-squared     =  0.9388
       Model      92.89741     7  13.2710586           Prob > F      =  0.0000
                                                       F(  7,    21) =   46.02
      Source         SS       df       MS              Number of obs =      29
. regress lnpp08 gg08 gpc08 im05 to08 tr08 lnpop08 e08
                                                                              
       _cons    -16.14669   2.830087    -5.71   0.000    -21.96402   -10.32936
     lnpop08     .0427795   .0935121     0.46   0.651    -.1494374    .2349964
        tr08    -.2238446   .1851951    -1.21   0.238    -.6045186    .1568294
        to08     .0354373   .0184216     1.92   0.065    -.0024289    .0733034
        im05     4.497787   8.980905     0.50   0.621    -13.96273     22.9583
        rd06     32.44556   12.59793     2.58   0.016     6.550141    58.34098
       gpc08     .0000218   .0000154     1.41   0.170    -9.93e-06    .0000535
        gg08     .1631522   .0516022     3.16   0.004     .0570824     .269222
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    60.4725517    33  1.83250157           Root MSE      =  .60188
                                                       Adj R-squared =  0.8023
    Residual    9.41867129    26  .362256588           R-squared     =  0.8442
       Model    51.0538804     7  7.29341149           Prob > F      =  0.0000
                                                       F(  7,    26) =   20.13
      Source         SS       df       MS              Number of obs =      34
. regress lnpp08 gg08 gpc08 rd06 im05 to08 tr08 lnpop08
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observation of collinearity between the percentage of households using the internet and 
governance, GNI per capita, R&D and English proficiency. 
We report no major problems with collinearity, normality, homoscedasticity and linearity (see 
Appendix 4). 
When R&D is excluded, the strength and significance of the governance estimate is reinforced. 
GNI per capita estimate becomes significant. The significance of English proficiency estimate 
reduces (table 21). 
Table 21: Stata Output for the Reduced Analytical Cross-sectional Model without R&D 
The Parsimonious Analytical model 
We exclude two variables: log of population and percentage of GDP engage in international trade. 
The STATA output is presented in the table 22. 
 
 
 
 
 
 
                                                                              
       _cons    -13.33008   2.630312    -5.07   0.000    -18.65038   -8.009768
     lnpop08    -.0450983    .087774    -0.51   0.610     -.222638    .1324414
        tr08    -.2617946   .2143131    -1.22   0.229    -.6952838    .1716946
        to08     .0184642   .0189594     0.97   0.336    -.0198848    .0568132
        im05     7.470329   9.195861     0.81   0.422    -11.13006    26.07071
       gpc08     .0000347   .0000149     2.33   0.025     4.55e-06    .0000648
        gg08     .2128988   .0450425     4.73   0.000     .1217917    .3040058
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    157.004028    45   3.4889784           Root MSE      =  .74634
                                                       Adj R-squared =  0.8403
    Residual    21.7236672    39  .557017107           R-squared     =  0.8616
       Model    135.280361     6  22.5467268           Prob > F      =  0.0000
                                                       F(  6,    39) =   40.48
      Source         SS       df       MS              Number of obs =      46
. regress lnpp08 gg08 gpc08 im05 to08 tr08 lnpop08
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Table 22: Stata Output for the Parsimonious Analytical Cross-sectional Model 
This model resembles to the previous model (reduced analytical model). Governance and R&D 
estimates are significant. English proficiency is close significance. GNI per capita and immigrants 
per capita are not at all significant. 
This result means that the predictor estimates behave in similar ways when we are controlling for 
population and international trade or not. This behaviour reinforces the validity of the parameter 
estimations. 
We report no major problems with collinearity, normality, homoscedasticity and linearity (see 
Appendix 4). 
When R&D is excluded, the strength and significance of the governance estimate is reinforced. 
The GNI per capita estimate becomes significant (table 23). 
Table 23: Stata Output for the Parsimonious Analytical Cross-sectional Model without R&D 
                                                                              
       _cons    -14.55509   1.446713   -10.06   0.000    -17.51854   -11.59163
        to08     .0247366   .0158679     1.56   0.130    -.0077674    .0572405
        im05      5.78797   8.932085     0.65   0.522    -12.50858    24.08452
        rd06     33.54829   12.48515     2.69   0.012     7.973617    59.12296
       gpc08     .0000177   .0000149     1.18   0.247    -.0000129    .0000482
        gg08     .1639838   .0515977     3.18   0.004     .0582907    .2696769
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    60.4725517    33  1.83250157           Root MSE      =  .60284
                                                       Adj R-squared =  0.8017
    Residual    10.1755113    28  .363411119           R-squared     =  0.8317
       Model    50.2970404     5  10.0594081           Prob > F      =  0.0000
                                                       F(  5,    28) =   27.68
      Source         SS       df       MS              Number of obs =      34
regress lnpp08 gg08 gpc08 rd06 im05 to08
                                                                              
       _cons    -14.19198   1.498124    -9.47   0.000     -17.2175   -11.16646
        to08     .0172514   .0173326     1.00   0.325    -.0177525    .0522553
        im05     6.760885   9.126094     0.74   0.463    -11.66964    25.19141
       gpc08     .0000347   .0000147     2.35   0.024     4.91e-06    .0000644
        gg08     .2150321   .0445986     4.82   0.000     .1249634    .3051007
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    157.004028    45   3.4889784           Root MSE      =   .7422
                                                       Adj R-squared =  0.8421
    Residual     22.585291    41  .550860756           R-squared     =  0.8561
       Model    134.418737     4  33.6046843           Prob > F      =  0.0000
                                                       F(  4,    41) =   61.00
      Source         SS       df       MS              Number of obs =      46
. regress lnpp08 gg08 gpc08 im05 to08
82 
The GNI per capita interaction model 
We will use the parsimonious model as the base model because we consider it to be the best trade-
off between simplicity and accuracy. We acknowledge that the impact of governance is different 
depending on the level of GNI per capita. We created an interaction term 
[gg08gpc08=gg08*gpc08] to the parsimonious model. The STATA output is the presented in 
table 24. 
Table 24: Stata Output for GNI per Capita Interaction Cross-sectional Model 
The R2 has increased by almost 0.06. However, the magnitude, the direction and significance of 
the estimation of the different variables does not change very significantly compared to the 
parsimonious model (governance, GNI per capita and R&D are significant, immigration and 
English proficiency are not), indicates that the model remains valid. The interaction variable is 
significant at 0.05 and negative. This suggests that the higher the GNI, the lower is the impact of 
the increase of one unit of governance. This result is in line with what we were anticipating with 
regards to the split patterns observed in the bivariate analysis. The regression diagnostics 
presented in Appendix 4 confirms the presence of collinearity in particular concerning the 
interaction term. The assumption normality, homoscedasticity and linearity are satisfactorily 
respected. 
When R&D is excluded, the strength of the governance estimate is reinforced (table 25). 
 
                                                                              
       _cons    -16.53697   1.246157   -13.27   0.000    -19.09387   -13.98006
        to08     .0335963   .0128043     2.62   0.014      .007324    .0598686
        im05     .3125568   7.228118     0.04   0.966    -14.51832    15.14343
        rd06     29.81348    9.97437     2.99   0.006     9.347766     50.2792
   gg08gpc08    -8.59e-06   2.07e-06    -4.15   0.000    -.0000128   -4.35e-06
       gpc08     .0000983   .0000228     4.32   0.000     .0000516     .000145
        gg08     .2986236   .0523206     5.71   0.000     .1912706    .4059767
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    60.4725517    33  1.83250157           Root MSE      =  .47964
                                                       Adj R-squared =  0.8745
    Residual    6.21150858    27  .230055873           R-squared     =  0.8973
       Model    54.2610432     6  9.04350719           Prob > F      =  0.0000
                                                       F(  6,    27) =   39.31
      Source         SS       df       MS              Number of obs =      34
. regress lnpp08 gg08 gpc08 gg08gpc08 rd06 im05 to08
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Table 25: Stata Output for GNI per Capita Interaction Cross-sectional Model without R&D 
The Percentage of GDP invested in R&D interaction model 
We will use the parsimonious model as the base model because we consider it to be the best trade-
off between simplicity and accuracy. We suppose that the impact of governance is different 
dependant the level of the percentage of GDP invested in R&D. We create an interaction term 
[gg08rd06=gg08*rd06] and introduce it in the parsimonious model. The STATA output is 
presented in the table 26. 
Table 26: Stata Output for the GDP invested in R&D Interaction Cross-sectional Model 
The interaction term is not significant and is strongly engaged in collinearity (Appendix 4). 
Consequently, we reject the interaction between governance and R&D.  
                                                                              
       _cons    -14.99861   1.295504   -11.58   0.000    -17.61692    -12.3803
        to08     .0187129   .0148121     1.26   0.214    -.0112235    .0486493
        im05     6.135965   7.798196     0.79   0.436    -9.624777    21.89671
   gg08gpc08    -7.48e-06   1.86e-06    -4.02   0.000    -.0000112   -3.72e-06
       gpc08     .0000967   .0000199     4.86   0.000     .0000565     .000137
        gg08     .3093131    .044736     6.91   0.000     .2188984    .3997278
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    157.004028    45   3.4889784           Root MSE      =  .63408
                                                       Adj R-squared =  0.8848
    Residual    16.0822868    40   .40205717           R-squared     =  0.8976
       Model    140.921741     5  28.1843483           Prob > F      =  0.0000
                                                       F(  5,    40) =   70.10
      Source         SS       df       MS              Number of obs =      46
. regress lnpp08 gg08 gpc08 gg08gpc08 im05 to08
                                                                              
       _cons    -14.73851   1.476658    -9.98   0.000    -17.76836   -11.70866
        to08     .0249427   .0159866     1.56   0.130    -.0078591    .0577446
        im05     4.372559    9.18335     0.48   0.638    -14.47012    23.21524
        rd06     48.26437   22.87205     2.11   0.044     1.334791    95.19395
    gg08rd06    -2.686399    3.48737    -0.77   0.448    -9.841891    4.469092
       gpc08     .0000173    .000015     1.15   0.261    -.0000136    .0000482
        gg08     .2101197   .0793005     2.65   0.013     .0474086    .3728309
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    60.4725517    33  1.83250157           Root MSE      =  .60726
                                                       Adj R-squared =  0.7988
    Residual    9.95668667    27  .368766173           R-squared     =  0.8354
       Model    50.5158651     6  8.41931084           Prob > F      =  0.0000
                                                       F(  6,    27) =   22.83
      Source         SS       df       MS              Number of obs =      34
regress lnpp08 gg08 gpc08 gg08rd06 rd06 im05 to08
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Comparing the Models 
The following table compares the different models. We have not included the R&D interaction 
model because of the absence of significance of the interaction term. 
Table 27: Comparison of the Cross-sectional Multivariate Models 
 
Full Analytical 
Model 
Reduced Analytical 
Model 
Parsimonious 
Analytical 
GNI interaction 
model 
Number of 
observations 
(n) 
20 34 34 34 
Variable 
engaged in 
collinearity 
Variable with 
VIF>10 
Governance None None Interaction term and 
GNP per capita 
Adjusted R2 0.8944 0.8023 0.8017 0.8745 
         
Log of 
publications 
per capita Coef. P>t Coef. P>t Coef. P>t Coef. P>t 
         
Governance -4.76E-03 0.9570 1.63E-01 0.0040 1.64E-01 0.0040 2.99E-01 0.0000 
GNI per 
capita 8.15E-05 0.0080 2.18E-05 0.1700 1.77E-05 0.2470 9.83E-05 0.0000 
% of GDP 
invested in 
R&D -3.46E+00 0.8740 3.24E+01 0.0160 3.35E+01 0.0120 2.98E+01 0.0060 
Immigrants 
per capita 5.90E+00 0.5530 4.50E+00 0.6210 5.79E+00 0.5220 3.13E-01 0.9660 
English 
proficiency 3.27E-02 0.1590 3.54E-02 0.0650 2.47E-02 0.1300 3.36E-02 0.0140 
% of GDP 
related to 
trade -4.63E-01 0.2170 -2.24E-01 0.2380     
Log of 
population -9.39E-02 0.3670 4.28E-02 0.6510     
% of 
households 
using internet 1.36E+00 0.2670       
Governance 
and GNP per 
capita 
interaction 
term        -8.59E-06 0.0000 
 
The adjusted R2s lie between 0.79 and 0.89. The full and GNP per capita interaction model have 
higher R2 but are probably over fitted. These two models have variables with VIF > 10. As 
exposed in the methods chapter, the VIF is a test for collinearity and values over 10 indicate 
problems with the inclusion of a specific variable.  
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Significance, direction and magnitude of the estimates are all similar in the reduced analytical 
model (with control variables) and the parsimonious (without control variables). Even with 
collinearity, the GNI per capita interaction model is in line with the estimates of these two 
models, supporting that interaction term introduced is valid.  
Within three models, the increase of 1 point in the scale of governance, holding the other 
covariates equal, increases the publications per capita from 16% to 29%. 
Excluding R&D to increase to number of countries included in the analysis systematically 
reinforces the strength and the significance of governance estimates. Furthermore, it does not 
change in an unexpected way the strength and significance of the other covariates. 
To understand the impact of the USA on the results (an outlier in terms of share of publications), 
we removed the USA from the data set and reran all the cross-sectional models. We report no 
change in terms of significance, direction and magnitude of the estimates (appendix 4). 
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Longitudinal analysis (1996 – 2008) 
A. Data description 
Evolution of share of publications and publications per capita 
The raw evolution of the share of publications (share in 2008 - share in 1996) and publications per 
capita (publication per capita in 2008 - publication per capita in 1996) for the 50 countries are 
presented in the following graphs. 
Figure 23: Evolution of Share and Publications per capita (1996-2008)  
 
Due to the importance of its share of publications, the USA behaves as an outlier in our data set. 
Consequently, as for the cross-sectionnal analysis, we will rerun, without the USA, all 
longitudinal multivariate models.  
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Figure 24: Evolution of Share and Publications per capita excluding USA (1996-2008)  
 
The USA, Japan and France have lost the most of both indicators. Singapore, Iceland and 
Denmark have performed the best in terms of publication per capita increase. However due to 
their small size, the publication share gain is small. China, without increasing significantly its 
productivity is the country that has increased its share the most. Countries like Australia or Korea 
have increased significantly both on productivity and share. These results suggest that the gravity 
centre of biomedical research may be moving towards the Asia/Pacific region. 
Percentage of evolution of share and publications per capita 
The picture is different when analyzed by the percentage of evolution in terms of share and 
productivity. The evolution is calculated as: ([value in 2008-value in 1996]/value in 1996). The 
figure below has log transformed these variable for better interpretation. 
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Figure 25: Percentage of Evolution in Share and Publications per capita (1996-2008) 
 
China, Singapore and Iran have presented the highest increase of share and productivity. The 
graph also suggests a high correlation between share and productivity evolution (due to the fact 
that the evolution of publication is faster than the evolution of the population) suggesting that only 
one of the two measures could be used as a dependant variable in dynamic analytical models.  
B. Description of variables and of the within and between variation 
The following table presents the description overall, between (countries) and within (each 
country) variation for the period 1996-2008.  
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Table 28: Overall, Between and Within Variation of all Panel Data Variables 
Variable Label Effect Mean Std. Dev. Min Max Observation
s 
                
Log of 
publications 
per capita 
lnpp overall -11.0 1.92 -15.15 -8.16 650 
    between   1.92 -14.60 -8.27 50 
    within   0.24 -12.00 -10.11 13 
                
Global 
Governance 
gg overall 4.3 5.3 -6.9 11.7 500 
    between   5.4 -5.5 11.2 50 
    within   0.7 1.3 7.0 10 
                
GNI per 
capita 
gpc overall 19 575  12 313 1 090 65 050 648 
    between   11 728 1 249 50 232 50 
    within   4 052 5 921 38 631 12.9 
                
% of GDP 
invested in 
R&D 
rd overall 1.49% 0.98% 0.08% 4.76% 466 
    between   0.98% 0.11% 4.11% 48 
    within   0.19% 0.18% 2.14% 9.7 
                
Average 
TOEFL® 
scores  
to overall 286.9 161.3 19.0 616.0 626 
    between   21.1 227.1 343.8 49 
    within   160.0 47.4 581.2 12.8 
                
Immigrants 
per capita 
im overall 0.0097 0.0176 -0.0362 0.0914 100 
    between   0.0159 -0.0195 0.0620 50 
    within   0.0078 -0.0197 0.0391 2 
                
% of 
households 
using internet 
e overall 26.84% 24.57% 0.01% 86.80% 632 
    between   17.56% 2.18% 56.84% 50 
    within   17.38% 20.96% 63.08% 12.6 
                
Log 
population 
lnpop overall 16.91 1.62 12.51 21.01 650 
    between   1.64 12.57 20.97 50 
    within   0.04 16.76 17.07 13 
                
International 
trade  
tr overall 64.6% 47.5% 12.4% 3.67 647 
    between   46.6% 19.4% 3.08 50 
    within   11.2% 13.9% 1.24 12.9 
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The description of the variables does not present any apparently invalid values and values are 
consistent year to year. However, for all variables, the variation between countries (for each year), 
is larger than the variation within each country during the 13 periods (except for English 
proficiency due to a change in the measurement method of the score). Data for immigrants per 
capita was available only for the year 2000 and 2005. To avoid drawing conclusion from an 
unbalanced dataset, we will run all models with and without immigrants per capita.  
C. Fixed or random effects? 
To provide consistency throughout our study we conducted the panel data analysis on the three 
most important models used during the cross sectional analysis: the full analytical model, the 
reduced analytical model and the parsimonious model. 
A priori, we assumed that the overall effect of unobserved variables was random, meaning that 
they were not correlated to the predictors. Indeed, during the 1996-2008 period, the effect of 
unobserved environmental factors, in particular country specific changes in research policies, in 
the economic structure or in international exchange regulations, may have produced specific 
impacts independent from the factors analyzed. Therefore, we made the assumption that this 
unobserved effect (in fact the time-invariant component of the error term) acted, in our sample of 
countries, as a random variable (with a Gaussian distribution) that has an impact independent of 
the predictors’ value (and in particular from the main predictor: governance). For example, 
countries may have decided to invest massively in biomedical research while others have invested 
in physical science and this policy could be decided independently for the level of governance or 
the percentage of GNP invested in R&D. 
However, our assumption was not confirmed by the Hausman tests we conducted. Indeed, they 
determined that for two of the three models tested, a fixed effect was more appropriate (see 
Appendix 4 for detailed analysis). Of course, the fixed-effects models control for all time-
invariant differences between the entities, so the estimated coefficients of the independent 
variables cannot be biased because of omitted time-invariant characteristics such as culture or 
religion. However, fixed effects mean that they are correlated to the independent variables. 
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D. Results 
The labels for the panel data analysis 
Table 29 presents the labels for each variable used in the panel data models. 
Table 29: Labels of the Panel Data Variables 
Variable Labels 
Log of publications per capita (articles / habitant) lnpp 
Global Governance  gg 
GNI per capita ($US) gpc 
% of GDP invested in R&D rd 
International trade (merchandise import and export) as a % 
of GDP tr 
% of households using internet e 
Average TOEFL® scores  to 
Immigrants per capita (immigrants / habitants) im 
Log of population (habitants) lnpop 
The full analytical model 
For this model, we are using a fixed effect. To control for heteroscedasticty, we use the “robust” 
option provided by STATA (Kennedy, 2008). The output is presented in the following table. 
Table 30: Stata Output for Full Analytical Panel Data Model 
 
Governance, international trade and the population size are significant at the 0.05 level. GNI per 
capita and the percentage of GDP allocated to R&D are not. In comparison to the cross-sectional 
model, these results are unexpected.  
                                                                              
         rho    .99883746   (fraction of variance due to u_i)
     sigma_e     .1856346
     sigma_u    5.4412878
                                                                              
       _cons    -66.75124   22.34068    -2.99   0.005    -111.7759   -21.72656
       lnpop     3.056926   1.374825     2.22   0.031     .2861493    5.827703
          tr     1.574432   .4297823     3.66   0.001     .7082628    2.440601
           e      .076294   .5573086     0.14   0.892    -1.046888    1.199476
          im     5.416452   3.659661     1.48   0.146     -1.95911    12.79201
          to     .0100072   .0082905     1.21   0.234    -.0067012    .0267155
          rd     14.91429   31.36394     0.48   0.637    -48.29557    78.12415
         gpc    -1.91e-06    .000033    -0.06   0.954    -.0000684    .0000645
          gg     .1134974   .0470012     2.41   0.020     .0187727    .2082222
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 45 clusters in id)
corr(u_i, Xb)  = -0.9472                        Prob > F           =    0.0000
                                                F(8,44)            =     10.95
       overall = 0.0861                                        max =         2
       between = 0.1232                                        avg =       1.7
R-sq:  within  = 0.6978                         Obs per group: min =         1
Group variable: id                              Number of groups   =        45
Fixed-effects (within) regression               Number of obs      =        77
. xtreg lnpp gg gpc rd to im e tr lnpop, fe robust
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After excluding immigrants per capita, GNI per capita becomes significant. Internet becomes 
quasi significant (.09). Governance remains in acceptable significance values (.085). International 
trade and population remain significant (table 31). 
Table 31: Stata Output for Full Analytical Panel Data Model without Immigrants per capita 
Reduced analytical model 
For this model, we are using a fixed effect. To control for heteroscedasticty, we use the “robust” 
option provided by STATA (Kennedy, 2008). Consistent with the cross-sectional analysis, we 
drop out the percentage of households using the Internet. The output is presented in the following 
table. 
 
 
 
 
 
 
                                                                              
         rho     .9984272   (fraction of variance due to u_i)
     sigma_e    .18499949
     sigma_u     4.661135
                                                                              
       _cons    -49.42316   13.47647    -3.67   0.001    -76.56617   -22.28016
       lnpop     2.230522   .7857064     2.84   0.007     .6480277    3.813015
          tr     1.088842   .1747006     6.23   0.000     .7369767    1.440707
           e     .3488389   .2033531     1.72   0.093    -.0607353     .758413
          to    -.0000224   .0001736    -0.13   0.898     -.000372    .0003272
          rd     11.48516   17.34513     0.66   0.511    -23.44972    46.42004
         gpc    -.0000215   7.28e-06    -2.96   0.005    -.0000362   -6.86e-06
          gg      .040607   .0230714     1.76   0.085    -.0058611    .0870751
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 46 clusters in id)
corr(u_i, Xb)  = -0.9299                        Prob > F           =    0.0000
                                                F(7,45)            =     15.64
       overall = 0.1699                                        max =         9
       between = 0.1986                                        avg =       7.1
R-sq:  within  = 0.4508                         Obs per group: min =         3
Group variable: id                              Number of groups   =        46
Fixed-effects (within) regression               Number of obs      =       326
. xtreg lnpp gg gpc rd to e tr lnpop, fe robust
93 
Table 32: Stata Output for Reduced Analytical Panel Data Model 
The significance, the magnitude and the direction and of the estimates are not different from the 
full analytical model. Interestingly, the variable immigrants per capita is not far from being 
significant. 
After excluding immigrants per capita, the overall significance, strength and direction of the 
estimates do not change (table 33).  
 
 
 
 
 
 
 
 
                                                                              
         rho     .9988647   (fraction of variance due to u_i)
     sigma_e    .18192588
     sigma_u    5.3962437
                                                                              
       _cons    -66.62681   22.28017    -2.99   0.005    -111.5295   -21.72407
       lnpop     3.043269   1.374359     2.21   0.032     .2734301    5.813107
          tr     1.582592   .4182151     3.78   0.000     .7397346    2.425449
          im     5.576558   3.318279     1.68   0.100    -1.110994    12.26411
          to     .0102203   .0083277     1.23   0.226    -.0065632    .0270038
          rd     14.23697   30.23566     0.47   0.640    -46.69899    75.17294
         gpc     2.03e-06   .0000145     0.14   0.889    -.0000271    .0000312
          gg     .1139009   .0463919     2.46   0.018     .0204041    .2073976
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 45 clusters in id)
corr(u_i, Xb)  = -0.9461                        Prob > F           =    0.0000
                                                F(7,44)            =     12.43
       overall = 0.0827                                        max =         2
       between = 0.1191                                        avg =       1.7
R-sq:  within  = 0.6977                         Obs per group: min =         1
Group variable: id                              Number of groups   =        45
Fixed-effects (within) regression               Number of obs      =        77
. xtreg lnpp gg gpc rd to im tr lnpop, fe robust
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Table 33: Stata Output for Reduced Analytical Panel Data Model without Immigrants per capita 
Parsimonious model 
For this model, we are using a random effect. To control for heteroscedasticty, we use the 
“robust” option provided by STATA (Kennedy, 2008). Consistent with the cross-sectional 
analysis, we drop out population and international trade. The output is presented in the following 
table. 
 
 
 
 
 
 
 
 
. 
                                                                              
         rho     .9982329   (fraction of variance due to u_i)
     sigma_e    .18667301
     sigma_u    4.4367703
                                                                              
       _cons    -47.83651   13.96713    -3.42   0.001    -75.96776   -19.70526
       lnpop     2.130156   .8144212     2.62   0.012     .4898277    3.770485
          tr     1.082219   .1727211     6.27   0.000     .7343407    1.430097
          to    -.0001414   .0001533    -0.92   0.361    -.0004501    .0001673
          rd     12.56012   17.66428     0.71   0.481    -23.01757    48.13781
         gpc    -9.92e-06   7.55e-06    -1.31   0.195    -.0000251    5.28e-06
          gg     .0433611   .0235156     1.84   0.072    -.0040018    .0907241
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 46 clusters in id)
corr(u_i, Xb)  = -0.9208                        Prob > F           =    0.0000
                                                F(6,45)            =     20.60
       overall = 0.1529                                        max =         9
       between = 0.1806                                        avg =       7.1
R-sq:  within  = 0.4388                         Obs per group: min =         3
Group variable: id                              Number of groups   =        46
Fixed-effects (within) regression               Number of obs      =       326
. xtreg lnpp gg gpc rd to tr lnpop, fe robust
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Table 34: Stata Output for Parsimonious Panel Data Model  
The results are interestingly different from the previous models: Governance remains significant 
while GNI per capita and R&D become significant.  
After excluding immigrants per capita, the overall significance, strength and direction of the 
estimates do not change (table 35).  
Table 35: Stata Output for Parsimonious Panel Data Model without Immigrants per capita 
                                                                              
         rho    .89883472   (fraction of variance due to u_i)
     sigma_e    .23686041
     sigma_u    .70601944
                                                                              
       _cons    -13.62077   1.552158    -8.78   0.000    -16.66295    -10.5786
          im     -1.04204   2.856382    -0.36   0.715    -6.640446    4.556367
          to      .001748   .0073252     0.24   0.811     -.012609    .0161051
          rd     47.99087   13.86239     3.46   0.001     20.82108    75.16066
         gpc     .0000496   .0000179     2.78   0.005     .0000146    .0000847
          gg     .1501538   .0287604     5.22   0.000     .0937844    .2065232
                                                                              
        lnpp        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                             Robust
                                                                              
                                     (Std. Err. adjusted for clustering on id)
corr(u_i, X)       = 0 (assumed)                Prob > chi2        =    0.0000
Random effects u_i ~ Gaussian                   Wald chi2(5)       =    241.93
       overall = 0.8479                                        max =         2
       between = 0.8657                                        avg =       1.7
R-sq:  within  = 0.3699                         Obs per group: min =         1
Group variable: id                              Number of groups   =        45
Random-effects GLS regression                   Number of obs      =        77
. xtreg lnpp gg gpc rd to im, re robust
                                                                              
         rho    .91158025   (fraction of variance due to u_i)
     sigma_e    .21384397
     sigma_u    .68662531
                                                                              
       _cons    -12.41513   .1965134   -63.18   0.000    -12.80028   -12.02997
          to    -.0001533   .0001549    -0.99   0.322     -.000457    .0001503
          rd     42.32026    10.1939     4.15   0.000     22.34059    62.29994
         gpc     .0000202   6.53e-06     3.09   0.002     7.38e-06     .000033
          gg     .1216553   .0174774     6.96   0.000     .0874002    .1559103
                                                                              
        lnpp        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                             Robust
                                                                              
                                     (Std. Err. adjusted for clustering on id)
corr(u_i, X)       = 0 (assumed)                Prob > chi2        =    0.0000
Random effects u_i ~ Gaussian                   Wald chi2(4)       =    188.56
       overall = 0.8534                                        max =         9
       between = 0.8753                                        avg =       7.1
R-sq:  within  = 0.1912                         Obs per group: min =         3
Group variable: id                              Number of groups   =        46
Random-effects GLS regression                   Number of obs      =       326
. xtreg lnpp gg gpc rd to, re robust
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E. Comparing the models 
The following table compares the different models on different criteria.  
Table 36: Comparison of the Longitudinal Panel Data Models 
 Full Analytical Model Reduced Analytical Model 
Parsimonious 
Analytical 
Number of 
observations (n) 
77 77 77 
R2 within 0.6978 0.6977 0.3699 
R2 between  0.1232 0.1191 0.8657 
R2 overall 0.0861 0.0827 0.8479 
       
 Coef. P>z Coef. P>z Coef. P>z 
       
Governance 1.13E-01 0.0200 1.14E-01 0.0180 1.50E-01 0.0000 
GNI per capita -1.91E-06 0.9540 2.03E-06 0.8890 4.96E-05 0.0050 
% of GDP 
invested in 
R&D 
1.49E+01 0.6370 1.42E+01 0.6400 4.80E+01 0.0010 
Immigrants per 
capita 5.42E+00 0.1460 5.58E+00 0.1000 -1.04E+00 0.7150 
English 
proficiency 1.00E-02 0.2340 1.02E-02 0.2260 1.75E-03 0.8110 
% of GDP 
related to trade 1.57E+00 0.0010 1.58E+00 0.0000   
Log of 
population 3.06E+00 0.0310 3.04E+00 0.0320   
% of households 
using internet 7.63E-02 0.8920     
 
Significance, direction and magnitude of the different estimates of governance are very consistent 
throughout the models. Governance is the only predictor to be significant in all the models tested.  
However, we note two interesting facts.  First, the international trade and the population size are 
significant predictors in the two most complete models. Second GNI per capita and the percentage 
of GDP invested in R&D are only significant in most parsimonious models. 
Within the range of these three models, the increase of 1 point of governance, holding the other 
covariates equal, increases the publications per capita from 11% to 15%. Compared to cross-
sectional analysis, panel data has reduced the range of effect of governance. One possible 
interpretation of this higher precision is that panel data is less sensible to collinearity, which is 
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important in this sample. Indeed, collinearity may have caused erratic behaviour of variables in 
the cross sectional analysis. 
The results do not change notably when immigrants per capita is removed, in particular regarding 
the effect of governance. However, it appears that immigrants per capita and GNI per capita are 
linked and both associated to publications per capita. Nevertheless, when combined in the two 
fullest models, immigrants per capita takes most of the variance. 
To account for its importance in terms of share of publication, we removed the USA from the data 
set and reran all the longitudinal models. As for the cross-sectional models, we report no change 
in terms of significance, direction and magnitude of the estimates (appendix 4). 
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Major quantitative findings 
Table 30, following this section, provides a summary of the statistical results of all cross-sectional 
and panel data analysis models considered valid. In our view, the most informative models have 
been the two most complete panel data models (full analytical and reduced analytical model). 
Indeed, with these models we were able to combine as many independent variables as possible 
while avoiding collinarities that occurred in the cross-sectional model. It is also important to keep 
in mind that, compared to the literature we have found, our models are much more complete in 
terms of theoretical constructs and independent variables analyzed. This exhaustiveness means 
that we provided an improved ceteris paribus analysis. We will review below the major findings.  
A. Governance 
The results suggest that there is a strong statistical association between governance and 
publications per capita. Two main reasons support this conclusion. 
First, governance is the independent variable the most consistently associated with publications 
per capita. Indeed, governance is significant in 6 of the 7 models tested. Furthermore, in the 
model where governance is not significant, strong collinearities explains its loss of statistical 
significance.  
Second, the strength of the estimates of the governance is important. Indeed, one point of 
governance (that ranges from -6.9 to 10.8), increases, depending on the model, from 11% to 29% 
the publications per capita ratio of a country, the other covariates held equal. This effect is more 
likely to be between 11% and 16%, the estimates of most models falling in that range. 
The strong statistical association between governance and publications per capita firmly supports 
the idea that the political structure is a factor of biomedical research productivity.  
B. The covariates 
The GNI per capita and the percentage of GDP invested in R&D were two important covariates to 
analysis in part because of previous evidence of their impact on biomedical research performance. 
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We report mixed results. Indeed, these two variables tend to be not significant in the most 
complete models (full and reduced analytical models), in particular in the panel data analysis. 
The effects of international trade and population on biomedical research performance are 
interesting. Although they were not significant in the cross-sectional analysis, they became 
significant in the two most complete panel data models. Consequently, we assume that their effect 
is mostly due to a within country effect, meaning that growth in international trade and in 
population within a country is a significant driver of its biomedical research performance. 
Immigrants per capita was not far from being significant in the two most complete panel models. 
Immigrants per capita appears to absorb variance that, if it had not been included in the models, 
would have been transferred to GNI per capita. 
We do not confirm with certitude the impact of English proficiency reported by others. The 
percentage of households connected to the internet, shown to be associated with many 
independent variables in the bivariate analysis, did not emerge as significant in the multivariate 
cross-sectional and panel data models. Population density was rejected in bivariate analysis 
because no pattern of association was found with publications per capita. The governance and 
GNP per capita interaction term was found to be significant in the cross sectional analysis. 
Finally, we have rejected the interaction term between governance and R&D 
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: Comparison of the Cross-Sectional and Longitudinal Models 
Full Analytical model Reduced Analytical model Parsimonious Analytical model GNI per capita interaction model
Cross-sectional Panel Data Cross-sectional Panel Data Cross-sectional Panel Data Cross-sectional
Number of 
observations 20 77 34 77 34 77 34 
Adjusted R2 0.8944  0.8023  0.8017  0.8745 
Overall R2 
 0.0861  0.0827  0.8479  
Coef. P>t Coef. P>z Coef. P>t Coef. P>z Coef. P>t Coef. P>z Coef. P>t 
              
Governance -4.76E-03 0.9570 1.13E-01 0.0200 1.63E-01 0.0040 1.14E-01 0.0180 1.64E-01 0.0040 1.50E-01 0.0000 2.99E-01 0.0000
8.15E-05 0.0080 -1.91E-06 0.9540 2.18E-05 0.1700 2.03E-06 0.8890 1.77E-05 0.2470 4.96E-05 0.0050 9.83E-05 0.0000
% of GDP 
invested in -3.46E+00 0.8740 1.49E+01 0.6370 3.24E+01 0.0160 1.42E+01 0.6400 3.35E+01 0.0120 4.80E+01 0.0010 2.98E+01 0.0060
Immigrants 
 
5.90E+00 0.5530 5.42E+00 0.1460 4.50E+00 0.6210 5.58E+00 0.1000 5.79E+00 0.5220 -1.04E+00 0.7150 3.13E-01 0.9660
proficiency  3.27E-02 0.1590 1.00E-02 0.2340 3.54E-02 0.0650 1.02E-02 0.2260 2.47E-02 0.1300 1.75E-03 0.8110 3.36E-02 0.0140
% of GDP 
-4.63E-01 0.2170 1.57E+00 0.0010 -2.24E-01 0.2380 1.58E+00 0.0000     
  
population -9.39E-02 0.3670 3.06E+00 0.0310 4.28E-02 0.6510 3.04E+00 0.0320       
households 
using internet 
1.36E+00 0.2670 7.63E-02 0.8920         
  
Governance 
and GNP per 
interaction 
            -8.59E-06 0.0000
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Chapter 5: Discussion 
 
For the purpose of the discussion, we will keep in mind the 6 advantages of our study that addressed 
the deficiencies of prior research summarized in the literature review. These were: focus on the 
biomedical sector, global, quantitative, cross disciplinary accounts for the role of time and account for 
co-evolution. We will also refer back to the concept map for guidance. 
Limits of the study 
Before reviewing and discussing the findings our study, we are mindful of the general limitations 
inherent this study, which is outside the realm of traditional health service research or econometrics. 
These limitations include construct and measurement of variables, sample construction, and analytical 
techniques. 
A. Construct and Measurements limitations 
The first limitation concerns the dependent variables. We are well aware that publications, drawn from 
a limited sample of journals and written in English cannot capture fully biomedical research. 
Numerous great research finding are published in more specialized but lower ranked journals. Other 
findings are not published at all in peer reviewed journals.  
The second limitation concerns the independent variables. As opposed to publications per capita, they 
are not specific to the biomedical sector. They reflect the environment or the system, in which all types 
of research or innovation may flourish. In interpreting the results, we should be mindful they are likely 
to be associated with non biomedical innovation as well. 
The third limitation is the level of variable transferability between levels of analysis. For example, the 
factor of physical proximity of research laboratories may not be reflected well in the measurement of 
density at a country level (a form of population gini or the number of research clusters by country may 
have had better measurement this concept). 
 
 102 
B. Sample construction limitations 
The sample construction method, based on a selection of top publishing countries, is not a random 
sample. Although the 50 countries represent 99% of all biomedical publications they represent only 
70% of the world’s population.  
C. Analytical techniques limitations 
Cross sectional linear regression and panel data rely on similar epistemological and mathematical 
assumptions. They can be qualified as “deterministic” in the sense that the model created a priori by 
the researcher has a strong association with the results. This influence is an advantage because it 
allows the researcher’s “thinking” to control for the statistical results. However, it may also limit the 
innovativeness of the findings. More open analytical techniques, such as Principal Component 
Analysis (PCA) to generate new key variables, may have provided different information and thus a 
different interpretation.  
Methodological lessons 
In Chapter 3, we had identified 6 additions to the extant research developed by this study. Amongst 
them was the importance of accounting for the role of time in the study of research and innovation. 
Although this point had been raised by several other scholars, (Consoli, 2009), we have not found 
valid quantitative studies that have operationalized this approach. In this section, we will discuss this 
point in the light of what we have learned by combining a cross-sectional analysis with a longitudinal 
analysis. We will focus on the disagreements between these two approaches and the unobserved effect 
in the panel data analysis. 
A. Disagreement between cross-sectional and longitudinal approach 
One of the objectives in combining the cross-sectional and the longitudinal approaches was to better 
understand the anticipated complex structure of our data. Over time, some disagreements appeared 
between these two approaches. Indeed, the GNI per capita and the percentage of GDP allocated to 
R&D, both significant factors in the cross-sectional analysis, were not significant in the two most 
complete panel data models. Conversely, the population size, international trade and immigrants per 
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capita, exhibited no significance in the cross-sectional models, but then became important in the panel 
data models. We will discuss the implication of this discrepancy more specifically in the following 
chapter. However, our point here is to stress the fact that the method can produced radically different 
results. In our view, and with a bit more experience on the topic, the longitudinal approach is a much 
more valid approach to study the dynamic of innovation in a rapidly changing world because they 
account for the current momentum. Cross sectional analysis gives a more accurate picture of the past.  
B. Understanding the unobserved effects in the longitudinal approach 
Prior to conducting the Hausman fixed or random specification tests, we had assumed that our data 
would demonstrate random unobserved effects. Indeed, during the 1996-2008 period, the effect of 
unobserved environmental factors, such as changes in research policies, the economic structure, or in 
international exchange regulations, may have produced a different impact depending on the country. 
Therefore, we initially made the assumption that these unobserved effects acted, in our sample of 
countries, as a random effect (they had an impact independently from the predictors’ value (and in 
particular from the main predictor: governance). For example, countries may have decided to invest 
massively in  biomedical research, while others invested in physical sciences and this policy could 
been decided independently of the level of governance, or of the level of the percentage of GDP 
invested in R&D. 
However, our assumption was not confirmed by the Hausman tests we conducted. Those tests 
determined that the fixed effect was more appropriate. Indeed, it appears that the unobserved time-
invariant characteristics that explain biomedical research performance are also associated with the 
observed factors (variables) that we have used. Another important assumption of the fixed effect 
models is that these time-invariant characteristics are unique to each country and should not be 
correlated with other countries.  
Our interpretation is that there is an underlying country specific “culture of science” that is 
interconnected within governance and the other covariates, and that impacts a country’s biomedical 
research performance. In other words, the countries that demonstrate that culture are also prone to be 
ranked high in governance and demonstrate a strong production of biomedical research. This 
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conclusion is line with prominent idea in the sociological and political science fields that culture, 
science, and modern democracy have co-evolved and influence one another. Simply stated, the 
specific national contexts are, besides the “objective” factors (governance, GNI per capita, % of GDP 
invested in R&D, etc.) fundamental in the performance of biomedical research performance.  
Finally, we need to stress that this “culture of science” effect does not undermine the importance of 
our observed factors, including (of course) governance. Indeed, in our view this “culture” is time-
constant for each country and therefore cannot cause change within a country during our short term 
period of analysis. The fixed models can then remove their effects so that we can assess our observed 
factors net effects over the period of time. 
The Role of the Covariates  
A. GNI per capita and the percentage of GDP allocated to R&D 
It is useful to review the GNI per capita and the percentage of GDP invested in R&D together because 
they are strongly linked. First, they both measure economic value and thus have both been classified as 
structural economic resources in our concept map. Second, the percentage of GDP allocated to R&D 
can be understood as the society’s relative value on R&D. However from an economic production 
standpoint, the absolute value (per capita) of R&D investments depends on the GDP per capita. By 
analyzing both together, we will get close to that absolute value.  
GNI per capita and the percentage of GDP invested in R&D were two important covariates to analyze 
in part, because of previous evidence of their impact on biomedical research performance, but also 
because of their political implications in the policy debate. Our study partly disagrees with previous 
work. Indeed, although these two variables are to some extent significant in the cross-sectional 
models, they are not significant in the most complete longitudinal models. Of course, we have to keep 
in mind the potential lag effect of R&D investments. Indeed, these investments do to not transform 
themselves instantly in research findings and publications. However, we think that within the 12-year 
period it is possible to observe some change in publications per capita due to a change in R&D 
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spending. One argument is that 12 years is the average completion time of a publicly funded clinical 
research project in France (French Ministry of Health, 2010). 
At this point, we need to keep in mind that, in our view, the most complete longitudinal panel data 
models are the most valid models we have used, meaning that we judge the level of evidence they 
provide is stronger than the other parsimonious or cross-sectional models.  
Our interpretation of these results is the following. While differences in economic resources dedicated 
to R&D have been important in determining the differences in biomedical research performance 
between countries until now, their increase over the last decade within a country has not produced 
significant differences in performance. A first hypothesis is that we have not been able to capture the 
true economic resources dedicated to biomedical research over that period of time. A second 
hypothesis is that there is a “short” (10 years) and “long” (history) term effect of economic resources. 
The wealth of a country is accumulated throughout its history, and certainly wealthy countries were 
able to develop concomitantly a vibrant biomedical research program. This long term process can 
explain today’s difference between the countries’ performances. However, in the short term, a sudden 
influx of cash does not produce per se a significant impact on biomedical research performance. This 
short term effect suggest that it takes much more than solely investing in economic resources to build, 
in a traditional political time frame (5 to 10 years), strong biomedical research. 
B. Population, international trade and immigrants per capita 
The effects of population and international trade specifically on biomedical research performance had 
not been studied at length. We report here interesting findings.  
Population and international trade behave in opposing ways from GNI per capita and the percentage of 
GDP invested in R&D. Indeed, although they are not significant in the cross-sectional analysis, they 
become significant in the longitudinal analysis (in the two most complete panel data models). 
Consequently, we assume that the population growth and the increase of international trade within a 
country are significant short term drivers of biomedical research performance. This view is also 
supported by the fact that the influx of immigrants (as a source of population increase and 
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international trade) was not far from being significant in longitudinal analysis. Going back to our 
concept map, these findings strongly highlight the importance and impact of human resources (their 
diversity and connectivity), and their critical mass as major drivers of today’s biomedical research.  
C. Summary of covariate findings 
We have to keep in mind that the covariates are defined in our concept map as structural variables. In 
the light of our findings, is appears that we have changed the pecking order of these variables: human 
resources and their critical mass have displaced short term drivers of biomedical research performance 
at the country level. Although management studies have pointed out the strategic importance of human 
resources in organizations, we have to admit that it was quite unexpected to demonstrate this 
significance at a national level. Nevertheless, this finding allows us to move forward confidently in the 
interpretation of governance, which first and foremost, reflects the organization of human interaction. 
Transformative Role of Governance 
We understand now from the previous section that human resources play an important (yet 
underestimated) role in biomedical research performance. In addition, the information we have 
gathered has led us to consider governance as the major factor of biomedical research, all other factors 
held equal. These results make our initial hypothesis clearly valid: “governance is the most significant 
factor of biomedical research performance” (excerpt of the research question Chapter 3). This 
relationship is striking not only because of the strength and consistency of the association, but also 
because of the little of attention given to this topic in past research and in the current political debate 
(at least within the biomedical sector). However, validating our hypothesis does not make us 
understand why governance impacts biomedical research. In the following sections, we will consider 
three explanations of the underlying mechanism. We have called them: the rational view, the political 
view and the innovation view. 
A. The rational view 
This first level of understanding uses governance in its simplest organizational capacity and is a direct 
application of the concept map. Governance has the ability to efficiently transform human and 
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financial resources into innovation. In this sense, governance is synonymous with rational 
organization. 
This rational view is supported by the fact the in all models (aside from governance) there is always a 
human or an economic resource variable that is significant. Our interpretation is that governance alone 
cannot do it, and that these resources have to be “engineered” by governance. This view is also 
supported by the GNI per capita and governance interaction model. Indeed, the more GNI per capita 
declines, the more publications per capita is associated with governance. In other words, in times of 
scarcity, governance pulls out more from financial resources when they are short. This effect would be 
called operational effectiveness in firms. A final fact supports this rational view: governance has a 
short term effect. Indeed, although it seems straightforward that financial resources such as the 
percentage of GDP invested in R&D or GNI per capita would have had an impact during the study 
period within a country (which turned out to be unsupported  by our conclusion) it was less obvious 
for governance. To make the assumption that a change in governance, (sometimes closely attached to a 
long lasting effect of national “culture”) would be associated with a change in publications per capita 
over the 12 year period was ambitious, however, because we found governance to be significant in 
both the cross sectional and the longitudinal data model, we assume that there was a within effect of 
governance Again, this suggests that governance is similar to the organization of a firm: if improved is 
has the potential to improve performance is the short run. Amongst the 6 World Bank governance 
indicators that constitute our global governance score, this view can be described by the “government 
effectiveness” indicator. 
This first level of interpretation could be defined in a simple, straightforward way: a good organization 
optimizes key resources. 
B. The political view 
The political view corresponds to the political nature of biomedical science. As mentioned in Chapter 
1, biomedical research is meant to serve first the citizens of a country by improving their health and 
boosting their economy. However, it is clear that because of the economic importance of the 
biomedical research sector and the number of stakeholders involved, the risk of private interests 
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overruling the system is also important. When this overruling occurs, it can take many forms, such as 
financial conflicts of interests in the conduct of clinical trials, government intrusion or political 
struggles on biomedical research priorities. In addition, the ethical dilemmas in human subject 
research create zones of uncertainty and consequently margins for political entrepreneurship. Simply 
put, private interests, when unmanaged, may reduce the performance of the biomedical research 
system as a whole. The country’s global output is then less than its achievable value.  
In this context, we assume that performance of this system depends upon the fair allocation of benefits 
and cost between the stakeholders. In our view, political governance organizes this allocation in a fair 
yet effective way. Although this assurance is obvious, it departs from today’s common understanding. 
Indeed, it is usually admitted, for example, that aggressive private lobbying or investigator conflicts of 
interest are “part of the game” in a high performing biomedical research country. However, we posit 
that accepting this state of affairs not only disservices the general public but also diminishes the ability 
of the industry to innovate. Indeed, accepting distorted political processes reinforces the established 
actors, and inhibits emerging actors, sometimes with promising innovations, from entering the game.  
Within this view, the practical mechanism by which governance promotes biomedical innovation can 
be described appropriately by three of the 6 World Bank governance indicators that constitute our 
global governance variable: “regulatory quality”, “rule of law” and “control of corruption”. Examples 
include regulations of market competition, respect of property rights or independence of policy 
making. Furthermore, countries with effective governance are also able, when they are correcting 
market failure, to channel the resources (not to subsidize a market that already exists) in order to fund 
a promising research front without a tangible economic value. However, in our understanding, the 
democratic process, or the ability for a country to understand the voices and needs of all its citizens 
and stakeholders and to transparently act upon them in the interest of the majority, is the most 
important mechanism of biomedical research performance. This mechanism is well described by the 
“voice and accountability” indicator that is included in our global governance score. The explanation 
of this mechanism is based upon the innovation process itself: it is a common understanding that 
innovations very frequently originate from small, emerging, and therefore economically and politically 
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weak actors. Countries that are able to reach down and support them innovate better than those who do 
not. 
C. The innovation view 
Past research has focused heavily on the innovation process (Dodgson, 2000) whether it is 
conceptualized as a linear process (the old view) or a complex system (the modern view). The two 
views we have presented in the previous sections do not explicitly explain how governance supports 
the innovation process. This explanation is the objective of this section. To do this, we will look again 
at the innovation process and see how governance supports it.  
Although organizations, firms or governments, would appreciate if innovation could be engineered as 
an industrial process, the reality is that innovation is better understood as a random or unpredictable 
occurrence. Indeed, it is quite clear that some major innovations have an accidental twist to their 
discovery. For example, in 1928, Alexander Fleming accidently discovered the anti-bacterial 
properties of a fungus named penicillium.  
Unpredictable does not mean impossible. As our research implicates; three major conditions need to 
be present in order to assure innovation in the context of unpredictability: diversity, volume and 
tolerance to failure.  
Diversity is necessary for innovation because is assures problems and solutions are framed and 
resolved differently, yielding the potential for a breakthrough innovation. In our work, population 
growth, immigrants per capita and international trade have measurable diversity. Diversity makes the 
notions of “common”, “usual” or “norm” obsolete. For example, today French scientists at the Necker 
Hospital, instead of trying to understand the origins of disease (traditional medicine), are unlocking the 
secrets of expanded life by studying highly resistant life forms such as radiation resistant bacteria 
(Radman, 2010). Tomorrow, biomedical scientist and physicians from China and India may 
completely challenge some fundamental biological assumptions made years ago by Western scientists 
to create new paradigms.  
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However, diversity alone is not sufficient. Diversity needs volume: one team of biologists and 
oncologists may not automatically produce breakthrough research, but one out of many such teams 
may be awarded with a Nobel Prize. In our work on population growth, GNP per capita of the 
percentage of GDP invested in R&D measure this concept of volume. 
Diversity and volume are strongly linked: increasing diversity means increased potential for 
breakthrough research. However, this also means an increased risk of failure. For each successful 
innovator there are numerous failed innovators. This reality necessitates a tolerance to failure; some 
call it resilience (Weick, 2007), for innovation. Indeed, if the system does not treat failure as a normal 
outcome, it reduces the incentives for diversity and the volume of research, and subsequently potential 
breakthrough research.  
In our understanding, facing these major conditions of innovation, an innovation system needs to 
present specific characteristics. These are summarized in the following table.  
Table 38: Properties of the Innovation Process and Implications for its System 
If innovation is unpredictable 
but is possible because of: 
Then the system needs the following characteristic: 
Diversity Integrate diversity: ideas, people, cultures 
Volume Channel sufficient resources even if research is far from the “norm” 
Tolerance to failure Resilience: accept failure as part of the innovation game 
 
The question now is whether governance provides a system where lucky draws are systematically 
captured and where failures are accepted. In our perspective, governance does precisely this in three 
ways. First, governance suggests that all positions, thoughts, ideas, and preferences of citizens are 
taken into account, not only the more influential. In fact, good political governance maximizes the 
diversity of the people and utilizes that diversity to improve the quality of life for it citizens. Second, 
governance is at ease with density and size because its precise purpose is to organize human lives at a 
country level. Finally, when we observe the top 10 performing countries in our sample, it is surprising 
to see that six (Denmark, Sweden, Norway, Iceland, Switzerland or the Netherlands) have common 
political attributes. More than other countries, they have developed effective safety nets for their 
citizens (for example the flexi-security employment system in Denmark). In terms of biomedical 
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research, this could mean that they are better prepared to support failures. Besides the “culture of 
science” that we identified earlier, this “culture of resilience” could actually be a second time-constant 
unobserved effect that combines itself in specific countries with “objective” governance to promote 
biomedical research performance.  
Biomedical research is stronger in well-governed countries because they are prepared to take 
advantage of diversity and volume and to support failure. In line with Christensen’s (2009) disruptive 
innovation theory, the real innovation in these countries may well be their political organizations 
rather than any biomedical products or technologies they have discovered.  
D. Leadership and Governance 
We have demonstrated that governance is a major determinant of biomedical research performance. 
We also know that leadership is needed to promote change in organisations and to create an 
environment that fosters biomedical discoveries and innovation (Hollingsworth, 2007). It is therefore 
interesting to draw a parallel between “good” leadership and “good” governance. 
For this purpose, we will compare the 6 governance indicators of the World Bank with a set of 
leadership skills identified by well known author, Daniel Goleman. For Goleman great leaders 
distinguish themselves from simply good ones by demonstrating higher Emotional Intelligence (EI). 
The 5 EI skills are self-awareness, self-regulation, motivation, empathy and social skills. The 
following table shows interesting links between good governance and good leadership. 
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Table 39: Leadership and Governance 
6 World Bank governance indicators Goleman emotional intelligence skills 
Voice and accountability Self awareness, empathy 
Regulatory quality Self regulation, social skills 
Rule of law Self regulation, social skills 
Government effectiveness Motivation 
Control of Corruption Self regulation, social skills 
Political stability Social skills 
 
E. Practical implications of Governance and of our Models 
Is it feasible to change governance enough to impact biomedical research performance? 
One point of governance is likely to increase from 11% to 16% the publications per capita ratio of a 
country, the other covariates held equal. However, is it reasonable to think that one point of change in 
governance can be achieved? Since 1996, the average global governance score has increased (up to 
2002) and then decreased leading to a negligible variation of -0.02 between 1996 and 2008. The 
decline between 2002 and 2008 (-0.2) was in particular due to the reduction of approximately one 
point of the higher end values (countries such as Denmark or Switzerland) and lower end (such as 
Venezuela or Iran). 
Figure 26: Evolution of Governance (1996-2008) 
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Within this global evolution, the “within” standard deviation of governance over the 1996-2008 period 
is 0.7 (table 28). Some countries have increased during this period their global governance much more 
than the standard deviation (Croatia +4.1 points, Iceland +1.8). Consequently, we can assume that the 
variation of one point of governance is feasible during a period of 12 year.  
Do our models make acceptable prediction?  
If we compare, Switzerland with the USA, we see that for a similar level of GNI per capita (US$46, 
460 versus US$46, 970 in 2008), the percentage of GDP invested in R&D (2.9% versus 2.6% in 2004) 
and similar population, immigrants per capita and international trade growths, Swiss teams have 
published in 2008 + 84% (raw number) or +7.5% (logarithmic) more articles per capita than American 
teams. However, there is a 2 points difference in the global governance score (10.4 for Switzerland 
versus 8.1 for the USA) that in our view explains the difference in biomedical research performance. 
If we make the assumption that 1 point of governance yields a 11% increase of publication per capita, 
the USA will increase the log of publication per capita by +25% if it increases governance to 10.4. 
This estimate is higher than the observed difference between Switzerland and the USA (+7%). 
However, we consider this difference to be acceptable in particular because we have not accounted for 
the difference in the other covariates. Altogether, it seems reasonable to assume that our models make 
acceptable prediction. 
Table 40: Switzerland versus the USA 
2008 Switzerland USA 
GNI per capita 46 460 46 970 
% of GDP invested in R&D 2.9% 2.6% 
Observed publication per capita 0.0002654 
(+84% compared to USA) 
0.000144 
Observed Ln (publications per capita) -8.2 
(+7.5% compared to USA) 
-8.8 
Global Governance 10.4 8.1 
Impact of Ln(publication per capita) if 
USA would increase to 10.4 its 
governance 
+25.4% N/A 
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Conclusion and implications for public health leaders 
A new order in a globalizing World 
Briefly stated, our results suggest that we need to change the ranking order of country level biomedical 
research performance factors, previously based on the prominence of economic resources. In our 
perspective, economic resources such as GNI per capita and the percentage of GDP allocated to R&D 
are still fundamental in the long run. However, a fast growth in population, international trade and 
immigration are today’s drivers of biomedical research performance. Most importantly, in a field 
where the politics and the mechanism of innovation are specific, governance is necessary to transform 
these resources into performance.  
Why should we care about these results now that they are known? 
Firstly, in the context of globalization and biomedical R&D productivity decline, research 
organizations, firms or countries may want to know where they should invest and with who they 
should partner. This new order could provide guidance for those decisions. It is interesting to see that 
what it really asks for is that countries make the best out globalization; if by globalization we mean the 
increasing international mobility of people, financial resources, and merchandises (Oxford University, 
2011). Indeed, globalization can make countries better off by providing human and economic 
resources while at the same time facilitating their collapse through the systemic risks (from epidemics 
to financial catastrophes) it creates. Only effective and resilient political governance can absorb and 
positively transform these sudden shocks. Secondly, our results have implications for other fields. 
Indeed, these findings may be useful to understanding research and innovation generation in other 
sectors. 
It is clear that this study was too theoretical to identify practical policy options necessary to improve 
the effectiveness of biomedical medical research policies. Knowing this limitation, we avoided doing 
so. At best it has clarified the order of importance of certain political, economic, sociological, or 
management factors of biomedical research performance. One path forward in this area of research 
would be to look more closely at the specific policies of the top and bottom performing countries. 
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Implications for public health leaders 
Our approach may give some general yet clear guidance to public health leaders, not only those 
involved in biomedical research but also those who are in charge of creating public health innovative 
solutions.  
First, they must clearly understand the true dynamics of innovation. They probably recognize that 
innovation needs diversity and volume whether it is availability of economic or human resources. But 
are they aware that success needs simultaneous failures? Treating failure as a normal outcome and 
designing resilient system is essential to generate biomedical innovation. 
Second, public health leaders must understand the political importance of biomedical research and the 
impact governance can have on its performance. With most OECD countries spending more than 10% 
of GDP on health and biomedical research, the political stakes are high. Political conflicts or 
inefficiencies will happen. Public health leaders must build a system of innovation based on good 
governance, whether it is within or outside their organization. To be innovative, they must promote the 
key elements of good governances such as accountability, bottom-up participation, transparency, 
internal process effectiveness, regulatory quality and rule of law. Before asking for more money, have 
they done as much as they can within their organization? Outside their organization, have they been 
advocates for good governance in the political system in general? 
Third, they must understand that good governance and good leadership have similarities in particular 
the importance of listening and self-regulation. 
Finally, public health leaders should see in globalisation an opportunity for innovative solutions. Do 
they collaborate enough with foreign agencies or universities? Do they hire enough international 
talents? Will tomorrow’s best treatments or public health prevention programs be conceived by 
researchers from emerging economies? We think that it is more than likely. 
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Appendices 
Appendix 1 
Literature search strategies 
Search within the biomedical body of knowledge  
Search strategy: 
The main search was conducted within PubMed, the primary biomedical database for medical and 
biomedical science. Pubmed is a popular term for the Index Medicus. We mixed a systematic search 
with a “spin-off” search.  
In the systematic search, the literature was screened by using 6 combinations of 6 keywords 
(“biomedical”, “innovation”, “research”, “science”, “politics”, “management”) linked by the “AND” 
Boolean operator. 
The “spin-off” search was done by: (1) reviewing the references of the articles selected in the 
systematic search; (2) identifying leading journals and browsing their content; (3) identifying leading 
authors and their published studies; (4) including additional relevant keywords in search algorithms 
(such “performance”, “productivity”, “organization”, “bibliometrics”, “future”).  
It quickly appeared that the number of studies meeting the “hard” criteria was very small. 
Consequently, we introduced two “soft” criteria to capture a sufficient amount of appropriate material 
for our literature review. The soft criteria were: (1) relevance for our study; (2) simplicity of use of the 
research findings. No limit of time was set. 
 
Search results: 
Precise search algorithms and findings of the systematic search are presented below. 
 
The search results within the biomedical body of knowledge are presented in the following table:  
Method Number of 
articles retrieved 
through the 
systematic 
search 
Number of 
articles 
selected 
Articles 
meeting the 
criteria 
("biomedical"[Title/Abstract] AND 
"innovation"[Title/Abstract]) AND 
"management"[Title/Abstract] 
12 0 0 
("biomedical"[Title/Abstract] AND 
"innovation"[Title/Abstract]) AND 
"politics"[Title/Abstract]) 
3 0 0 
("biomedical"[Title/Abstract] AND 
"research"[Title/Abstract]) AND 
"management"[Title/Abstract] 
470 0 0 
("biomedical"[Title/Abstract]) AND 
("research"[Title/Abstract])) AND 
("politics"[Title/Abstract]) 
40 3 0 
("biomedical"[Title/Abstract]) AND 
("science"[Title/Abstract])) AND 
("management"[Title/Abstract]) 
101 0 0 
("biomedical"[Title/Abstract] AND 
"science"[Title/Abstract]) AND 
"politics"[Title/Abstract] 
18 1 0 
Total 644 4 0 
Method Number of 
articles 
retrieved 
Number of 
articles 
Selected 
Articles meeting 
the “hard” 
criteria 
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Search within the social science  
Search strategy: 
The literature review was enlarged outside the biomedical literature into social science fields with the 
assumption that the factors impacting research and innovation indentified would be transferable to the 
biomedical sector. 
Web of Science® administered by ISI was the database chosen for this search. By enlarging the scope 
of the literature, it became obvious that the amount of academic discussion around innovation, 
research and science within the social science realm was  vast. To extract useful findings from the 
immense amount of information, a review was conducted in order to systematically and quickly 
indentify the leading authors, papers, or research fronts. As in the search within PubMed, this strategy 
mixed a four step systematic search using keywords and a spin-off search. 
Concerning the systematic search, a first step was conducted using 3 combinations of the following 
key words using the “AND” Boolean operator: “innovation”, “research” and “science” and 
“biomedic*” (the use of truncated key words is possible in Web of Science® and increases the search 
sensitivity to word families). The second step focused on 6 social science fields. These fields (political 
science, economics, sociology, history, geography and management) were found to contribute 
significantly to the study of innovation and were thought to provide constructs and variables valuable 
to our work. The 4 initial key words (“innovation”, “research” and “science”, “biomedic*”) were 
matched with the following keywords using the “AND” Boolean operator: “polit*”, “econom*”, 
social*”, “geograph*”, “histor*” and “manage*”. This yielded 36 searches (6 for each social science 
discipline). In step 3, the specific literature of governance was done by matching “governance” and 
“polit”. Step 4 comprised of a specific review on the topic of the evaluation of research and innovation 
output using a combination of the following the key words using the “AND” Boolean operator: 
“Innovation”, “research”, “science”, “evaluation”, “measurement”.  
For each of the four steps, the articles retrieved were ranked according the number of citations. No 
limit of date of publication was set. The titles and the journal names of the top 10 articles were 
reviewed (top 50 for step 3). Usually a clear cut-off pattern in terms of number of citations was found 
in terms between top articles and the rest. To increase the number of studies selected, “soft” criteria 
((1) relevance for our study, (2) simplicity of use of the research findings) were introduced in tandem 
with the “hard” criteria.  
The spin-off started from the articles selected in steps 1 to 4. Their upstream and downstream citation 
map was followed and relevant articles selected. When the spin-off search lead to the identification of 
an interesting research front (a core set of studies on a specific sub-topic), additional keywords 
specific were included in the search. The titles and the abstract were reviewed. The selection used the 
same hard and soft criteria.  
Precise search algorithms and findings for each of the four steps are presented below: 
 
Step 1: Broad search on innovation, research and science in the biomedical sector 
Key word with topic 
section 
Number of 
articles 
retrieved 
Number of articles 
selected meeting soft 
criteria 
Number of articles 
selected meeting hard 
criteria 
“Innovation” AND 
“biomedic*” 
238 4 0 
“Research” AND 
“biomedic*” 
9821 0 0 
“Science” AND “biomedic” 3458 2 0 
through the 
systematic 
search 
“soft” criteria  
Systematic search within PubMed 644 4 0 
Spin-off search NA 49 6 
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Total 10297 6 0 
 
Step 2: Systematic search with social science key words  
Keyword set 
number 1  
in the topics 
Key word set  
number 2 
Keyword set  
Number 3 
Number of 
articles 
retrieved 
Number of articles 
selected meeting 
soft criteria 
Number of 
articles 
selected 
meeting hard 
criteria 
Innovation 
Research 
Science 
Polit* Biomedic* 361 254 7 0 
Econom* 11 0 
Sociol* 6 0 
Histor* 6 0 
Geograp* 3 0 
Manag 8 0 
Total    41 0 
 
Step 3: Governance 
Key words Number of articles 
retrieved 
Number of articles 
selected meeting soft 
criteria 
Number of articles 
selected meeting hard 
criteria 
“Govern* AND polit*” 5 350 5 0 
 
Step 4: Evaluation of research 
 
 
Search results 
The search results in the following table.  
 Number of articles 
retrieved through the 
systematic search 
Number of articles 
selected meeting the “soft 
criteria” 
Articles meeting the 
“hard” criteria 
 
Systematic search    
Step 1 : innovation 10 297 6 0 
Step 2 : 6 social science 
sectors and innovation 361 254 41 0 
Step 3 : governance 5 350 5 0 
Step 4 : research 
evaluation > 100 000 7 0 
Spin-off search NA 69 0 
 
Key words Number of articles 
retrieved 
Number of articles 
selected meeting soft 
criteria 
Number of articles 
selected meeting hard 
criteria 
“Innovation”, “research”, 
“science”, “evaluation”, 
“measurement” 
> 100 000 7 0 
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Search using bibliometric tools to identify cutting edge research  
Science Watch®, a science monitoring tool developed by ISI, was used to identify cutting-edge 
articles and research reports within the “business and economics” topic.  Research fronts (research 
fronts are clusters of highly cited papers on a particular topic) are categorized into “emerging” (rapidly 
increasing), “classic” (seminal), “new” (new seminal) (ISI 2010). The title and abstract were reviewed. 
The hard and soft selection criteria were used. The following table summarizes this search strategy: 
 
Source Time Method Number of 
articles 
selected 
meeting the 
“soft criteria” 
Articles 
meeting the 
“hard” criteria 
 
Science Watch from 
ISI 
From April 2008 
to August 2009 
With “business and 
economics” look up for 
article on innovation a 
within “emerging» classic”, 
“new” research fronts. 
3 0 
 
Grey literature analysis 
We first searched websites of organisations that are known for the quality of their research and for 
which there was a high probability that they would have conducted research on biomedical innovation. 
We also performed a Google scholar key words search. The title and the abstract of the first 50 
references provided by Google potential documents were reviewed. The criteria were: (1) relevance 
for our study; (2) simplicity of use of the research findings (3); trustfulness of the authors and his 
organization. The following tables present the results of this strategy. 
 
Source Time Method Number of 
document 
selected 
Websites OECD, European 
Union, Unesco, the World Bank, 
US National Academy of Science, 
American think Tanks (Rand, 
Kaiser, Urban Institute and 
Brookings) 
No limit of 
time 
Hand search 14 
Google scholar No limit of 
time 
Non systematic combination of the 
following (context, process and 
output) key words : 
science, research, biomedical, 
innovation  
politics, management, organization 
articles, patents, award, prizes, 
scientometrics, bibliometrics 
 
Bookshelf review 
A broad “bookshelf review” was conducted in university and general bookstores, aiming at identifying 
salient book-length studies on research and innovation. The selection criteria were: (1) relevance for 
our study; (2) simplicity of use of the findings; (3) trustfulness of the authors and the publisher. The 
following tables present the results of this strategy. 
 
Method Number of books 
salient book-length studies on innovation in general 3 
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and university bookstores 
 
The search of quantitative variables data sets  
We searched the websites of the major international agencies: OECD, the World Bank, Unesco and the 
UN. Unexpectedly, the databases found were also helpful to generate new ideas of variables or 
constructs to complement our search. We were able to find data for all constructs and variables. 
 
Source Time Variables 
World bank governance indicators 1996-2008 Governance indicators per year 
Essential development indicators 1996-2008 GDP per capita 
UNESCO Science and technology and 
WorldBank database 
1996-2008 Number of patents per year granted by 
XXX for a given year 
TOEFL scores 1996-2008 Average TOEFL score of all candidates in 
a country within a given year  
Appendix 2  
Linking construct families with the search strategies 
 
 
WOS: web of sciences / Sys: systematic search / SO: spinoff search / total of 179 documents 
Origin 1 Critical mass
Economic 
resources Governance
Human 
resources
Actors and 
their behavior Total
WOS - SO 1,5% 5,3% 15,9% 3,8% 8,3% 34,8%
PubMed - SO 6,8% 6,1% 5,3% 4,5% 5,3% 28,0%
Grey literature 0,0% 2,3% 3,8% 0,0% 0,8% 6,8%
WOS - Economics  - Sys 0,8% 3,8% 2,3% 0,0% 0,0% 6,8%
WOS - Management - Sys 0,0% 0,0% 0,0% 2,3% 1,5% 3,8%
WOS- Political - Sys 0,0% 0,0% 3,0% 0,0% 0,8% 3,8%
WOS- Sociology - Sys 0,0% 0,8% 3,0% 0,0% 0,0% 3,8%
PubMed - Innovation - Sys 0,0% 0,0% 3,0% 0,0% 0,0% 3,0%
WOS - Innovation - Sys 0,8% 0,8% 0,0% 0,8% 0,8% 3,0%
WOS - History - Sys 0,0% 0,8% 1,5% 0,0% 0,0% 2,3%
Science watch 0,0% 0,0% 0,0% 0,8% 0,8% 1,5%
WOS - Geography - Sys 1,5% 0,0% 0,0% 0,0% 0,0% 1,5%
Bookshelf 0,0% 0,0% 0,8% 0,0% 0,0% 0,8%
Total 11,4% 19,7% 38,6% 12,1% 18,2% 100,0%
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Appendix 3 
4 step method to identify the 97 top biomedical journals used as a base in our study 
Step 1: a selection of 72 biomedical research categories was identified in the “Web of Science” search 
engine; 
Step 2: all journals associated with one discipline were ranked using the 2009 EigenfactorTM index. 
The top 10 journals were selected (or top 5 if there were less than 10 journals in the discipline. 
Because journals could belong to several topics, the journals could appear in different rankings. This 
initial phase brought out a first sample of 498 journals.  
Step 3: to increase to selection of highly respected journals that are in positions to publish 
breakthrough findings, we narrowed the 498 journals to the top 97 journals re-ranked according to 
their EigenfactorTM ranking. All of these 97 journals are written in English. 
Step 4: we extracted the numbers of articles published in the 97 journals for each of the 50 countries 
for each year between 1996 and 20081... 
 
The following table summarizes these 4 steps. 
 
 Definition Number of journals 
selected 
Step 1 Indentify 72 biomedical research topics NA 
Step 2 
Rank journals within each discipline according to their EigenfactorTM. 
Select top 10 in each discipline (or top 5 if less than 10 journals in the 
discipline) 
498 journals 
Step 3 Re-rank and extract top 97 according to the 2009 EigenfactorTM 97 journals 
Step 4 
Construct the variable by extracting the number of articles published in the 
97 journals for each year between 1996 and 2008 and for each country 
selected 
97 journals 
 
                                                 
1
 To do this, the 97 journals were divided into two groups: group 1 to 48 and group 49 to 97. Indeed, it was 
necessary to split the 97 journals in two groups because Web of Science limits search algorithms to 50 key words 
(50 key words corresponding to 48 journals titles plus two key words for “country origin” and “year”) 
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The 97 Top biomedical journals Ranked according to the eigenfactor order: 
1 Nature 50  Pediatrics  
2  Proceedings of the National Academy of Sciences of 
the United States of America  
51   Journal of bacteriology  
3  Science 52  Diabetes  
4  The Journal of biological chemistry  53  Circulation Research  
5  New England journal of medicine  54  Nature Biotechnology  
6  Cell 55  Developmental cell  
7  The Journal of neuroscience  56  Diabetes care  
8  Circulation 57  Clinical infectious diseases  
9  The Journal of immunology  58  Nature Reviews Cancer   
10  Blood 59  The American journal of human genetics  
11  Cancer research  60  Human molecular genetics  
12  Lancet 61  Nature Reviews Immunology  
13  Journal of the American Medical Association (JAMA)  62  Molecular microbiology  
14  Nucleic acids research  63  Biomaterials  
15  Journal of clinical oncology  64  FASEB journal  
16  Molecular and cellular biology  65  Journal of neurophysiology  
17  Nature genetics  66  Arthritis and rheumatism  
18  The Journal of clinical investigation  67  Annals of internal medicine  
19  Neuron  68  Developmental Biology  
20  Molecular cell  69  Genome research  
21  EMBO Journal  70  Cancer  
22  Genes and development  71  Journal of clinical microbiology  
23  Journal of experimental medicine  72  Infection and immunity  
24  Oncogene  73  Journal of infectious diseases  
25  Current Biology  74  Genetics  
26  Nano letters  75  The Journal of physiology  
27  Biochemistry  76  Cancer Cell  
28  Journal of virology  77 
American journal of respiratory & critical care 
medicine  
29  Journal of cell biology  78  Nature Structural & Molecular Biology  
30 Biochemical and biophysical research communications  79  Hepatology  
31  Journal of the American College of Cardiology  80  Endocrinology  
32  Nature Medicine   81  European journal of neuroscience  
33  Clinical Cancer Research  82  Arteriosclerosis, thrombosis, and vascular 
biology  
34  Development 83  International journal of cancer  
35  Nature Immunology  84  Nature Reviews Neuroscience  
36  Nature neuroscience  85  Biological Psychiatry  
37  Biophysical journal  86  Archives of internal medicine  
38  Bioinformatics  87  Chest  
39  Journal of cell science  88  Stroke  
40  Nature Reviews Molecular Cell Biology  89  Materials Science and Engineering 
41  Neurology  90  American Journal of Psychiatry  
42  Applied and environmental microbiology  91  Journal of medicinal chemistry  
43  Journal of clinical endocrinology & metabolism  92  Nature Reviews Genetics  
44  British Medical Journal  93  Journal of neurochemistry  
45  Neuroimage  94  Journal of the American Society of Nephrology  
46  PLoS Biology  95  Kidney international  
47  Gastroenterology  96  Antimicrobial agents and chemotherapy  
48  Immunity  97  American journal of cardiology 
49  FEBS letters    
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Governance indicators 
Data points for governance indicators (2007) (Kaufmann, 2008) 
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Data source of governance indicators (2007) (Kaufmann 2008) 
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Mean margin of error for “control of corruption” (2007) (Kaufmann, 2008) 
 
 
Change over time of “voice & accountability” (1998-2007) (Kaufmann, 2008) 
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Constructing the global governance score 
 
If we want to consider the 6 indicators as items of a score and sum them to synthesize the 
information we will have to demonstrate (Falissard, 2001):  
• A construct validity: the six items must be related in a conceptual way; 
• A structural validity of a scale containing the 6 items: the six items must be related in a 
statistical way. This relation will be demonstrated by assessing the “one-dimensionality” 
of the 6 indicators using a Principal Component Analysis followed by a Scree Plot and by 
assessing the internal consistency of the 6 indicators as items of a unique scale using 
Cronbach alpha coefficient. 
Construct validity 
Method 
The construct validity of the scale is based on an intuitive analysis of how all 6 indicators are 
linked to the concept of governance. It is  done using the theory and research behind the 
governance indicators and projection how theory, measure and intuition related (Fallissard, 2001).  
 
Results 
The research provided by Kauffman on governance was based on the rationale that the 6 
governance indicators are different conceptual attributes of governance. Two arguments support 
this affirmation. First, the 6 indicators measure different attributes while being related to a unique 
dimension. Indeed, one could easily imagine a country ranking well on one indicator and poorly 
on another, while both relate to of the notion of governance. For example, “Voice and 
Accountability” may be good because the government “hears well” the population (law are passed 
according to the public will), while Government Effectiveness scores poorly because the 
government is poorly executing its policies. In a similar way, it is possible to imagine that the 
policies or the government bodies related to each governance indicator would be independent. 
Second, the indicators’ numerical values are congruent with our intuitive expectations: Western 
European countries with a long tradition of democratic governance (Sweden, England, France) 
present higher values than countries where governance is problematic (Iraq, Iran, Afghanistan). 
 
Validity of structure  
The question assessing the validity of structure of a potential scale using the 6 indicators as items 
here are (Falissard, 2001):  
• Does a scale constructed by the 6 indicators have a one-dimensional structure? 
• Does a scale constructed by the 6 indicators have a good internal consistency? 
• Are the items independent (hence provide different information)? 
We will use the year 2000 to explore these relationships. 
 
Assessing the “one-dimensionality” of the 6 indicators 
Method 
The approximation of the number of dimensions of the 6 indicators will be done using Principal 
Component Analysis followed by a Scree Plot. 
 
Results 
The PCA analysis for the year 2000 and the Scree plot clearly shows that the 6 indicators have a 
one-dimensional spatial distribution. The first component aggregates 91.14% of information. 
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The Scree plot of eigenvalues after Principal Component Analysis (PCA) also clearly in favour in 
a one dimensional pattern: 
 
 
Assessing the internal consistency of the 6 indicators 
Method 
The internal consistency of the 6 indicators as items of a unique scale will be assessed by using 
the Cronbach alpha coefficient. An alpha value above 0.7 will be considered sufficient. 
 
Results 
                                                                                            
            ps00     0.3942    0.8113    0.0001    0.4283    0.0526    0.0146             0 
            cc00     0.4175   -0.0711   -0.3607   -0.3129    0.3233    0.6987             0 
            va00     0.3922   -0.1341    0.8863   -0.1269    0.1359    0.0898             0 
            ge00     0.4203   -0.1264   -0.2358   -0.1835    0.4872   -0.6934             0 
            rq00     0.4052   -0.5436   -0.1330    0.6835   -0.2307    0.0468             0 
            rl00     0.4192    0.0855   -0.1052   -0.4490   -0.7640   -0.1437             0 
                                                                                            
        Variable      Comp1     Comp2     Comp3     Comp4     Comp5     Comp6   Unexplained 
                                                                                            
Principal components (eigenvectors) 
                                                                              
           Comp6       .0193903            .             0.0032       1.0000
           Comp5       .0336545     .0142642             0.0056       0.9968
           Comp4       .0765474     .0428929             0.0128       0.9912
           Comp3        .195009      .118461             0.0325       0.9784
           Comp2        .207139     .0121297             0.0345       0.9459
           Comp1        5.46826      5.26112             0.9114       0.9114
                                                                              
       Component     Eigenvalue   Difference         Proportion   Cumulative
                                                                              
    Rotation: (unrotated = principal)             Rho              =    1.0000
                                                  Trace            =         6
                                                  Number of comp.  =         6
Principal components/correlation                  Number of obs    =        50
. pca rl00 rq00 ge00 va00 cc00 ps00
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Scree plot of eigenvalues after pca
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The Cronbach alpha value of 0.9795 for the year 2000 suggests that, if the 6 indicators are 
considered as a scale, the scale has a strong internal consistency: 
 
 
Assessing the interdependency of the items 
Method 
A Spearman correlation matrix of the 6 indicators will analyze correlation and redundancy of the 
indicators to assess co-linearity. A correlation of more than 0.8 will define redundancy. 
 
Results 
The correlation matrix, for the year 2000, shows that many inter-indicator correlations have a 
value above 0.8 thus demonstrating partial redundancy. 
 
However, previous research conducted by the author has led to analysis of the 6 governance 
indicators in 23 OCDE countries. The correlation between indicators was not as high (most 
correlations below 0.8). One explanation could be that emerging countries may create “hyper-
correlation”. Indeed, in the countries that the original data (surveys, reports) used to calculate the 
6 governance indicators is very limited (see 5.2). Hence, calculating different indicators on the 
same data may create correlation amongst indicators. 
 
Results 
The summary of the results are presented in the following table.  
Validity of a score based on the 6 
governance indicators 
Method Result 
Construct validity Conceptual analysis Yes 
Structural validity 
One-dimensionality : PCA and 
Scree plot Yes 
Internal consistency using 
Cronbach alpha Yes 
Non redundancy : using spearman 
correlation matrix 
No but some explanation provide 
to high this redundancy may exist 
 
The construct validity, the one-dimensionality, and the internal consistency all support the 
possibility of using a global governance scale containing the 6 indicators as items. The sum of the 
values of all six indicators, that we will call the “Global Governance “score, is the simplest way to 
synthesize the information contained in the scale. 
 
Scale reliability coefficient:      0.9795
Number of items in the scale:            6
Average interitem covariance:     .7603674
Test scale = mean(unstandardized items)
. alpha rl00 rq00 ge00 va00 cc00 ps00
        ps00     0.9318   0.8751   0.9165   0.8910   0.9067   1.0000 
        cc00     0.9518   0.9359   0.9628   0.8846   1.0000 
        va00     0.9146   0.8542   0.8680   1.0000 
        ge00     0.9496   0.9561   1.0000 
        rq00     0.9115   1.0000 
        rl00     1.0000 
                                                                    
                   rl00     rq00     ge00     va00     cc00     ps00
(obs=50)
. spearman rl00 rq00 ge00 va00 cc00 ps00
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Fixed versus random effect: a brief technical note 
Panel data demands that the investigator determines whether the data have random variation 
across variables and years for entities, countries or no random variations. Technically, this means 
knowing if the time-invariant component of the error term is “fixed” or “random”. The fixed 
effect model is applicable if we believe that this unobserved effect, modelled as the time-invariant 
component of our error term (µ), is correlated with predictors, hence specific to each entity. The 
random effects model assumes that µ is uncorrelated with predictors (Kennedy, 2008;Wooldridge, 
2009). 
Fixed effects models are more likely to be consistent, but random effects models are more 
efficient by reducing the confidence intervals (Kennedy, 2008) Using a random effect method on 
fixed effect data yields non valid estimates (Kennedy, 2008). In practice, random effects models 
are usually preferred when the data have a large number of entities. With 50 countries our study 
we will consider our sample “large”. 
The Hausman test is appropriate to see if the random effects model is consistent by comparing it 
to the fixed effects model. If the estimates are different then we will reject random effects and use 
fixed effects; if the estimates are similar, then we will use the more efficient random effects 
model. 
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Appendix 4 
Arguments in favour of the log transformation of the dependent variable 
Logging a dependent variable with a highly skewed data can avoid breaching OLS estimator 
assumptions in three ways (Kennedy, 2008; Kleinbaum, 2008;Wooldridge, 2009;Falissard, 1998). 
First, it improves the specification of the model. Second, it reduces heteroscedasticty. Third, it can 
transform a non-normal error term into a normally distributed error term. In addition, it allows for 
interpreting marginal effects in percent rather than unit terms (and getting elasticity as a result). 
Improving the specification of the model 
If a distribution of a variable is non-linear it may cause a specification error by inappropriately 
specifying its relationship to another. Understanding the true relationship of the variable to others 
may require the log transformation. Specification errors can cause biased and inconsistent 
estimates (Kleinbaum, 2008).  
Log transformations improve model specification best when the underlying variable is related to a 
growth rate that has a geometric or exponential growth pattern (Wooldridge, 2009) . If all 
observations are assumed to follow the same growth pattern, the log transformation rescales the 
difference between observations accounting for the exponential growth pattern. Observations can 
then be plotted using a straight line (mathematically, the log of an exponential of a number is the 
raw number).  
The literature review presented in Chapter 2 has pointed out the importance of the path 
dependency of science, meaning that science builds on itself to progress. Mathematically, the 
production of science can then be viewed as an exponential function. In this sense, mathematical 
models with exponential functions have been used to analysis scientific production. In our case, is 
seems reasonable to posit that the number of articles in a given year are related to the number of 
articles from the previous years.  
One way of checking this, is to analyze the distribution of the growth (in percentage) of the 50 
countries (graph on the right). If we assume that each country lies somewhere on an exponential 
growth curve, then the distributions of the logs of the percentage of growth between the two dates 
(1996-2008) should produce normal results. The graph on the right confirms this assumption. It 
also reinforces publications per capita as a valid construct of biomedical research.Consequently, 
the distances between countries in terms of publications per capita are naturally impacted by this 
exponential growth curve of biomedical research. Computing the log of this variable allows us to 
rescale the difference between countries independently of their position on this growth curve and 
the distribution should be less skewed, improving the specification of the model.  
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Reducing heteroscedasticity 
Because we are dealing with a highly skewed dependant variable, the log transformation is 
expected to improve homoscedasticity, meaning that variances of the error terms for each value of 
the independent variables are more similar (Kleinbaum, 2008;Wooldridge, 2009). 
Transforming a non-normal error term into a normally distributed error 
One assumption of OLS is that the error terms have to be normally distributed (or equivalently the 
distribution of the dependent variable conditional on the regressors is normally distributed). This 
assumption is different than the dependent variable being normally distributed. However, the 
distribution of the dependant variable can have an impact on the distribution of the error terms 
and can be reduced by log transformation (Kleinbaum, 2008). 
Comparing the neperian log to the other transformation functions 
Although natural (neperian) log seemed the most appealing transformation function, we 
benchmarked it against three other transformation options: log base 10, square root and square 
transformations. The neperian log transformation was the most effective in normalizing the 
skewed data.  
Results 
The log transformation allows a better use of the information contained in the bulk of the data 
(countries like Spain, Japan, Korea or Argentina) and reduces the influence of outliers (such as 
India, Ukraine or Switzerland). The following graphs presents the distribution of log transformed 
dependant variable. 
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This improvement is confirmed by the change in the normal distribution graphs that appears more 
balanced (right). 
 
 
It is useful to say that, we also compared the linear regression diagnostics of the logged dependant 
variable with the non logged variable. While the results are not reported, the log transformation 
improved homoscedasticity, the normality of the error terms and the R2 of all models tested.  
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Bivariate analysis between governance and the other covariates 
Governance and the log of patents per capita (2002) 
Although patents per population will not be kept in the multivariate analysis, it is insightful to 
check if governance and patents per population displays a similar pattern as governance and 
publications per capita (below).  
 
 
 
The straight line pattern and the correlation coefficient (0.83) demonstrate that publications per 
capita and patents globally behave the same way. This confirms previous findings that suggested 
that publications and patents are strongly related. However, this also supports the need to exclude 
patents in the multivariate models if we want to avoid a collinearity problem. 
  
ARG
AUS
AUT
BEL
BRA
CAN
CHE
CHL
CHN
COL
CZE
DEU
DNK
EGY
ESP
FIN
FRA
GBR
GRC
HRV
HUN
IND
IRL
ISL
ISR
ITA
JPN
KEN
KOR
LUX
MEX
NLD
NORNZL
PER
POL
PRT
RUS
SAU
SGP
SVK
SVN
SWE
THA
TUR
UKR
USA
VEN
ZAF
-
5
0
5
10
15
G
o
ve
rn
an
ce
-18 -16 -14 -12 -10 -8
Log of patents per capita
Governance and the log of patents per capita (2002)
  
134 
Governance and GNI per capita (2008) 
Past research has demonstrated an association between the economic production of a country and 
governance (Kaufmann, 2010). Using GNI per capita at PPP; the graphic analysis and correlation 
coefficient (0.84) confirms this relationship.  
 
 
 
However, we show that the relation flattens out around 40,000 US dollars, after which an increase 
of GNI per capita is not associated to an increase of governance. This pattern resembles to the 
pattern between publications per capita and GNI per capita and pledges again for the evaluation of 
interaction of GNI per capita and governance. 
The risk of collinearity is highly present. A colinearity test, the Variance Inflation factor, will be 
run in the multivariate models. 
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Governance and the Percentage of GDP in R&D (2006) 
The graphic analysis presents a curvilinear or logarithmic pattern between governance and 
percentage of GDP invested in R&D. The correlation coefficient is medium 0.49, but probably 
not reflecting the true strength of the association relationship in the first (left) par of the curve.as 
for GNP per capita, the risk for collinearity is high and appropriate diagnostic tests will be 
conducted in the multivariate model. 
 
 
 
Governance and Percentage of GNP related to international trade (2008) 
Singapore is a strong outlier that prevents a precise analysis. The correlation coefficient is weak 
0.26. When Singapore is removed, the graphic pattern and the correlation coefficient (0.23) still 
remain insignificantly associated. Consequently, we will assume that the risk for collinearity is 
low. 
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Governance and immigration per capita (2005) 
The graphic displays an unsophisticated S curve pattern. The bulk of the countries stand in the 
middle part of the graph (figure below).  
 
 
 
Although it does not resemble to a straight line, the correlation coefficient is quite high 0.61, 
possibly due to the outliers at the two extremes. We consider that the risk of collinearity is 
medium. 
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Governance and English proficiency (2008) 
Iran is a strong outliner in terms of TOEFL scores. When, dropping Iran, English proficiency and 
governance display a cleaner pattern (below). The coefficient also improves, moving from 0.62 
with Iran to 0.63 without Iran. The risk for multicollinearity is high and appropriate diagnostic 
tests will be conducted in the multivariate models. 
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Governance and Percentage of households using internet (2008)  
It is worthwhile noting that one of the 6 initial governance indicators (Voice and Accountability) 
includes a measure of how information circulates in the country. This indicator means that the 
percentage of household using the Internet and governance are conceptually linked.  
The relation between governance and the percentage of households using the internet is displayed 
by a straight line (below). No “flattening of the curve” is observed. This pattern is supported by a 
strong correlation coefficient (0.82).  
 
 
 
The risk for multicollinearity is high and appropriate diagnostic tests will be conducted in the 
multivariate models. 
Governance and the log of population (2008)  
As for the analysis of relationships between publications per capita and population, we will use 
the log of population. A weak negative pattern is displayed. The correlation coefficient, negative, 
is also small -0.29. Consequently, we will assume that the risk for collinearity is low. 
 
Correlation and Scatterplot matrix of the all the covariates besides governance 
The following scatterplot and correlation matrixes have guided us into identifying the association 
between covariatess (excluding governance).  
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Given the paucity of research in this field, there is no way to justify a minimum correlation level. 
We will arbitrarily assume that 0.4 indicated strength. Consequently, the following associations 
are considered significant:  
• GNI per capita and percentage of GNP invested in R&D 
• GNI per capita and immigration per capita 
• GNI per capita and English proficiency 
• GNI per capita and the percentage of households using internet 
• R&D and percentage of households using internet 
• English proficiency and percentage of households using internet 
• English proficiency and the log of the population 
Although these associations do not mean collinearitiy necessarily, they are important enough the 
exert caution.  
 
Testing the assumption for linear regression models 
Full analytical model 
Testing for collinearity: 
We calculate the Variance Inflation Factor (VIF). Consistent with previous findings, governance, 
GNI per capita and the percentage of households using the internet are the variables the most 
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engaged in collinearity. Governance has a VIF over 10 indicating that it reduces the quality of the 
regression (Kleinbaum, 2008). However this also demonstrates the transformative role of 
governance. This model may be over-fitted.  
 
VIF test results: 
 
Testing regression assumptions: normality, homoscedasticity and linearity: 
The residuals present a normal probability plot (below right) and demonstrate that the residuals 
are normally distributed. The values of the residuals vary depending upon the fitted values (below 
left) indicating heterogeneity, especially in the lower/middle range of the data (Hungary, Spain).  
On the other hand, at each extreme China and the USA fit well. Overall the pattern seems linear. 
Figure 22 and Figure 23: Full Analytical Model Regression Diagnostic Plots 
 
Reduced analytical model 
Testing for collinearity: 
As anticipated, the Variance Inflated Factors are lower than in the full analytical model. Variables 
are below the VIF=10 threshold. Thus the model is not engaged in serious collinearity problems. 
 
VIF test results: 
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Testing regression assumptions: normality, homoscedasticity and linearity: 
The residuals present a normal probability plot (below right). The values of the residuals vary 
depending upon the fitted values (below left), indicating some degree of heterogeneity, especially 
in the middle range of the data (Hungary, Spain).  However, the variation seems less than in the 
full analytical model. On the other hand, at each extreme China and the USA fit well. Overall the 
pattern appears linear. 
 
Figure 33 and figure 34: Reduced Analytical Model Regression Diagnostic Plots 
 
 
The Parsimonious Analytical model Parsimonious model  
Testing for collinearity: 
The collinearity of each variable is low and similar to the reduced analytical model. 
Consequently, collinearity is not considered a threat for this model. 
 
VIF test results: 
 
 
Testing regression assumptions: normality, homoscedasticity and linearity: 
The residuals present an improved normal probability plot compared to the reduced analytical 
model (below right). The values of the residuals are displayed quite consistently around 0 (below 
left) indicating an improved homoscedasticity, even if the increased variance is observed in the 
middle range (Italy, Greece, South Africa). Overall the pattern seems linear.  
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Figure 35 and Figure 36: Parsimonious Analytical Model Regression Diagnostic Plots 
 
The GNI per capita interaction model 
Collinearity test 
The variance inflation factors are very high in this model for the interaction term and GNI per 
capita variable. However, this result does not change the magnitude, significance and direction of 
the estimates (except immigrants, for which the magnitude in smaller) compared to the 
parsimonious model suggested that collinearity does not have a major impact. 
 
VIF test results: 
 
Testing regression assumptions: normality, homoscedasticitiy and linearity  
The residuals do not depart too much form a normal probability plot, similar to the parsimonious 
model (below left). The values of the residuals are displayed quite consistently around 0 
indicating homoscedasciticity (below right). Overall the patterns seem linear. 
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Figure 24 and Figure 25: GNI Interaction Model Regression Diagnostic Plots 
 
The Percentage of GDP invested in R&D interaction model 
Collinearity test: 
VIF of the interaction term is above 10 indicating collinearity issues.  
 
VIF test results: 
With a non significant interaction term and collinearity that changes estimates compared to the 
parsimonious model (confirmed by a VIF above 10) we reject the interaction between governance 
and R&D.  
Hausman test 
For each model, we ran a fixed effect model. We then ran a random effect model (results 
presented below). The decision between using random and fixed effect model is best guided by 
the Hausman test (Kennedy, 2008). This tests the null hypothesis (H0) that the coefficient 
estimated by the efficient random effects estimator are the same as the ones estimated by the 
consistent fixed effect estimator. If they are (insignificant P-value, Prob>chi2 larger than 0.05) 
then it is safe to use the random effects. The Hausman test for each test and the determination are 
given below. 
 
Model Prob>chi2 We used 
Full analytical model 0.000 Fixed effect 
Reduced analytical model 0.000 Fixed effect 
Parsimonious model 0.0962 Random effect 
Predictive model 0.000 Fixed effect 
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The Hausman for the full analytical model 
 
The Hausman test for reduced analytical model 
 
The Hausman test for the parsimonious model 
 
                (V_b-V_B is not positive definite)
                Prob>chi2 =      0.0000
                          =       33.88
                  chi2(7) = (b-B)'[(V_b-V_B)^(-1)](b-B)
    Test:  Ho:  difference in coefficients not systematic
            B = inconsistent under Ha, efficient under Ho; obtained from xtreg
                           b = consistent under Ho and Ha; obtained from xtreg
                                                                              
       lnpop      3.056926    -.0081168        3.065043        1.727572
          tr      1.574432     .2899916        1.284441        .3476623
           e       .076294    -.1529579        .2292519        .6072595
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          to      .0100072     .0022565        .0077507        .0067088
          rd      14.91429     49.45679       -34.54249        22.33716
         gpc     -1.91e-06     .0000514       -.0000533        .0000357
          gg      .1134974     .1310902       -.0175928        .0411242
                                                                              
                   fixed        random       Difference          S.E.
                    (b)          (B)            (b-B)     sqrt(diag(V_b-V_B))
                      Coefficients     
        on a similar scale.
        estimators for anything unexpected and possibly consider scaling your variables so that the coefficients are
        sure this is what you expect, or there may be problems computing the test.  Examine the output of your
Note: the rank of the differenced variance matrix (7) does not equal the number of coefficients being tested (8); be
. hausman fixed random
                (V_b-V_B is not positive definite)
                Prob>chi2 =      0.0000
                          =       34.62
                  chi2(6) = (b-B)'[(V_b-V_B)^(-1)](b-B)
    Test:  Ho:  difference in coefficients not systematic
            B = inconsistent under Ha, efficient under Ho; obtained from xtreg
                           b = consistent under Ho and Ha; obtained from xtreg
                                                                              
       lnpop      3.043269    -.0171842        3.060453        1.688335
          tr      1.582592     .2957705        1.286821        .3296143
          im      5.576558    -.0585644        5.635122        .8426122
          to      .0102203      .001642        .0085783        .0063888
          rd      14.23697      49.9821       -35.74513        20.84829
         gpc      2.03e-06     .0000455       -.0000435        9.34e-06
          gg      .1139009     .1350453       -.0211444        .0412821
                                                                              
                   fixed        random       Difference          S.E.
                    (b)          (B)            (b-B)     sqrt(diag(V_b-V_B))
                      Coefficients     
        on a similar scale.
        estimators for anything unexpected and possibly consider scaling your variables so that the coefficients are
        sure this is what you expect, or there may be problems computing the test.  Examine the output of your
Note: the rank of the differenced variance matrix (6) does not equal the number of coefficients being tested (7); be
. hausman fixed random
                Prob>chi2 =      0.0962
                          =        7.88
                  chi2(4) = (b-B)'[(V_b-V_B)^(-1)](b-B)
    Test:  Ho:  difference in coefficients not systematic
            B = inconsistent under Ha, efficient under Ho; obtained from xtreg
                           b = consistent under Ho and Ha; obtained from xtreg
                                                                              
          im     -1.370214     -1.04204       -.3281741        1.353255
          to      .0154501      .001748        .0137021        .0095467
          rd      40.80185     47.99087       -7.189028        29.14484
         gpc      .0000275     .0000496       -.0000222        .0000129
          gg      .0346084     .1501538       -.1155454        .0449742
                                                                              
                   fixed        random       Difference          S.E.
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        on a similar scale.
        estimators for anything unexpected and possibly consider scaling your variables so that the coefficients are
        sure this is what you expect, or there may be problems computing the test.  Examine the output of your
Note: the rank of the differenced variance matrix (4) does not equal the number of coefficients being tested (5); be
. hausman fixed random
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Hausman for the predictive model 
 
                (V_b-V_B is not positive definite)
                Prob>chi2 =      0.0000
                          =       78.03
                  chi2(2) = (b-B)'[(V_b-V_B)^(-1)](b-B)
    Test:  Ho:  difference in coefficients not systematic
            B = inconsistent under Ha, efficient under Ho; obtained from xtreg
                           b = consistent under Ho and Ha; obtained from xtreg
                                                                              
          rd      48.31156     62.85825       -14.54669        1.643894
          gg     -.0039053     .1409149       -.1448201        .0133068
                                                                              
                   fixed        random       Difference          S.E.
                    (b)          (B)            (b-B)     sqrt(diag(V_b-V_B))
                      Coefficients     
. hausman fixed random
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Sensitivy analysis: testing with and without the USA 
Cross-sectional Full Analytical Model with the USA 
Cross-sectional Full Analytical Model without the USA 
                                                                              
       _cons    -14.23906   3.015883    -4.72   0.001    -20.87697   -7.601147
         e08     1.355141   1.158948     1.17   0.267    -1.195686    3.905967
     lnpop08    -.0939459   .0998663    -0.94   0.367      -.31375    .1258583
        tr08    -.4626236    .353198    -1.31   0.217    -1.240007    .3147599
        to08     .0326558   .0216031     1.51   0.159    -.0148922    .0802038
        im05     5.899043   9.649502     0.61   0.553    -15.33937    27.13745
        rd06    -3.459248   21.29008    -0.16   0.874    -50.31841    43.39991
       gpc08     .0000815   .0000253     3.22   0.008     .0000257    .0001372
        gg08    -.0047649   .0871337    -0.05   0.957     -.196545    .1870151
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    35.3607933    19  1.86109438           Root MSE      =  .44339
                                                       Adj R-squared =  0.8944
    Residual    2.16250046    11  .196590951           R-squared     =  0.9388
       Model    33.1982928     8  4.14978661           Prob > F      =  0.0000
                                                       F(  8,    11) =   21.11
      Source         SS       df       MS              Number of obs =      20
. regress lnpp08 gg08 gpc08 rd06 im05 to08 tr08 lnpop08 e08
                                                                              
       _cons    -14.31045   2.990165    -4.79   0.001    -20.97295   -7.647948
         e08     1.109824   1.256225     0.88   0.398     -1.68922    3.908867
     lnpop08    -.0743732   .1029097    -0.72   0.486    -.3036703    .1549239
        tr05     -.612985   .4130395    -1.48   0.169    -1.533294    .3073244
        to08     .0296211   .0219698     1.35   0.207    -.0193307    .0785729
        im05      3.29014   10.09548     0.33   0.751    -19.20399    25.78427
        rd06    -7.302349   21.40183    -0.34   0.740     -54.9886     40.3839
       gpc08     .0000923   .0000294     3.14   0.011     .0000268    .0001577
        gg08     .0007699   .0868486     0.01   0.993    -.1927409    .1942806
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    33.1751421    18  1.84306345           Root MSE      =  .44186
                                                       Adj R-squared =  0.8941
    Residual    1.95237826    10  .195237826           R-squared     =  0.9411
       Model    31.2227638     8  3.90284548           Prob > F      =  0.0000
                                                       F(  8,    10) =   19.99
      Source         SS       df       MS              Number of obs =      19
. regress lnpp08 gg08 gpc08 rd06 im05 to08 tr05 lnpop08 e08
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Cross-sectional Reduced Analytical Cross-sectional Model with the USA 
Cross-sectional Reduced Analytical Cross-sectional Model without the USA 
Cross sectional Parsimonious Analytical Model with the USA 
                                                                              
       _cons    -16.14669   2.830087    -5.71   0.000    -21.96402   -10.32936
     lnpop08     .0427795   .0935121     0.46   0.651    -.1494374    .2349964
        tr08    -.2238446   .1851951    -1.21   0.238    -.6045186    .1568294
        to08     .0354373   .0184216     1.92   0.065    -.0024289    .0733034
        im05     4.497787   8.980905     0.50   0.621    -13.96273     22.9583
        rd06     32.44556   12.59793     2.58   0.016     6.550141    58.34098
       gpc08     .0000218   .0000154     1.41   0.170    -9.93e-06    .0000535
        gg08     .1631522   .0516022     3.16   0.004     .0570824     .269222
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    60.4725517    33  1.83250157           Root MSE      =  .60188
                                                       Adj R-squared =  0.8023
    Residual    9.41867129    26  .362256588           R-squared     =  0.8442
       Model    51.0538804     7  7.29341149           Prob > F      =  0.0000
                                                       F(  7,    26) =   20.13
      Source         SS       df       MS              Number of obs =      34
. regress lnpp08 gg08 gpc08 rd06 im05 to08 tr08 lnpop08
                                                                              
       _cons     -15.8082   3.031607    -5.21   0.000    -22.05192   -9.564491
     lnpop08     .0264998   .1034724     0.26   0.800    -.1866056    .2396053
        tr05     -.230066   .1982063    -1.16   0.257    -.6382795    .1781476
        to08     .0349894    .018859     1.86   0.075    -.0038515    .0738303
        im05     5.214931   9.155351     0.57   0.574    -13.64087    24.07073
        rd06     32.59321   12.80516     2.55   0.017     6.220501    58.96592
       gpc08     .0000202   .0000168     1.21   0.239    -.0000143    .0000547
        gg08     .1619165   .0527753     3.07   0.005     .0532238    .2706093
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    58.7082145    32   1.8346317           Root MSE      =  .61165
                                                       Adj R-squared =  0.7961
    Residual    9.35289461    25  .374115784           R-squared     =  0.8407
       Model    49.3553199     7  7.05075998           Prob > F      =  0.0000
                                                       F(  7,    25) =   18.85
      Source         SS       df       MS              Number of obs =      33
. regress lnpp08 gg08 gpc08 rd06 im05 to08 tr05 lnpop08
                                                                              
       _cons    -14.55509   1.446713   -10.06   0.000    -17.51854   -11.59163
        to08     .0247366   .0158679     1.56   0.130    -.0077674    .0572405
        im05      5.78797   8.932085     0.65   0.522    -12.50858    24.08452
        rd06     33.54829   12.48515     2.69   0.012     7.973617    59.12296
       gpc08     .0000177   .0000149     1.18   0.247    -.0000129    .0000482
        gg08     .1639838   .0515977     3.18   0.004     .0582907    .2696769
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    60.4725517    33  1.83250157           Root MSE      =  .60284
                                                       Adj R-squared =  0.8017
    Residual    10.1755113    28  .363411119           R-squared     =  0.8317
       Model    50.2970404     5  10.0594081           Prob > F      =  0.0000
                                                       F(  5,    28) =   27.68
      Source         SS       df       MS              Number of obs =      34
regress lnpp08 gg08 gpc08 rd06 im05 to08
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Cross sectional Parsimonious Analytical Model without the USA 
 
Cross sectional GNI per Capita Interaction Cross-sectional with the USA 
 
Cross sectional GNI per Capita Interaction Cross-sectional without the USA 
 
                                                                              
       _cons     -14.6688   1.464065   -10.02   0.000    -17.67281   -11.66479
        to08     .0265541   .0161469     1.64   0.112    -.0065766    .0596847
        im05     6.045314   9.000588     0.67   0.508    -12.42237      24.513
        rd06     33.01772   12.59077     2.62   0.014     7.183588    58.85185
       gpc08      .000015   .0000154     0.97   0.340    -.0000167    .0000466
        gg08      .167476     .05215     3.21   0.003      .060473     .274479
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    58.7082145    32   1.8346317           Root MSE      =  .60705
                                                       Adj R-squared =  0.7991
    Residual    9.94987834    27  .368514012           R-squared     =  0.8305
       Model    48.7583361     5  9.75166723           Prob > F      =  0.0000
                                                       F(  5,    27) =   26.46
      Source         SS       df       MS              Number of obs =      33
. regress lnpp08 gg08 gpc08 rd06 im05 to08
                                                                              
       _cons    -16.53697   1.246157   -13.27   0.000    -19.09387   -13.98006
        to08     .0335963   .0128043     2.62   0.014      .007324    .0598686
        im05     .3125568   7.228118     0.04   0.966    -14.51832    15.14343
        rd06     29.81348    9.97437     2.99   0.006     9.347766     50.2792
   gg08gpc08    -8.59e-06   2.07e-06    -4.15   0.000    -.0000128   -4.35e-06
       gpc08     .0000983   .0000228     4.32   0.000     .0000516     .000145
        gg08     .2986236   .0523206     5.71   0.000     .1912706    .4059767
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    60.4725517    33  1.83250157           Root MSE      =  .47964
                                                       Adj R-squared =  0.8745
    Residual    6.21150858    27  .230055873           R-squared     =  0.8973
       Model    54.2610432     6  9.04350719           Prob > F      =  0.0000
                                                       F(  6,    27) =   39.31
      Source         SS       df       MS              Number of obs =      34
. regress lnpp08 gg08 gpc08 gg08gpc08 rd06 im05 to08
                                                                              
       _cons     -16.5821   1.262884   -13.13   0.000      -19.178   -13.98621
        to08     .0346242   .0130616     2.65   0.013     .0077757    .0614726
        im05     .5485026   7.322818     0.07   0.941    -14.50377    15.60077
        rd06     29.52884   10.10178     2.92   0.007     8.764331    50.29336
   gg08gpc08    -8.48e-06   2.10e-06    -4.03   0.000    -.0000128   -4.16e-06
       gpc08     .0000955   .0000235     4.07   0.000     .0000472    .0001437
        gg08     .2990187   .0529372     5.65   0.000     .1902046    .4078328
                                                                              
      lnpp08        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    58.7082145    32   1.8346317           Root MSE      =  .48526
                                                       Adj R-squared =  0.8716
    Residual    6.12237533    26  .235475974           R-squared     =  0.8957
       Model    52.5858391     6  8.76430652           Prob > F      =  0.0000
                                                       F(  6,    26) =   37.22
      Source         SS       df       MS              Number of obs =      33
. regress lnpp08 gg08 gpc08 gg08gpc08 rd06 im05 to08
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Longitudinal Full Analytical Panel Model with the USA 
 
Longitudinal Full Analytical Panel Model without the USA 
 
 
Longitudinal Reduced Analytical Model with the USA 
                                                                              
         rho    .99883746   (fraction of variance due to u_i)
     sigma_e     .1856346
     sigma_u    5.4412878
                                                                              
       _cons    -66.75124   22.34068    -2.99   0.005    -111.7759   -21.72656
       lnpop     3.056926   1.374825     2.22   0.031     .2861493    5.827703
          tr     1.574432   .4297823     3.66   0.001     .7082628    2.440601
           e      .076294   .5573086     0.14   0.892    -1.046888    1.199476
          im     5.416452   3.659661     1.48   0.146     -1.95911    12.79201
          to     .0100072   .0082905     1.21   0.234    -.0067012    .0267155
          rd     14.91429   31.36394     0.48   0.637    -48.29557    78.12415
         gpc    -1.91e-06    .000033    -0.06   0.954    -.0000684    .0000645
          gg     .1134974   .0470012     2.41   0.020     .0187727    .2082222
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 45 clusters in id)
corr(u_i, Xb)  = -0.9472                        Prob > F           =    0.0000
                                                F(8,44)            =     10.95
       overall = 0.0861                                        max =         2
       between = 0.1232                                        avg =       1.7
R-sq:  within  = 0.6978                         Obs per group: min =         1
Group variable: id                              Number of groups   =        45
Fixed-effects (within) regression               Number of obs      =        77
. xtreg lnpp gg gpc rd to im e tr lnpop, fe robust
                                                                              
         rho    .99887021   (fraction of variance due to u_i)
     sigma_e    .18643174
     sigma_u    5.5433883
                                                                              
       _cons    -67.59862    21.5125    -3.14   0.003    -110.9827   -24.21453
       lnpop     3.106674   1.329959     2.34   0.024     .4245556    5.788792
          tr     1.632856   .4478703     3.65   0.001     .7296399    2.536073
           e     .2336299   .5867303     0.40   0.692    -.9496244    1.416884
          im     5.787824   3.785551     1.53   0.134    -1.846467    13.42211
          to     .0109266   .0082747     1.32   0.194    -.0057609    .0276142
          rd      20.0954   31.63438     0.64   0.529    -43.70141    83.89222
         gpc    -.0000152   .0000359    -0.42   0.674    -.0000877    .0000572
          gg     .1215919   .0445225     2.73   0.009     .0318037      .21138
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 44 clusters in id)
corr(u_i, Xb)  = -0.9525                        Prob > F           =    0.0000
                                                F(8,43)            =     13.08
       overall = 0.1369                                        max =         2
       between = 0.1777                                        avg =       1.7
R-sq:  within  = 0.7075                         Obs per group: min =         1
Group variable: id                              Number of groups   =        44
Fixed-effects (within) regression               Number of obs      =        75
. xtreg lnpp gg gpc rd to im e tr lnpop, fe robust
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Longitudinal Reduced Analytical Model without the USA 
 
  
                                                                              
         rho     .9988647   (fraction of variance due to u_i)
     sigma_e    .18192588
     sigma_u    5.3962437
                                                                              
       _cons    -66.62681   22.28017    -2.99   0.005    -111.5295   -21.72407
       lnpop     3.043269   1.374359     2.21   0.032     .2734301    5.813107
          tr     1.582592   .4182151     3.78   0.000     .7397346    2.425449
          im     5.576558   3.318279     1.68   0.100    -1.110994    12.26411
          to     .0102203   .0083277     1.23   0.226    -.0065632    .0270038
          rd     14.23697   30.23566     0.47   0.640    -46.69899    75.17294
         gpc     2.03e-06   .0000145     0.14   0.889    -.0000271    .0000312
          gg     .1139009   .0463919     2.46   0.018     .0204041    .2073976
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 45 clusters in id)
corr(u_i, Xb)  = -0.9461                        Prob > F           =    0.0000
                                                F(7,44)            =     12.43
       overall = 0.0827                                        max =         2
       between = 0.1191                                        avg =       1.7
R-sq:  within  = 0.6977                         Obs per group: min =         1
Group variable: id                              Number of groups   =        45
Fixed-effects (within) regression               Number of obs      =        77
. xtreg lnpp gg gpc rd to im tr lnpop, fe robust
                                                                              
         rho    .99885457   (fraction of variance due to u_i)
     sigma_e    .18289095
     sigma_u    5.4008003
                                                                              
       _cons    -67.15662   21.55167    -3.12   0.003    -110.6197   -23.69353
       lnpop     3.063077   1.336572     2.29   0.027     .3676231    5.758532
          tr      1.65166   .4408155     3.75   0.001      .762671    2.540649
          im     6.220463   3.540599     1.76   0.086    -.9198356    13.36076
          to     .0114676   .0085112     1.35   0.185    -.0056968    .0286321
          rd     17.71036     30.258     0.59   0.561    -43.31071    78.73143
         gpc    -2.74e-06   .0000156    -0.18   0.861    -.0000342    .0000287
          gg     .1220939   .0445455     2.74   0.009     .0322593    .2119284
                                                                              
        lnpp        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                             Robust
                                                                              
                                    (Std. Err. adjusted for 44 clusters in id)
corr(u_i, Xb)  = -0.9492                        Prob > F           =    0.0000
                                                F(7,43)            =     14.07
       overall = 0.1256                                        max =         2
       between = 0.1644                                        avg =       1.7
R-sq:  within  = 0.7063                         Obs per group: min =         1
Group variable: id                              Number of groups   =        44
Fixed-effects (within) regression               Number of obs      =        75
. xtreg lnpp gg gpc rd to im tr lnpop, fe robust
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Longitudinal Parsimonious Analytical Model with the USA 
 
 
Longitudinal Parsimonious Analytical Model without the USA 
 
 
  
                                                                              
         rho    .89883472   (fraction of variance due to u_i)
     sigma_e    .23686041
     sigma_u    .70601944
                                                                              
       _cons    -13.62077   1.552158    -8.78   0.000    -16.66295    -10.5786
          im     -1.04204   2.856382    -0.36   0.715    -6.640446    4.556367
          to      .001748   .0073252     0.24   0.811     -.012609    .0161051
          rd     47.99087   13.86239     3.46   0.001     20.82108    75.16066
         gpc     .0000496   .0000179     2.78   0.005     .0000146    .0000847
          gg     .1501538   .0287604     5.22   0.000     .0937844    .2065232
                                                                              
        lnpp        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                             Robust
                                                                              
                                     (Std. Err. adjusted for clustering on id)
corr(u_i, X)       = 0 (assumed)                Prob > chi2        =    0.0000
Random effects u_i ~ Gaussian                   Wald chi2(5)       =    241.93
       overall = 0.8479                                        max =         2
       between = 0.8657                                        avg =       1.7
R-sq:  within  = 0.3699                         Obs per group: min =         1
Group variable: id                              Number of groups   =        45
Random-effects GLS regression                   Number of obs      =        77
. xtreg lnpp gg gpc rd to im, re robust
                                                                              
         rho    .89753063   (fraction of variance due to u_i)
     sigma_e     .2413723
     sigma_u    .71435656
                                                                              
       _cons    -13.69015   1.646625    -8.31   0.000    -16.91747   -10.46282
          im    -.9901004   2.934597    -0.34   0.736    -6.741804    4.761603
          to      .002096   .0078167     0.27   0.789    -.0132246    .0174165
          rd     47.91581    13.9466     3.44   0.001     20.58098    75.25064
         gpc     .0000485     .00002     2.43   0.015     9.36e-06    .0000876
          gg     .1517233   .0304267     4.99   0.000     .0920881    .2113585
                                                                              
        lnpp        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                             Robust
                                                                              
                                     (Std. Err. adjusted for clustering on id)
corr(u_i, X)       = 0 (assumed)                Prob > chi2        =    0.0000
Random effects u_i ~ Gaussian                   Wald chi2(5)       =    234.15
       overall = 0.8426                                        max =         2
       between = 0.8617                                        avg =       1.7
R-sq:  within  = 0.3683                         Obs per group: min =         1
Group variable: id                              Number of groups   =        44
Random-effects GLS regression                   Number of obs      =        75
. xtreg lnpp gg gpc rd to im, re robust
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